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NANOG is a master transcription factor critical for the acquisition of both embryonic and 
induced pluripotency. Here we have further analyzed NANOG’s function in adult tissues and 
cancer. First we have uncovered NANOG expression in adult tissues, where it is restricted to 
the basal layer of epithelia. To determine its function we have used genetically modified mice 
with gain-of-function (inducible Nanog transgenic mice). In adult tissues, we have discovered 
that ubiquitous NANOG overexpression promotes hyperplasia of specific epithelia such as 
esophagus and forestomach, and transcriptionally activates key mitotic mediators selectively in 
stratified epithelia, but not in other tissues. Specifically, we have observed that NANOG can 
directly bind and regulate the mitotic Aurka gene in epithelial cells. The mitotic function of 
NANOG is also maintained in cancers that are derived from stratified epithelia, specifically, 
squamous cell carcinomas. Therefore, we analyzed the oncogenic effect of NANOG in vivo in 
squamous cell carcinomas. In a tumor resistant mouse background (C57BL/6) we have found 
Nanog overexpression in epithelia promotes squamous cell carcinoma by directly activating 
epithelial-mesenchymal transition (EMT) and stemness genes. These results unravel NANOG 
as an oncogenic driver in skin tumors and strengthen the idea of pluripotency transcription 
factors as tumorigenic in a cancer context. NANOG is gaining relevance in cancer since its 
expression has been detected in a large panel of tumors and cancer cell lines, but its presence in 
human cells is confounded by the presence of multiple and highly similar paralogs. In 
particular, there are three paralogs encoding functional proteins, namely, NANOG1, NANOG2 
and NANOGP8, and at least eight additional paralogs that do not encode full-length NANOG 
proteins. We have examined NANOG family expression using a multi-NANOG PCR that 
amplifies the three functional paralogs and most of the non-functional ones. As anticipated, we 
found that human embryonic stem cells (ESCs) express large amounts of NANOG1 and, 
interestingly, they also express NANOG2. In contrast, most human cancer cells tested express 
NANOGP8 and the non-coding paralogs NANOGP4 and NANOGP5. Notably, in some cancer 
cell lines, the NANOG protein levels produced by NANOGP8 are comparable to those 
expressed by NANOG1 in pluripotent cells. NANOGP8 presents 2 aminoacid changes in 
important domains of the protein, therefore we wanted to address if it maintains its pluripotent 
activity during reprogramming of differentiated cells to induced pluripotency. Our study 
demonstrates that NANOGP8 is as active as NANOG1 in the reprogramming of human and 
murine fibroblasts into induced pluripotent stem cells (iPSCs). These results demonstrate that 
cancer-associated NANOGP8 can contribute to promote de-differentiation and/or cellular 
plasticity. Altogether, we conclude that NANOG is functional in specific adult tissues and its 
overexpression is relevant in cancer.  
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NANOG es un factor de transcripción crítico para la adquisición de pluripotencia embrionaria e 
inducida. En este trabajo nos hemos enfocado en el papel de NANOG en tejidos adultos y en 
cáncer. En primer lugar, hemos descubierto la expresión de NANOG en tejidos adultos, 
específicamente en la capa basal del epitelio estratificado. En segundo lugar, utilizando ratones 
modificados genéticamente, hemos descubierto que la sobreexpresión de NANOG activa 
mediadores de mitosis claves que promueven hiperplasia de muchos epitelios, incluyendo el 
estómago no glandular y el esófago. Esta función mitótica de NANOG también se mantiene en 
aquellos cánceres que derivan del epitelio estratificado, específicamente, carcinomas de células 
estratificadas. Adicionalmente, hemos analizado el efecto oncogénico de NANOG in vivo en 
este tipo de carcinomas. En una cepa de ratón resistente a la formación de tumores (C57BL/6), 
hemos encontrado que sobreexpresión de Nanog específicamente en epitelios promueve la 
progresión a carcinomas de células estratificadas in vivo, a través de la activación de genes 
relacionados a transición epitelio-mesenquimal y a desdiferenciación, o troncalidad. Estos 
resultados demuestran que NANOG posee capacidad tumorigénica en tumores cutáneos, 
reforzando la idea de que factores de transcripción relacionados a pluripotencia son 
oncogénicos. En línea con otros estudios, hemos confirmado expresión de NANOG en un gran 
número de tumores y líneas celulares humanas que le dan relevancia a NANOG como marcador 
tumoral. En humanos, existen un gran número de parálogos de NANOG con un alto grado de 
similitud que dificulta la detección de NANOG en muestras humanas. Concretamente, existen 
tres genes parálogos que codifican proteínas funcionales, NANOG1, NANOG2 y NANOGP8, 
aparte de estos, también existen otra serie de parálogos que no codifican proteína al no poseer 
un marco abierto de lectura. Hemos examinado la expresión de los miembros de la familia 
NANOG utilizando una estrategia de PCR “multi-NANOG” que es capaz de amplificar todos los 
páralogos que dan lugar a proteína, así como a la mayoría de los que no. Hemos encontrado que 
células madre embrionarias expresan gran cantidad de NANOG1, y también de NANOG2. En 
contraste, la mayoría de las líneas celulares de cáncer humanas analizadas expresaban 
NANOGP8, y los parálogos no codificantes NANOGP4 y NANOGP5. Hemos comprobado que 
la expresión de proteína derivada de NANOGP8 en líneas tumorales es comparable a la de 
NANOG1 en líneas pluripotentes. NANOGP8 presenta dos cambios de aminoácidos en 
dominios importantes de la proteína, por lo tanto queríamos saber si mantiene su actividad 
pluripotente durante reprogramación de células diferenciadas a pluripotencia inducida. Nuestro 
estudio demuestra que NANOGP8 es tan activo como NANOG1 en la reprogramación de 
fibroblastos humanos y de ratón a células madre pluripotentes inducidas. Estos resultados 
demuestran que NANOGP8 asociado al cáncer puede contribuir a promover desdiferenciación 
y/o plasticidad celular. En conclusión, hemos demostrado que NANOG es funcional en tejidos 
adultos específicos y su sobreexpresión es relevante en el cáncer. 
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• ALDH: aldehyde dehydrogenase 
• AP: alkaline phosphatase 
• Aurka: aurora kinase A 
• Aurkb: aurora kinase B 
• ALT: alanine transaminase 
• BCC: basal cell carcinoma 
• bp: base pair 
• CDC20: cell division cycle 20 
• cDNA: complementary DNA 
• CDX2: caudal-type homeobox protein 2 
• ChIP: chromatin immunoprecipitation 
• CK: cytokeratin 
• CoIP: co-immunoprecipitation 
• CSC: cancer stem cell 
• cSCC: cutaneous squamous cell carcinoma 
• CXCR: CXC chemokine receptor  
• DMBA: 7,12-dimethylbenz(a)anthracene 
• DMEM: Dulbecco’s modified Eagle’s medium 
• DMR: differentially methylated region 
• DNA: deoxyribonucleic acid  
• DOX: doxycycline 
• ECL: enhanced chemiluminescence 
• EMT: epithelial-mesenchymal transition 
• Erk: extracellular signal-related 
• ESCC: esophageal squamous cell carcinoma 
• ESCs: embryonic stem cells  
• Esrrb: estrogen-related receptor beta  
• Fgf: fibroblast growth factor 
• GPCR: G-protein-coupled receptors  
• GSEA: gene set enrichment analysis 
• Gsk3: glycogen synthase kinase 3 
• H&E: hematoxylin and eosin 
• HDAC: histone deactelyase 
• HMG: high mobility group 
• HNSCC: head and neck squamous cell carcinoma 
• HPV: human papilloma virus 
• HSC: hematopoietic stem cell 
• ICM: inner cell mass 
• IFE: interfollicular epidermis 
• IHC: immunohistochemistry 
• iPSCs: induced pluripotent stem cells 
• ISH: in situ hybridization 
• JAK: Janus-associated tyrosine kinase  
• K5: cytokeratin 5 
• Kif20a: kinesin family member 20A 
• KO: knock-out 
• LIF: leukemia inhibitory factor 
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• MAPK: mitogen-activated protein kinase  
• MEFs: Mouse embryonic fibroblasts 
• MET: mesenchymal-epithelial transition 
• miRNA: microRNA  
• NLS: nuclear localization signal 
• NuRD: nucleosome remodeling deacetylase 
• OCT3/4: octamer-binding transcription factor 3/4  
• ORF: open reading frame 
• OSKM: Oct4, Sox2, Klf4 and cMyc 
• PcG: polycomb group 
• Pdgfra: platelet derived growth factor receptor alpha 
• PGCs: primordial germ cells 
• PI3K: phosphatidylinositol-3-OH kinase 
• PITX2: pituitary homeobox 2  
• PKC: protein kinase C 
• Prrx1: paired related homeobox 1 
• PTM: post-translational modification 
• qRT-PCR: quantitative real-time PCR 
• RNA: ribonucleic acid 
• rtTA: reverse tetracycline transactivator 
• SC: stem cell 
• SCC: squamous cell carcinoma 
• SDF-1: stromal cell-derived factor-1 
• siRNA: small interfering RNA 
• SpSCC: spindle cell carcinoma 
• TBIL: total bilirubin 
• TE: trophectoderm 
• Tet: ten eleven translocation enzymes 
• TNF!: tumor necrosis factor alpha 
• TPA: 12-O-tetradecanoylphorbol-13-acetate 
• UPS: ubiquitin-proteasome system 
• WR: tryptophan-rich domain 
• WT: wild-type 
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1. Pluripotency-associated transcription factor NANOG 
NANOG is a homeodomain-containing transcription factor, which was first discovered in 
embryonic stem cells (ESCs) for its capacity of maintaining the pluripotency and self-renewal 
of these cells (Chambers et al., 2003; Mitsui et al., 2003).  
1.1. NANOG in embryonic development 
Nanog is crucial during embryogenesis, as shown by the fact that Nanog-null embryos present 
early embryonic lethality (Mitsui et al., 2003). Specifically, it is expressed at two points during 
development, firstly for the correct specification of a pluripotent epiblast from the inner cell 
mass (ICM) at the blastocyst stage (Mitsui et al., 2003; Silva et al., 2009), and secondly it is 
also important for the development of primordial germ cells (PGCs) at E11.5 (Chambers et al., 
2007; Yamaguchi et al., 2009) (Figure 1).   
In the ICM there are distinct subpopulations of cells. One of these subpopulations selectively 
expresses Nanog that then commits to become the epiblast, meanwhile the other subpopulation 
expresses GATA-binding factor 6 (GATA6) and commits into the primitive endoderm. The 
epiblast gives rise to the embryo proper maintaining pluripotency, while the primitive endoderm 
gives rise to extraembryonic structures (Chazaud et al., 2006) (Figure 1). 
Nanog is also crucial for PGC development, the precursors for oocyte and spermatozoa, which 
undergo extensive reprogramming (Surani et al., 2007). Nanog is expressed at E11.5 
(Yamaguchi et al., 2005), where PGCs go through epigenetic remodeling including reactivation 
of the inactive X chromosome (female cells) and DNA demethylation (Surani et al., 2007)  
(Figure 1); features shared by naïve pluripotent cells (Welling and Geijsen, 2013). Conditional 
knockdown of Nanog in migrating PGCs resulted in apoptosis of these cells (Yamaguchi et al., 
2009), confirming its requirement for the specification of the germ cell lineage. 
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Figure 1. Nanog expression during embryonic development  
The zygote is totipotent and maternally inherits many epigenetic modifiers and transcription factors, which promote development to 
the blastocyst stage. Nanog expression in the inner cell mass (ICM) of the early blastocyst (E3.5) defines the specification of the 
epiblast. Pluripotency in epiblast cells is shown by X reactivation and maintenance of demethylation. Once cells start to commit into 
different lineages, DNA methylation appears. Only the primordial germ cells directly derive from the epiblast and maintain their 
pluripotency where Nanog expression is required, associated to erasure of imprinting, DNA demethylation and X reactivation in 
these cells. Modified from (Chazaud et al., 2006). 
 
1.2. Structure of NANOG 
NANOG is a transcription factor with a single homeodomain that binds to DNA (Jauch et al., 
2008). The Nanog gene encodes a 305-aminoacid protein, whose general structure consists of 
an N-terminal, a homeobox and a C-terminal domain (Chambers et al., 2003; Mitsui et al., 
2003; Wang et al., 2003) (Figure 2).  
Nanog is conserved in the mammalian lineage, both placental and non-placental. Additionally it 
has shown to possess orthologs in eutherians, birds, axoltl and teleosts (Booth and Holland, 
2004; Camp et al., 2009; Canon et al., 2006; Dixon et al., 2010; Schuff et al., 2012).  No clear 
homologues appear in invertebrates (Booth and Holland, 2004), and Nanog seems to have 
evolved only in vertebrates (Theunissen et al., 2011). Most pluripotency genes are well 
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conserved between eutherian mammals (Theunissen et al., 2011) and although Nanog is central 
in this transcriptional network (Wang et al., 2006b), it is poorly conserved between species 
(only ~54% between mouse and human) (Chambers et al., 2003; Mitsui et al., 2003; Wang et 
al., 2003). 
Figure 2. Structure of human 
NANOG 
Summary of functional and structural 
domains of human NANOG. Red 
triangle shows cleavage site mediated 
by caspases. Black line shows NLS 
sites. Abbreviations: NLS, nuclear 
localization signal; HD, domeodomain; 
C1, C-terminal subdomain 1; WR, 
tryptophan-rich subodomain; C2, C-
terminal subdomain 2. 
 
 
1.2.1. Homeobox domain 
The homeobox gene superfamily can be subdivided into classes, which contain numerous gene 
families. NANOG forms part of the ANTP class, and its closest sequence similarity is 50% with 
the NK2 family (Wang et al., 2003). The NANOG homeodomain comes out as a variant, since 
it lacks the N-terminal TN domain specific of the NK family, indicating it does not belong to 
any previously isolated subfamilies (Figure 3) (Harvey, 1996). The NANOG homeobox is the 
most conserved domain between its orthologs  (85% identity between mouse and human) 
(Figure 3) (Canon et al., 2006; Chambers et al., 2003; Mitsui et al., 2003). The homeodomain 
determines the DNA binding specificity, and contains three alpha helices (helix I, helix II and 
helix III), where helix III is involved in DNA recognition (Gehring et al., 1994; Gruschus et al., 
1997; Liu et al., 1990) (Figure 3). The importance of this homeodomain has been further 
elucidated by a recent study, showing that the homeodomain of different Nanog orthologs is 
enough to establish pluripotency in Nanog knock-out (KO) mouse somatic cells (Theunissen et 
al., 2011).  
Figure 3. Homeodomain 
comparison between Nanog 
orthologues and NK-like 
class genes.  
Sequence alignment of the 
homeodomains of Nanog 
orthologs and related mouse 
NK-like ANTP class proteins. 
Identical amino acids are 
highlighted in black. Red frame 
indicates residues unique to 
Nanog orthologs. Identity 
scores relative to mouse Nanog 
are shown on the right and 
were calculated using 
ClustalW2. Adapted from 
(Theunissen et al. 2011). 
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The consensus DNA sequence bound by NANOG has still to be clarified, and although different 
ChIP-seq studies have been carried out in embryonic stem cells (ESCs) (Boyer et al., 2005; Loh 
et al., 2006), the DNA binding sequence of NANOG still remains unclear.  
Transcription factors require a nuclear import process to activate target genes, normally 
mediated by a nuclear localization signal (NLS) composed of short stretches of highly basic 
aminoacid residues (Kalderon et al., 1984). In human NANOG, two nuclear localization signals 
(NLS) have been identified within the homeodomain (Chang et al., 2009; Do et al., 2007) 
(Figure 2). 
1.2.2. Transactivation domains  
Both the C-terminal and N-terminal regions of NANOG have transcription-related activities 
(Pan and Pei, 2003). The N-terminal region is serine rich, and appears to act as an interference 
domain, because its deletion leads to enhanced transactivation of target promoters (Figure 2) 
(Chang et al., 2009). The lack of the first serine residue was demonstrated to be essential for 
self-renewal of murine ESCs (Das et al., 2011). As described below, the N terminus is also 
important for many post-translational modifications that also have a direct effect on NANOG’s 
function.  
The C terminus can be divided into three subdomains, C1, tryptophan-rich (WR) subdomain, 
and C2 (Figure 2). The C-terminal region has two potent transactivation domains, WR and C2, 
which mediate transcriptional activation (Do et al., 2009; Oh et al., 2005; Pan and Pei, 2005). 
Specifically, the glutamine motif in the WR subdomain and the acidic residues in CD2 are 
required for the transcriptional activation activity of the C terminus of human NANOG (Figure 
2) (Do et al., 2009).  
Additionally, the C terminus is key for NANOG’s function since it is essential for 
homodimerization directly through its WR subdomain (Mullin et al., 2008; Wang et al., 2008). 
NANOG’s dimerization is indispensable for pluripotency maintenance and self-renewal of 
ESCs (Mullin et al., 2008; Wang et al., 2008). Mutations of the tryptophan residues to alanine in 
the WR impede its dimerization and monomeric NANOG has impaired interaction to its known 
partners, Sall4, Zfp198, Dax1, Nac1 and Oct4 (Wang et al., 2008) (Figure 2).   
1.3. NANOG post-translational modifications 
Pluripotency-associated transcription factors are highly expressed in pluripotent cells and 
become rapidly downregulated when these become differentiated. A number of different post-
translational modifications (PTM) have been described that can regulate the levels of these 
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pluripotency factors to achieve an optimum balance between pluripotency and differentiation 
(Cai et al., 2012). To date, NANOG has been described to undergo phosphorylation, 
ubiquitylation, and caspase-mediated cleavage.   
Phosphorylation 
NANOG has been known to be a phosphoprotein for quite some time (Yates and Chambers, 
2005), but only a recent study using mass spectrometry has demonstrated that human NANOG 
can be phosphorylated at multiple sites on its N terminus at proline-directed sites (Brumbaugh 
et al., 2014). Regarding its significance, one of the first functional studies described 
phosphorylation at multiple Ser/Thr-Pro motifs, which leads to recognition and binding of the 
prolyl isomerase Pin1 to NANOG. This interaction leads to stabilization of NANOG by 
preventing proteasome-mediated degradation. The presence of Pin1 and Pin1-Nanog 
interactions is important for mouse ESC self-renewal and teratoma formation (Moretto-Zita et 
al., 2010). An in vitro screening approach of a subset of kinases, revealed ERK2 and CDK1 
could directly phosphorylate NANOG, therefore creating a potential connection between key 
signaling pathways and NANOG (Brumbaugh et al., 2014).  
Ubiquitylation 
The ubiquitin-proteasome system (UPS) is the main pathway responsible for eliminating 
intracellular proteins (Lecker et al., 2006). A PEST motif (rich in proline, glutamine, serine, and 
threonine) in the N terminus of human NANOG was recently described to undergo 
ubiquitylation. Deletion of this PEST motif increased the stability and half-life of NANOG 
(Ramakrishna et al., 2011) (Figure 2). 
Cleavage 
Another type of PTM which can lead to rapid modifications of ESC function are mediated by 
site-specific proteases, not only known for their cell death program execution (Earnshaw et al., 
1999), but also for other functions in specific contexts such as cell differentiation (Arama et al., 
2003; Feinstein-Rotkopf and Arama, 2009). Upon differentiation of ESCs, caspase activity 
increased and specific sites in the N terminus and the homeodomain of mouse and human 
NANOG were identified (Figure 2). Caspase-3 can directly mediate ESC differentiation by 
cleavage of NANOG, leading to its destabilization and subsequent degradation (Fujita et al., 
2008). 
1.4. NANOG in embryonic stem cells 
ESCs are derived from the ICM of mammalian blastocysts. They are characterized by 
pluripotency, giving them capacity to differentiate into all cell types (Evans and Kaufman, 
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1981; Martin, 1981), as well as by self-renewal, which gives them the capacity to divide 
symmetrically and form two identical stem cell daughters (Burdon et al., 2002). One of the most 
important pathways through which mouse ESCs maintain their self-renewal in culture is 
signaling through the leukemia inhibitory factor (LIF) (Smith et al., 1988; Williams et al., 
1988). LIF is usually provided to cultured ESCs as a recombinant protein or through a feeder 
layer of embryonic fibroblasts. LIF ultimately acts by activating STAT3, among others, through 
binding to LIF receptor and gp130 heterodimers that activate Janus-associated kinases (JAK) 
(Figure 4) (Burdon et al., 2002; Niwa et al., 1998). NANOG was first discovered for its ability 
to maintain mouse ESC self-renewal independently of the LIF/Stat3 pathway (Chambers et al., 
2003; Mitsui et al., 2003). Specifically, the Jak-Stat3 pathway activates KLF4 that in turn 
activates SOX2. On the other hand, JAK also activates the phosphatidylinositol-3-OH kinase 
(PI3K)-Akt pathway, which regulates TBX3 expression that in turn stimulates NANOG. Both 
SOX2 and NANOG promote expression of the Oct4 endogenous locus and therefore self-
renewal of ESCs (Niwa et al., 2009) (Figure 4). 
 
Figure 4. Embryonic self-renewal through the LIF signal pathway. 
LIF binds to the heterodimer LIFR and gp130 activating JAK by phosphorylation. JAK activation phosphorylates Stat3, which 
translocates into the nucleus activating KLF4 and promoting expression cMYC. The PI3K/Akt pathway is also activated stimulating 
transcription of Tbx3. TBX3 and KLF4 activate Nanog and Sox2, respectively, which in turn maintain expression of Oct3/4. 
 
Although NANOG is a key player in pluripotency of ESCs, studies have shown it does this in 
conjunction with other transcription factors, specifically OCT4 and SOX2. NANOG, together 
with SOX2 and OCT4 form the core transcriptional regulatory circuitry in ESCs (Boyer et al., 
2005; Loh et al., 2006). OCT4 is a member of the POU class of homeodomain proteins that can 
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recognize an 8-bp DNA site through two DNA binding domains (POUS and POUHD), each 
contacting 4 bp in the major groove (Falkner and Zachau, 1984; Klemm and Pabo, 1996; 
Parslow et al., 1984; Phillips and Luisi, 2000). Oct4 is expressed in pluripotent cells and 
specifies the ICM during embryonic development by counteracting differentiation into TE 
(Nichols et al., 1998). Oct4 repression in mouse ESCs causes loss of self-renewal and 
differentiation into TE (Niwa et al., 2000) (Figure 5). SOX2 is a member of the Sry-related 
high mobility group (HMG) box family of transcription factors that interacts with the DNA 
through the minor groove (Bowles et al., 2000). SOX2 is important for epiblast maintenance 
(Avilion et al., 2003) and Sox2-deficient mouse ESCs differentiate into TE (Ivanova et al., 
2006; Masui et al., 2007).  
Figure 5.  Lineage segregation in the blastocyst. 
The morula stage at E3.0 shows distinct and mosaic expression of two transcription factors caudal-type homeobox protein 2 
(CDX2) and octamer-binding transcription factor 3/4 (OCT3/4; also known as POU5F1) which decide the first cell fate to form the 
trophectoderm (TE) or the inner cell mass (ICM), respectively. Oct4 and Cdx2 regulate each other in a negative reciprocal manner 
to specify both lineages. The second cell fate decision occurs from the ICM, which segregates into the primitive endoderm (PE) and 
epiblast lineages. In this case Nanog positive cells specify into the epiblast that gives rise to the embryo proper, meanwhile Gata6 
positive cells specify to the PE. Nanog and Gata6 also regulate their expression negatively. Modified from (Arnold and Robertson, 
2009). 
  
OCT4, SOX2 and NANOG cooperatively maintain the regulatory network responsible for self-
renewal and pluripotency (Chambers and Tomlinson, 2009). OCT4, SOX2 and NANOG co-
occupy many regulatory loci (Boyer et al., 2005; Loh et al., 2006), suggesting they may act 
coordinately to maintain the transcriptional program required for pluripotency. Additionally, 
studies have shown these core factors can cooperatively both activate and repress a number of 
target genes. Activation has been shown to involve recruitment of other transcriptional 
coactivators such as p300 when OCT4, SOX2 and NANOG bind together at active enhancers 
(Chen et al., 2008). On the other hand, silencing of developmental regulators is also important 
to maintain pluripotency, because expression of these developmental factors is associated with 
commitment to particular lineages This silencing appears to be mediated by Polycomb (PcG) 
group proteins, which are epigenetic regulators that facilitate maintenance of cell state through 
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gene silencing. Cobinding of OCT4, SOX2 and NANOG together with PcG proteins could 
mediate this silencing. (Bernstein et al., 2006; Boyer et al., 2006; Lee et al., 2006). 
NANOG’s role in pluripotency has been questioned by recent reports showing that Nanog-
deficient ESCs can maintain their pluripotency. Two different concepts have emerged, 
establishment and maintenance of pluripotency. NANOG seems to be essential for the 
establishment of naïve pluripotency, clearly shown by (1) Nanog deletion fails in the formation 
of germ cells (Chambers et al., 2007), (2) the ICM of Nanog-deficient cells is unable to generate 
a pluripotent naïve epiblast (Messerschmidt and Kemler, 2010), and (3) a Nanog-deficient ICM 
cannot give rise to ESCs (Chambers and Tomlinson, 2009; Mitsui et al., 2003).   
The main characteristics of ESCs with naïve or ground state pluripotency are that (1) they can 
form chimeras by reincorporating into the epiblast at the blastocyst stage and produce functional 
soma and germ cells, (2) both X chromosomes are activated in female cells, (3) they maintain 
self-renewal through the LIF/Stat3 pathway, (4) they commit when fibroblast growth factor 
(Fgf4)/Erk pathway is stimulated (Nichols and Smith, 2009). This last feature has led to the 
discovery that blockade of the MAPK/Erk pathway, as well as of glycogen synthase kinase-3 
(Gsk3) with selective small molecule inhibitors (2i) is sufficient to stabilize and sustain ESCs 
with full pluripotency (Ying et al., 2008). Allelic regulation of Nanog could be key in regulation 
of naïve state pluripotency since cells in the naïve epiblast of the blastocyst as well as ESCs 
grown in 2i conditions switch from a monoallelic to a biallelic expression (Miyanari and Torres-
Padilla, 2012). This observation of Nanog’s allelic regulation has been challenged by two recent 
publications and therefore should be further studied (Faddah et al., 2013; Filipczyk et al., 2013).  
1.5. NANOG in reprogramming  
In 2006, Takahashi and Yamanaka were able to reprogram differentiated somatic cells to an 
ESC-like state by ectopic expression of four transcription factors (Oct4, Sox2, Klf4 and cMyc, 
abbreviated here as OSKM) (Takahashi and Yamanaka, 2006). These induced pluripotent stem 
cells (iPSCs) share the same properties with ESCs, including pluripotency and self-renewal. 
They rely on the same signaling pathways such as LIF and 2i addition, the core transcription 
factors (OCT4, SOX2 and NANOG) and share similar gene expression profiles (Hanna et al., 
2010; Yamanaka, 2009).  
Surprisingly, Nanog is not among the “Yamanaka” reprogramming factors and is dispensable at 
the initial steps of reprogramming. Nevertheless, Nanog has been shown to be essential at later 
steps of reprogramming (Faddah et al., 2013; Silva et al., 2008; Sridharan et al., 2009), where it 
is required to complete reprogramming to a “fully” reprogrammed state or what is known as the 
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naïve or ground pluripotent state (Chambers and Tomlinson, 2009). In the case of murine cell 
reprogramming, addition of mouse Nanog accelerates reprogramming with the “Yamanaka” 
cocktail (OSKM) (Hanna et al., 2009) and promotes the transition from pre-iPSCs to iPSCs. 
(Silva et al., 2009) 
Nanog-deficient somatic cells cannot acquire a fully reprogrammed state and remain in a pre-
iPS stage (Silva et al., 2009). It still remains unclear how Nanog plays this role during 
reprogramming. Some studies have shown that Nanog not only acts through direct regulation of 
genes involved in pluripotency, but also by physically interacting with chromatin remodellers 
such as NuRD (nucleosome remodeling deacetylase) and Tet1/2 (ten eleven translocation 
enzymes) (Festuccia et al., 2013). Nanog requirement during reprogramming can be bypassed 
by overexpressing NANOG target genes such as Esrrb together with 5’azacytidine treatment, a 
known DNA demethylating agent (Festuccia et al., 2012). Another study has shown that Nanog 
is dispensable during reprogramming by modifying the culture conditions. In detail, addition of 
ascorbic acid (vitamin C) to the medium permits Nanog-deficient cells to achieve complete 
reprogramming (Schwarz et al., 2014), this also is connected with epigenetic remodeling since 
ascorbic acid has been shown to directly stimulate Tet activity and induce DNA methylation in 
ESCs (Blaschke et al., 2013) (Figure 6).  
Figure 6. Requirement of NANOG during reprogramming. 
Initiation of reprogramming starts with transduction of somatic differentiated cells, in this case retroviruses or lentiviruses 
containing the “Yamanaka” factors Oct4, Klf4, Sox2 and cMyc. cMyc is not required in the reprogramming cocktail but increases the 
efficiency. This leads to appearance of cells in a transitional state known as pre-iPSCs, where there is expression of some 
pluripotency genes but these cells are prone to lineage commitment and have not acquired pluripotent features. Nanog is not 
required in this initial phase. In the establishment stage pre-iPSCs need to undergo complete reprogramming. Nanog expression is 
essential for this stage and it does this by inducing Esrrb expression and contributing to demethylation by recruiting Tet1. Nanog 
requirement can only be bypassed by overexpressing its target gene Esrrb used together with demethylating agent 5-azacytidine, or 
by adding to the medium ascorbic acid which is known to be a cofactor for Tet. iPSCs are 2i/LIF responsive, reactivate the inactive 
X chromosome, contribute to chimerism and can give rise to germline transmission. Once pluripotency is established, Nanog is no 
longer required in the maintenance phase and can be deleted without compromising self-renewal. 
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1.6. NANOG variants in the genome 
1.6.1. Human variants 
At least 11 NANOG paralogs have been identified in the human genome, which complicates its 
detection (Booth and Holland, 2004). The founding member of the family, NANOG1 or 
embryonic NANOG, is highly expressed in human embryonic stem cells (hESCs) (Chambers et 
al., 2003; Mitsui et al., 2003; Wang et al., 2003). In addition, NANOG1 is an important 
component of the “Thomson” cocktail (OCT4, SOX2, LIN28 and NANOG1) for the 
reprogramming of human cells into iPSCs (Yu et al., 2007). As mentioned before its 
homeodomain is functionally conserved among different species, demonstrated by a study 
where human NANOG1 can replace mouse Nanog in the pre-iPSC to iPSC transition of murine 
cells (Theunissen et al., 2011). NANOG2 is another paralog that is the product of a duplication 
event and lies on the same chromosome as NANOG1. It shares a similar intron/exon structure 
and a highly conserved promoter region. Recently NANOG2 was found in human leukemic cells 
(Eberle et al., 2010). However, it is not known whether NANOG2 is expressed in human 
embryonic stem cells (hESCs). In addition to NANOG1 and NANOG2, there are 9 intronless 
paralogs, named NANOGP2 to NANOGP10, under the control of promoter sequences unrelated 
to their parental NANOG1 and 2 genes (Booth and Holland, 2004). NANOGP8 is of particular 
interest because it is the only NANOG intronless paralog with an intact protein coding capacity 
and, indeed, its encoded protein only differs in 2 amino acids from NANOG1 (Zbinden et al., 
2010). Of note, the two amino acids divergent in NANOGP8 relative to NANOG1 are located 
in important domains for transcriptional regulation (Chang et al., 2009; Do et al., 2009; Pan and 
Pei, 2005), opening the possibility that the function of NANOGP8 could differ from that of 
NANOG1 (Figure 7). Interestingly, NANOGP8 is expressed in many human cancer cell lines, 
where it has been reported to increase many properties associated with cancer stem cells, 
including clonogenicity and tumorigenicity (Ambady et al., 2010; Ishiguro et al., 2012; Jeter et 
al., 2009; Jeter et al., 2011; Uchino et al., 2012; Zbinden et al., 2010; Zhang et al., 2013; Zhang 
et al., 2010; Zhang et al., 2006a). However, there is no direct information on the activity of 
NANOGP8 in ESCs or in pluripotency assays.  
INTRODUCTION!!!
 
 31!
 
Figure 7. NANOG variants in the human genome 
(A) Coding human NANOG variants gene structure. NANOG1 and NANOG2 have an exon/intron structure. Exons are 
represented by horizontal bars; 5’ and 3’ UTR are white; the coding region is blue and the homeodomain is colored in 
red. Introns are represented by lines and length in nucleotides is written underneath the introns. Green triangles indicate 
the start codon (ATG) and the black circle indicates the stop codon (TGA). NANOGP8 is a retrogene that lacks introns. 
NANOG1, NANOG2 and NANOGP8 have a functional ORF and give rise to NANOG protein. Modified from (Booth and 
Holland, 2004). 
(B) Alignment report comparing the protein sequence of NANOG1 to NANOG2 and NANOGP8. Shade (with solid black) 
indicates residues that differ from NANOG1. Residues that match the NANOG1 sequence exactly are indicated as ‘.’. 
Gaps are indicated as ‘-’. The last black shaded ‘.’ indicates the STOP codon.  
1.6.2. Mouse variants 
A total of four variants have been identified in the mouse genome, although they are not related 
to the human variants. In mouse, Nanog variants differ depending on the strain analyzed. Two 
pseudogenes, denoted NanogPa and NanogPb, have been found in the C57BL/6 genome (Booth 
and Holland, 2004). These pseudogenes are critically disrupted by mutations and do not 
conserve a functional ORF.  
Additionally, two retrogenes have been found in different strains, denoted NanogPc and 
NanogPd. Both retrogenes conserve a functional ORF when compared to Nanog. NanogPc 
presents eight missense mutations and one nonsense mutations which terminates the ORF 49 
codons earlier compared to Nanog. NanogPd presents six missense mutations and a deletion in 
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the ORF of 30 bp. NanogPc is found in 129/Ola and M. spretus, and NanogPd is found in 
strains 129/Ola, CBA, in M. m. castaneus and M. spretus. Further analysis revealed that 
NanogPd conserves its pluripotent function shown by its capacity to confer LIF-independent 
self-renewal potential to ESCs (Robertson et al., 2006).  
2. Expression of pluripotency factors in adult tissues 
In adult tissues, a population of stem cells is responsible for homeostasis and repair by 
replenishing senescent or damaged cells (Blanpain et al., 2007). As other stem cells, these adult 
or somatic stem cells have the capacity to self-renew and to generate multiple differentiated cell 
types (Simons and Clevers, 2011). Unlike ESCs, these cells have limited potential and are 
thought to give rise to cells within the tissue of residence. As shown before, ESCs depend on a 
cohort of pluripotent genes whose elimination results in commitment into different lineages. 
Some of these pluripotency genes are also active in rare adult cells, suggesting a common origin 
of these cell types and showing similarities between embryonic and adult stem cells.  
2.1. OCT4 
Initial studies of Oct4 indicated it could have a potential role in adult tissues. Its expression was 
observed in a variety of adult stem cell compartments, as well as in cultured progenitor cells, 
where it was thought to play a role in self-renewal analogous to ESCs. This was further 
supported by analysis of an inducible-Oct4 mouse model, which showed that ubiquitous 
overexpression of Oct4 led to suppression of differentiation in the intestine and dysplasia of 
epithelia along with expansion of progenitor cells (Hochedlinger et al., 2005).  
A recent study using a conditional KO of Oct4 has put its role in adult tissues in question. In 
detail, Oct4 was deleted in specific populations by using different promoters driving Cre 
expression (used promoter/targeted tissue: Villin promoter/intestine, Mx-1 promoter/bone 
marrow, Mx-1 promoter/liver, Nestin promoter/brain, liver, and Keratin15 promoter/hair 
follicles). Contradicting the previous studies, deletion in all tissues did not lead to any 
abnormalities or impaired regenerative capacity (Lengner et al., 2007). The previous results 
were attributed to Oct4 pseudogenes that have been identified which could be “contaminating” 
detection of Oct4 (Liedtke et al., 2007).  
2.2. SOX2 
Sox2 has been shown to be expressed in multiple adult stem and progenitor cells, with a key role 
in tissue homeostasis and regeneration (Sarkar and Hochedlinger, 2013). It is expressed in 
neurogenic regions of the central nervous system, where extracted Sox2+ neural progenitor cells 
INTRODUCTION!!!
 
 33!
grow in culture and give rise to different cell types, such as neurons, astrocytes and 
oligodendrocytes, therefore showing multipotency and capacity to self-renew (Ellis et al., 
2004). Its importance in neurogenesis in the hippocampus and in neural progenitor cells has 
been shown by in vivo and in vitro deletion (Cavallaro et al., 2008; Favaro et al., 2009; Ferri et 
al., 2004; Suh et al., 2007). Sox2+ cells have also been detected in a variety of tissues, 
associated to its expression pattern during development. It is expressed in stem and progenitors 
cells of many tissues, including the adult retina (Taranova et al., 2006), trachea (Que et al., 
2009), tongue epithelium (Okubo et al., 2009), testes, forestomach, trachea, anus, cervix, 
esophagus and lens (Arnold et al., 2011; Juuri et al., 2012). In the skin, it is expressed in the 
dermal papilla of the hair follicle (Biernaskie et al., 2009; Driskell et al., 2009), known to 
constitute a well-known epidermal stem cell population (Driskell et al., 2011).  
Its different roles during embryonic development and adult tissues appear to be regulated by 
binding to other transcription factors. In ESCs, SOX2 binding to NANOG and OCT4 creates a 
core transcriptional network in charge of maintaining self-renewal and inhibiting differentiation 
of these cells (Boyer et al., 2005; Kim et al., 2008). In neurons, where NANOG and OCT4 are 
not present, SOX2 binds to transcription factor Brn2 to activate Nestin, known to be associated 
to neural progenitor cells (Tanaka et al., 2004). In stratified epithelial cells, SOX2 interacts with 
epithelial stem cell transcription factor p63, as shown by a recent study where both bind and 
have overlapping genomic targets in squamous cell carcinoma cells (Watanabe et al., 2014a).  
3. Expression of pluripotency factors in cancer 
In addition to NANOG, many other reprogramming factors, notably including SOX2, KLF4, 
OCT4, LIN28 or MYC, are overexpressed in human cancers and, in some cases, play a driving 
oncogenic role (Suva et al., 2013). It is hypothesized that reprogramming factors in cancer 
contribute to cellular plasticity and this could be a critical oncogenic feature (Suva et al., 2013).  
3.1. NANOG 
Expression of NANOG in cancer was first detected in germ cell tumors (Chambers and Smith, 
2004; Sperger et al., 2003). The oncogenic potential of NANOG has also been demonstrated in 
many in vitro studies, where it has been shown to promote proliferation, xenograft growth, and 
migration and invasion (Table 1). Many of these studies have also determined the NANOG 
variant that is being expressed. Several studies indicate NANOGP8 and not NANOG1 could be 
expressed in cancer (Table 1). Its tumorigenicity has been demonstrated in vivo in breast cancer 
where overexpression of Nanog in MMTV-Wnt-1 mice accelerates mammary tumorigenesis 
and metastasis (Lu et al., 2013). 
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Table 1. Expression of Nanog in cancer 
Origin Effect NANOG Targets 
Upstream 
regulators of 
NANOG 
NANOG 
variant 
distinction 
Reference 
Breast and ovarian 
carcinoma  Chemoresistance MDR-1 
Hyaluronan(HA)-
CD44 pathway No 
(Bourguignon et al., 
2008) 
Ovarian carcinoma  Chemoresistance and CSC population - miR-214 No (Xu et al., 2012) 
Breast carcinoma 
Cell cycle 
progression, G0/G1 
arrest, and 
proliferation 
Cyclin D1 - No (Han et al., 2012) 
Ovarian carcinoma  Migration and invasion 
Inhibition of 
FOXJ1 and 
Ecadherin 
- No (Siu et al., 2013) 
Colorectal carcinoma Tumor formation and metastasis - - NANOGP8  
(Zhang et al., 2012b, 
2013) 
Colorectal carcinoma Invasion and metastasis Snail/Slug - No (Meng et al., 2010) 
Colorectal carcinoma Tumorigenesis  - c-Jun  and ß-Catenin/TCF4 
NANOGP8 
and 
NANOG1 
(Ibrahim et al., 2012) 
Colorectal carcinoma  Tumor initiation  EpCAM - (Lin et al., 2012) 
Colorectal carcinoma Immune evasion Tcl1a  - (Noh et al., 2012) 
Gastric carcinoma Overexpression in gastric tumors - - 
NANOGP8 
and 
NANOG1 
(Zhang et al., 2010) 
Head and neck SCC  Chemoresistance miR-21 
Hyaluronan(HA)-
CD44 pathway 
PKC! 
No 
(Bourguignon et al., 
2012a) 
(Bourguignon et al., 
2009) 
Head and neck SCC  Chemoresistance miR-302 Hyaluronan(HA)-CD44 pathway No 
(Bourguignon et al., 
2012b) 
Head and neck SCC  CSC with EMT features  - GSK3ß No (Shigeishi et al., 2013) 
Hepatocellular 
carcinoma 
Invasion and 
metastasis Nodal/Smad3 - No (Sun et al., 2013) 
Hepatocellular 
carcinoma 
Chemoresistance, 
self-renewal, and 
tumorsphere 
formation 
IGF2 and 
IGFR1 - No (Shan et al., 2012) 
Lung carcinoma EMT and CSC properties ABCB1 - No (Chiou et al., 2010) 
Prostate carcinoma Tumorigenesis - - NANOGP8 (Jeter et al., 2009) 
Glioblastoma 
CSC proliferation, 
motility and tumor 
survival 
FAK - No (Ho et al., 2012) 
Glioblastoma Self-renewal and tumorigenesis GLI1 Hedgehog/GLI1 
NANOGP8 
and 
NANOG1 
(Zbinden et al., 2010) 
(Po et al., 2010) 
  
Interestingly, Nanog has been previously associated with the important tumor suppressor p53 in 
ESCs. TP53 gene is mutated or deleted in 50% of human tumors (Hollstein et al. 1991). In 
ESCs, p53 can suppress Nanog’s expression either by direct or indirect mechanisms; directly by 
binding to Nanog’s promoter or indirectly by recruitment of a H3 histone deacetylase (Lin et al. 
2004). Further studies have also linked this to cancer, where NANOG and p53 establish a 
functional negative loop in glioblastoma (Zbinden et al., 2010).  
Another interest for NANOG in cancer is the search for cancer stem cell markers. Common 
properties between cancer stem cells (CSC) and embryonic stem cells point out to ESC markers 
as CSC markers. NANOG and OCT4 are among these. Distinctively, NANOG overexpression 
is highly correlated with malignancy and chemoresistance of squamous cell carcinomas 
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(Bourguignon et al., 2012a; Bourguignon et al., 2012b; Chang et al., 2013; Chen et al., 2013; 
Du et al., 2012; Watanabe et al., 2014b; Ye et al., 2008), where there is a lack of in vivo studies. 
3.2. OCT4 
OCT4 was identified to have a key role in driving germ cell tumors and is currently used as a 
diagnostic marker for these tumor types (Gidekel et al., 2003).  
3.3. SOX2 
SOX2 has been demonstrated to be an oncogene in epithelial cancers by multiple studies. 
Specifically, the SOX2 locus is amplified in human squamous cell carcinomas (SCC) of the 
lung and esophagus, as well as in small cell lung carcinomas (Bass et al., 2009; Rudin et al., 
2012); a clear feature of an oncogene.  
SOX2 overexpression alone in progenitor cells of epithelia is insufficient to drive 
tumorigenesis. A recent study has shown SOX2 requires activated STAT3 to drive its 
tumorigenic role in SCC. Overexpression of SOX2 in the basal layer of epithelia demonstrated 
SCC arise only in the forestomach, since expansion of the progenitor cell population leads to 
exposure to the bile acid-rich environment and posterior inflammation. Inflammation together 
with SOX2 expression is responsible for carcinoma formation (Liu et al., 2013).  
4. Squamous cell carcinoma 
Squamous cell carcinomas (SCC) are the most common cancers from ectodermal origin with 
more than 300,000 deaths per year (Goon et al., 2009; Madan et al., 2010). This type of cancer 
arises from squamous cells, which serve as a barrier in the skin, esophagus, lung and cervix. 
These epithelia are constantly being exposed to environmental aggressions (specially the skin 
and the oral mucosa epithelia), and therefore must be in constant renewal. This renewal relies on 
a population of adult epithelial stem cells, which need to constantly self-renew to maintain the 
homeostasis of this tissue. Specifically, progenitors in the basal layer differentiate as they 
migrate towards the surface ultimately turning into keratinized cells. In the case of the 
epidermis, different populations of stem cells have been extensively characterized (Figure 8) 
(Arwert et al., 2012; Barker et al., 2010; Blanpain and Fuchs, 2009). One of the common 
characteristics of squamous neoplasias is the alteration of differentiation, as well as thickening 
of the epithelium with increased proliferation. Although there are many subtypes of SCC, 
depending on their site of manifestation and with different risk factors, they are all likely to 
share disruption of similar pathways that coordinate the squamous differentiation and 
proliferation pattern (Janes and Watt, 2006).  
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4.1. Cutaneous squamous cell carcinoma 
Non-melanoma skin cancer is the most frequent malignancy in fair-skinned populations. Of 
these diagnosed non-melanoma skin cancers, 80% were basal cell carcinomas (BCC) and 20% 
were cutaneous squamous cell carcinomas (cSCC) (Lomas et al., 2012). Unlike almost all 
BCCs, cSCCs are associated with a substantial risk of metastasis (Alam and Ratner, 2001). 
Exposure to sunlight is one of best-known causes of this type of cancer, specifically there are 
studies showing that ultraviolet radiation induces p53 mutations by formation of thymidine 
dimers in invasive cSCC (Backvall et al., 2005; Brash et al., 1991).  
4.2. Esophageal squamous cell carcinoma 
Esophageal carcinoma is the sixth leading cause of cancer-associated mortality with an overall 
5-year survival of 15%-20%. Squamous cell carcinoma is the most prevalent form of 
esophageal carcinoma worldwide, although adenocarcinoma also has high incidence in many 
western countries. The major risk for esophageal squamous cell carcinoma (ESCC) is alcohol 
and tobacco consumption. One of the main problems is that most patients present metastasis at 
the time of diagnosis, and treatment consists in combination approaches of surgery and 
chemotherapy (Pennathur et al., 2013). 
In squamous epithelia, proliferation is confined to the basal layer, which gives rise to 
differentiating epithelial layers (suprabasal layer). Normally, in epithelial tissues a small group 
of stem cells is responsible for tissue homeostasis (Figure 8) (Blanpain and Fuchs, 2009). The 
esophageal epithelium seems to be unique, since to date, a population of quiescent stem cells 
that maintains homeostasis and repair has not been identified. Instead, a single layer of 
progenitor cells equally contributes to both these processes (Doupe et al., 2012). 
4.3. Head and neck squamous cell carcinoma 
This type of SCC includes lesions in the oral cavity, larynx and pharynx, and about 550,000 
new cases are diagnosed each year (Siegel et al., 2012). Although tobacco and alcohol are a risk 
factor for this disease, currently the major risk factor is infection with oncogenic human 
papilloma virus (HPV) (D'Souza et al., 2007). This type of cancer arises from the growth of a 
single stem cell or from a population of tumor initiating cells that have acquired self-renewal 
capacity (Lobo et al., 2007). The most frequent driving genes that have been identified are TP53 
(mutated in 50-80% of the cases), CDKN2A, PI3KA, PTEN, HRAS (Molinolo et al., 2009), and 
NOTCH1 (acting as a tumor suppressor in this context) (Agrawal et al., 2011; Stransky et al., 
2011).  
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4.4. DMBA/TPA chemical carcinogenesis as a model for squamous cell 
carcinoma 
The use of multi-stage chemical carcinogenesis models is one of the best models to study in 
vivo the development of tumors, and to evaluate the impact of genetic manipulation on tumor 
initiation, promotion and progression (Abel et al., 2009). 
The initial stage involves provoking mutations in key genes in epidermal progenitor cells by 
exposing them to a chemical mutagen. 7,12-Dimethylbenz(a)anthracene (DMBA) is a 
frequently used initiating agent. DMBA causes initiation by mutations that activate Hras in 
most cases (Balmain et al., 1984; Quintanilla et al., 1986), although mutation of Kras has also 
been observed. To give rise to tumors, the cellular targets of these mutations are required to be 
epidermal stem cells, specifically the hair follicle bulge stem cells (Lapouge et al., 2011; White 
et al., 2011) and/or the interfollicular epidermis (IFE) stem cells (Brown et al., 1998; Vitale-
Cross et al., 2004) (Figure 8 and 9). In humans, mutations in the Ras family are found in 30% 
of all cancers, and this is also extends to SCCs (Corominas et al., 1991; Spencer et al., 1995; 
van der Schroeff et al., 1990). There are numerous studies showing that activation of different 
pathways in the skin stem cells leads to different tumor phenotypes. For example, expression of 
ßcatenin induced hair-follicle tumors (Gat et al., 1998); expression of GLI1 or GLI2 leds to 
formation of basal cell carcinomas (Grachtchouk et al., 2000; Nilsson et al., 2000); and in 
agreement with the above, Hras has specifically shown to induce keratoacanthomas, papillomas 
and squamous carcinomas (Brown et al., 1998).  
Figure 8. Skin stem cell populations. 
Schematic representation of the skin epidermis with the 
different stem cell (SC) compartments and markers 
identifying each population. Bulge SCs are multipotent 
and reside in the non-cycling portion of the hair follicle. 
The interfollicular epidermis (IFE) also has SCs in the 
basal layer of the epidermis. There are also sebaceous 
gland and isthmus progenitor cells between the 
sebaceous gland and the bulge. Modified from (Alcolea 
and Jones, 2014).  
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Expression of activating mutations of Ras is not sufficient to induce SCC. The second step that 
is required in chemical carcinogenesis is the promotion stage. This stage consists on amplifying 
the population of mutated cells by using chemical agents or wounding that promote not only 
proliferation, but increased self-renewal of the stem cell population and inflammation (Perez-
Losada and Balmain, 2003). One of the best-known tumor promoting agents is the phorbol ester 
12-O-tetradecanoylphorbol-13-acetate (TPA). Further evidence that mutations must occur in the 
stem cell population is shown by the fact that after DMBA treatment, TPA treatment even after 
one year can still promote papilloma formation (Morris, 2000; Morris et al., 1997; Morris et al., 
1986). One of the main targets of phorbol esthers is the protein kinase C (PKC) pathway, 
particularly of two of its isoenzymes PKC! and PKC". One of PKC’s downstream effects is the  
activation of Ras and the ERK cascade which promotes proliferation (Griner and Kazanietz, 
2007). PKC! and PKC" have also shown to mediate inflammation through overexpression of 
CXC chemokine receptor 2 (CXCR2) in keratinocytes, and through tumor necrosis alpha 
(TNF!) and activation of Stat3 respectively. Many mechanisms have been studied for TPA 
tumor promotion, but in summary it is necessary for skin tumor development by inducing 
inflammation and proliferation (Rundhaug and Fischer, 2010). After repeated application of the 
phorbol esther TPA, papillomas arise after some weeks. Papillomas are benign tumors 
consisting on clonal outgrowths of the skin with a stromal core and hyperplastic epidermis 
(Yuspa, 1998).  
The last step in chemical carcinogenesis assays is progression of papillomas to invasive SCCs 
or what is known as the conversion stage. This occurs spontaneously and requires additional 
events such as loss of tumor suppressors or other promoting factors independent of TPA. One 
example is the loss of TP53, where DMBA/TPA experiments in p53 KO mice show enhanced 
malignant progression (Kemp et al., 1993) (Figure 9). The conversion rate also varies with the 
genetic background. In the FVB strain up to 50% of papillomas convert to SCCs, meanwhile in 
the C57BL/6 strain this is a very rare event (Hennings et al., 1993). Additional analysis has 
shown that Mus musculus inbred mice are much more susceptible than the Mus spretus strain. 
By comparing resistant M. spretus to the FVB strain, different networks were identified for 
susceptibility, including mitosis and cell proliferation genes; and interleukin 1 antagonist 
activity (Quigley et al., 2009).  
SCCs can yet progress further undergoing epithelial-mesenchymal transtion (EMT) and turn 
into undifferentiated spindle cell carcinomas (SpSCC) (Klein-Szanto, 1989). Elevated Hras and 
TGFß signaling seem to mediate this transition (Cui et al., 1996; Oft et al., 2002). Recently, 
these SpSCC have been identified to have frequent Ink4/Arf deletions and upregulated EMT 
transcription factors (Wong et al., 2013) (Figure 9).  
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Figure 9. DMBA/TPA chemical carcinogenesis protocol in mice.  
Initiation starts with a single topical application of the mutagen DMBA. Repeated topical applications of TPA during 10-40 weeks 
after initiation promote proliferation and inflammation expanding the initiated stem cell (SC) population. After 6-12 weeks of TPA 
application, papillomas start appearing. Further mutations and driving events cause a fraction of papillomas to spontaneous convert 
to SCC. Lastly, EMT and increased TGFß and Hras signaling promote a final progression stage to a very invasive carcinoma known 
as spindle cell carcinoma.  
 
The importance of the chemical carcinogenesis assay is that it can model human cancer. Human 
cancer is also a multi-sequential process with different associated events leading to neoplasias. 
In this model, initiation occurs in a single stem cell, which could also resemble the cancer stem 
cell model and posterior progression to malignant carcinoma is an additional step in the tumor 
evolution. 
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1. Analyze the expression of transcription factor Nanog in adult tissues.  
2. Determine the role of NANOG in adult tissues and homeostasis using a ubiquitous 
inducible-Nanog transgenic mouse model.   
3. Determine the role of NANOG in squamous cell carcinomas by using an epithelia-
specific inducible-Nanog transgenic mouse model. 
4. Determine the role of NANOG in epithelial cells and human squamous cell carcinoma 
cell lines. 
5. Analyze the expression of human NANOG variants in cancer.  
6. Analyze the capacity of human NANOG variants to induce reprogramming. 
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1. Analizar la expresión de NANOG en tejidos adultos de ratón. 
2. Determinar el papel de Nanog en tejidos adultos utilizando un modelo de ratón 
modificado genéticamente que sobreexpresa Nanog de forma ubicua. 
3. Determinar el papel de Nanog en carcinogénesis epitelial utilizando un modelo de ratón 
que sobreexpresa Nanog en la capa basal del epitelio. 
4. Determinar el papel de NANOG en células epiteliales y derivadas de carcinomas de 
células escamosas humanas.  
5. Determinar la expresión de las variantes humanas de NANOG en cáncer.  
6. Elucidar la capacidad de las variantes humanas de NANOG para inducir reprogramación 
de células diferenciadas de humano y de ratón. 
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1. Animal Experimentation 
1.1. Transgenic mouse model 
Mice were housed at the specific pathogen-free (SPF) barrier area of the Spanish National 
Cancer Research Centre (CNIO), Madrid. Mice were observed on a daily basis and sacrificed 
when they showed overt signs of morbidity in accordance to the Guidelines for Humane 
Endpoints for Animals Used in Biomedical Research from the Council for International 
Organizations of Medical Sciences (CIOMS). All animal procedures were performed according 
to protocols approved by the CNIO-ISCIII Ethics Committee for Research and Animal Welfare 
(CEIyBA). We used three different transgenic mouse models, (1) the tetO-Nanog mouse (kindly 
provided by Konrad Hochedlinger and Rudolf Jaenisch) contains the Nanog-cDNA under the 
control of the doxycycline (DOX)-responsive promoter (tetO) inserted downstream of the 
Col1a1 locus, as described elsewhere for the generation of OCT4 inducible mice (Hochedlinger 
et al., 2005); (2) the Rosa26::rtTA (kindly provided by Konrad Hochedlinger and Rudolf 
Jaenisch) mouse contains the reverse tetracycline transactivator (rtTA) inserted within the 
ubiquitously expressed Rosa26 allele (Hochedlinger et al., 2005); and (3) the K5-rtTA mouse 
(kindly provided by Silvio Gutkind) contains a transgene with the reverse tetracycline 
transactivator (rtTA) cloned downstream from the bovine cytokeratin promoter (K5, specifically 
expressed in the basal layer of stratified epithelia) (Vitale-Cross et al., 2004).  
The ubiquitous Nanog-inducible mice (Results Part I) correspond to the genotype Col1a1tetO-
Nanog/+;Rosa26rtTA/+ (abbreviated as TG), and as a control, Col1a1+/+;Rosa26rtTA/+ or Col1a1tetO-
Nanog/+;Rosa26+/+  mice were used (abbreviated as CTR). Mice between 3-8 months of both sexes 
were used for the experiments with a mixed 129Sv/C57BL6 background. Transgene expression 
was induced by addition of doxycycline to the drinking water of mice, two doses were used, 0.2 
mg/ml (LOW DOX) and 2 mg/ml (HIGH DOX) in a 7.5% sucrose solution. For long-term 
treatment using LOW DOX, a 2% sucrose solution was used. Doxycycline containing water 
was changed every 2-3 days.   
The epithelia specific Nanog-inducible mice (Results Part II) correspond to the genotype 
Col1a1tetO-Nanog/+; K5-rTAtg/. (abbreviated as TG), and as a control  Col1a1tetO-Nanog/+ (abbreviated 
as CTR). Mice carrying these alleles were backcrossed at least five time with wild type 100% 
pure C57BL/6 mice to have them in this background. Littermate mice between 5-8 months of 
both sexes were used for all experiments, except for the chemical carcinogenesis assay where 
mice were between 8-10 weeks old at the start of the treatment.  
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1.2. Topical TPA application 
To induce epidermal proliferation, tail skin from a group of five mice per genotype (CTR and 
TG) in the telogen (resting) phase of the hair cycle was topically treated every 48 hr with TPA 
(20 nmol in acetone) (cat # P8139; Sigma) for a total of four doses. Five control mice of each 
genotype were treated with acetone alone. Mice were sacrificed 24 hr after the last TPA 
treatment, and the tail skin was analyzed.  
1.3. Chemical carcinogenesis assay 
Twelve age-matched (8-10 weeks old) mice of each genotype, CTR and TG were given 
doxycycline in their drinking water, which was changed every 2-3 days throughout the entire 
treatment. 48 hours after, a single dose of 100 nmol of DMBA (cat # D3254; Sigma) in 0.2 ml 
acetone was topically applied to the shaved dorsal skins to induce DNA mutation. One week 
later, 17 nmol TPA (cat # P8139; Sigma) in 0.2 ml acetone was administered topically to the 
same area of the shaved dorsal skin with two administrations per week (Tuesday and Friday) for 
15 weeks. Fifteen weeks after this, mice were sacrificed for histopathological analysis. Mice 
were evaluated weekly for papilloma development. Only tumors that had attained a size of 1 
mm were counted. Mice with tumors larger than 1.5 cm were sacrificed considering humane 
endpoint before the end of the treatment, and analyzed histopathologically. 
1.4. Histolopathology, immunohistochemistry and in situ hybridization  
Tissue samples were fixed in 10% buffered formalin, embedded in paraffin and sectioned at a 
thickness of 2.5 mm. Consecutive sections were stained with hematoxylin and eosin (H&E) and 
processed for immunohistochemistry (IHC) performing antigen retrieval in a VENTANA 
DISCOVERY XT (Roche) with CC1 buffer and incubating them with the following three 
antibodies against NANOG: Novus Biologicals, NB100-58842 lot# 5-1 (Part I and Part II, 
Figures 26, 27, and 28), but the provider discontinued the commercialization of this antibody 
and for this reason we also used Calbiochem, SC1000 (Part I) and Cell Signaling Technology, 
D2A3, 8822 (Part II, Figures 31 and 33). Other antibodies used were: phospho-Akt1/PKBa 
(S473) (Epitomis, EP2109Y, 2118-1), AURKA (Becton Dickinson, 610938), CK5 (Covance, 
PRB-160P), CK6 (Covance, PRB-169P), E-CADHERIN (BD Biosciences, 610182), Ki67 
(Master Diagnóstica, 000310QD), LORICRIN (Covance, PRB-145P), OCT4 (Abcam, 
Ab19857), P63 (Sigma, P3737), SOX2 (Cell Signaling, 3728), phospho-Stat3 (Tyr705) (Cell 
Signaling Technology, D23A7, 9145) and VIMENTIN (Cell Signaling Technology, D21H3, 
5741). Following incubation with the primary antibodies, positive cells were visualized using 
3,3-diaminobenzidine tetrahydrochloride plus (DAB+) as a chromogen. Counterstaining was 
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performed with hematoxylin. Digital slides were acquired with a MIRAX SCAN (Zeiss), 
images captured with the Pannoramic Viewer Software (3DHISTECH) and image analysed and 
quantified with the AxioVision software (Zeiss).  
For in situ hybridization (ISH) of Nanog, mouse tissues were fixed overnight in 4% 
paraformaldehyde, embedded in paraffin, and cut in 7 !m thick sections. In situ hybridization 
was carried out as previously described (Mallo et al., 2000) using a mouse Nanog anti-sense 
probe. This probe corresponds to the complete coding region of the mouse Nanog gene 
(positions 216 to 1133 of RefSeq NM_028016) cloned as a PCR product in the pCR®II-TOPO 
cloning vector (Invitrogen). The vector was linearized with BamHI and transcribed using 
T7RNApol. Digital slides were acquired with a MIRAX SCAN (Zeiss) and images were 
captured with the Pannoramic Viewer Software (3DHISTECH). 
ISH of miR-21 was performed with a miR-21 Exiqon probe and following the manufacturers’ 
instructions (Exiqon) using the Discovery XT immunohistochemistry system (Ventana Medical 
Systems). 
2. In vitro experimentation 
2.1. Cell lines  
A detail description of cell lines used is provided in Table 2. 
Table 2. Cell lines 
 
Cell line Origin Phenotype Culture conditions Reference 
NTERA2 
Human testis malignant 
pluripotent embryonal 
carcinoma lung 
metastasis 
Human 
teratocarcinoma 
DMEM supplemented with 
glutamine 2mM; 10% fetal 
bovine serum and antibiotic-
antimycotic solution 
(Andrews et al., 
1984) 
TE1 Human ESCC Human ESCC 
DMEM supplemented with 
glutamine 2mM; 10% fetal 
bovine serum and antibiotic-
antimycotic solution 
(Nishihira et al., 
1993; Nishihira et al., 
1979) 
TE2 Human ESCC Human ESCC 
DMEM supplemented with 
glutamine 2mM; 10% fetal 
bovine serum and antibiotic-
antimycotic solution 
(Nishihira et al., 
1993; Nishihira et al., 
1979) 
TE5 Human ESCC Human ESCC 
DMEM supplemented with 
glutamine 2mM; 10% fetal 
bovine serum and antibiotic-
antimycotic solution 
(Nishihira et al., 
1993; Nishihira et al., 
1979) 
TE12 Human ESCC Human ESCC 
DMEM supplemented with 
glutamine 2mM; 10% fetal 
bovine serum and antibiotic-
antimycotic solution 
(Nishihira et al., 
1993; Nishihira et al., 
1979) 
CAL33 
Oral cavity carcinoma 
(tongue), moderately 
differentiated, 69 year-
old male 
Human HNSCC 
 
DMEM supplemented with 
glutamine 2mM; 10% fetal 
bovine serum and antibiotic-
antimycotic solution 
(Gioanni et al., 1988) 
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Cal27 
Oral cavity carcinoma 
(tongue), poorly 
differentiated. 56 year-
old male 
Human HNSCC 
 
DMEM supplemented with 
glutamine 2mM; 10% fetal 
bovine serum and antibiotic-
antimycotic solution 
(Gioanni et al., 1988) 
HN6 
Base of tongue, well to 
moderately 
differentiated. 54 year-
old male 
Human HNSCC 
 
DMEM supplemented with 
glutamine 2mM; 10% fetal 
bovine serum and antibiotic-
antimycotic solution 
(Easty et al., 1981) 
SCC2 Oral cavity SCC Human HNSCC  
DMEM supplemented with 
glutamine 2mM; 10% fetal 
bovine serum and antibiotic-
antimycotic solution 
(Grenman et al., 
1991; Krause et al., 
1981) 
SCC40 Tongue SCC Human HNSCC  
DMEM supplemented with 
glutamine 2mM; 10% fetal 
bovine serum and antibiotic-
antimycotic solution 
(Grenman et al., 
1991; Krause et al., 
1981) 
SCC38 Primary SCC of glottic larynx 
Human HNSCC 
 
DMEM supplemented with 
glutamine 2mM; 10% fetal 
bovine serum and antibiotic-
antimycotic solution 
(Grenman et al., 
1991; Krause et al., 
1981) 
SCC42B Larynx-supraglottic SCC 
Human HNSCC 
 
DMEM supplemented with 
glutamine 2mM; 10% fetal 
bovine serum and antibiotic-
antimycotic solution 
(Grenman et al., 
1991; Krause et al., 
1981) 
SCC29 Alveolus SCC Human HNSCC  
DMEM supplemented with 
glutamine 2mM; 10% fetal 
bovine serum and antibiotic-
antimycotic solution 
(Grenman et al., 
1991; Krause et al., 
1981) 
Hela Cervix carcinoma Human cervix adenocarcinoma 
DMEM supplemented with 
glutamine 2mM; 10% fetal 
bovine serum and antibiotic-
antimycotic solution 
(Gey et al., 1952) 
HepG2 Liver hepatocellular carcinoma 
Human 
hepatocellular 
carcinoma 
DMEM supplemented with 
glutamine 2mM; 10% fetal 
bovine serum and antibiotic-
antimycotic solution 
(Knowles et al., 
1980) 
MCF-7 Invasive breast ductal carcinoma 
Human breast 
adenocarcinoma 
RPMI supplemented with 
glutamine 2mM; 10% fetal 
bovine serum and antibiotic-
antimycotic solution 
(Soule et al., 1973) 
MDAMB231 
Breast carcinoma, cells 
derived from metastatic 
site: pleural effusion 
Human breast 
adenocarcinoma 
RPMI supplemented with 
glutamine 2mM; 10% fetal 
bovine serum and antibiotic-
antimycotic solution 
(Cailleau et al., 1974) 
NCI-H69 Small cell lung cancer 
Human small 
cell lung 
carcinoma 
RPMI supplemented with 
glutamine 2mM; 10% fetal 
bovine serum and antibiotic-
antimycotic solution 
(Gazdar et al., 1980) 
NCI-H727 Lung carcinoid 
Human well 
differentiated 
neuroendocrine 
cell line 
RPMI supplemented with 
glutamine 2mM; 10% fetal 
bovine serum and antibiotic-
antimycotic solution 
(Gazdar et al., 1985; 
Gazdar et al., 1988) 
A549 Lung carcinoma 
Human alveolar 
adenocarcinoma 
 
DMEM supplemented with 
glutamine 2mM; 10% fetal 
bovine serum and antibiotic-
antimycotic solution 
(Giard et al., 1973) 
U2OS Bone Human osteosarcoma 
DMEM supplemented with 
glutamine 2mM; 10% fetal 
bovine serum and antibiotic-
antimycotic solution 
(Ponten and Saksela, 
1967) 
SAOS Bone Human osteosarcoma 
DMEM supplemented with 
glutamine 2mM; 10% fetal 
bovine serum and antibiotic-
antimycotic solution 
(Ponten and Saksela, 
1967) 
HCT-116 Colon cancer Human DMEM supplemented with (Brattain et al., 1981) 
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colorectal 
carcinoma 
glutamine 2mM; 10% fetal 
bovine serum and antibiotic-
antimycotic solution 
T-24 Urinary bladder tumor 
Human 
transitional cell 
carcinoma 
DMEM supplemented with 
glutamine 2mM; 10% fetal 
bovine serum and antibiotic-
antimycotic solution 
(Bubenik et al., 1973) 
EJ138 Urinary bladder tumor 
Human 
transitional cell 
carcinoma 
DMEM supplemented with 
glutamine 2mM; 10% fetal 
bovine serum and antibiotic-
antimycotic solution 
(Lin et al., 1985) 
Hs895T Melanoma lung metastasis 
Human 
melanoma 
DMEM supplemented with 
glutamine 2mM; 10% fetal 
bovine serum and antibiotic-
antimycotic solution 
ATCC 
22Rv1 Prostatic carcinoma xenograft 
Human prostate 
carcinoma 
RPMI supplemented with 
glutamine 2mM; 10% fetal 
bovine serum and antibiotic-
antimycotic solution 
(Sramkoski et al., 
1999) 
PC3 Protstatic carcinoma bone metastasis 
Human prostate 
carcinoma 
RPMI supplemented with 
glutamine 2mM; 10% fetal 
bovine serum and antibiotic-
antimycotic solution 
(Kaighn et al., 1979) 
Du145 Protstatic carcinoma brain metastasis 
Human prostate 
carcinoma 
RPMI supplemented with 
glutamine 2mM; 10% fetal 
bovine serum and antibiotic-
antimycotic solution 
(Stone et al., 1978) 
LNCAP Protstatic carcinoma lymph node metastasis 
Human prostate 
carcinoma 
RPMI supplemented with 
glutamine 2mM; 10% fetal 
bovine serum and antibiotic-
antimycotic solution 
(Horoszewicz et al., 
1983) 
MCA3D 
Mouse primary 
keratinocytes treated 
with DMBA and Ca+2 
Mouse 
immortalized 
keratinocytes 
Ham’s F12 supplemented 
with glutamine 2mM; 10% 
fetal bovine serum and 
antibiotic-antimycotic 
solution 
(Kulesz-Martin et al., 
1983; Quintanilla et 
al., 1991) 
PDV 
Mouse primary 
keratinocytes 
transformed with 
DMBA 
Mouse 
transformed 
keratinocytes 
Ham’s F12 supplemented 
with glutamine 2mM; 10% 
fetal bovine serum and 
antibiotic-antimycotic 
solution 
(Fusenig et al., 1978; 
Quintanilla et al., 
1991) 
PB 
Mouse papilloma 
induced with 
DMBA/TPA 
Mouse 
papilloma 
Ham’s F12 supplemented 
with glutamine 2mM; 10% 
fetal bovine serum and 
antibiotic-antimycotic 
solution 
(Yuspa et al., 1986) 
MSC11B9 Mouse SCC induced with DMBA/TPA Mouse SCC 
DMEM supplemented with 
glutamine 2mM; 10% fetal 
bovine serum and antibiotic-
antimycotic solution 
(Burns et al., 1991) 
Pam212 
Mouse primary 
keratinocytes 
spontaneously 
tranformed 
Mouse 
transformed 
keratinocytes 
DMEM supplemented with 
glutamine 2mM; 10% fetal 
bovine serum and antibiotic-
antimycotic solution 
(Yuspa et al., 1980) 
CarB 
Mouse carcinoma 
induced with 
DMBA/TPA 
Mouse SpCC 
Ham’s F12 supplemented 
with glutamine 2mM; 10% 
fetal bovine serum and 
antibiotic-antimycotic 
solution 
 
(Buchmann et al., 
1991) 
 
CarC 
Mouse carcinoma 
induced with 
DMBA/TPA 
Mouse SpCC 
DMEM supplemented with 
glutamine 2mM; 10% fetal 
bovine serum and antibiotic-
antimycotic solution 
 
(Buchmann et al., 
1991) 
 
MATERIALS AND METHODS!!!
 
 56!
MSC11A5 
Mouse carcinoma 
induced with 
DMBA/TPA 
Mouse SpCC 
DMEM supplemented with 
glutamine 2mM; 10% fetal 
bovine serum and antibiotic-
antimycotic solution 
(Burns et al., 1991) 
  
Human embryonic stem cells HES2 (NIH code ES02) were grown in DMEM/F12 supplemented 
with KnockOut™ serum replacement (KSR, 20%, Invitrogen), non-essential aminoacids 
(Lonza), !-mercaptoethanol (Gibco), mouse embryonic fibroblasts (MEFs)-conditioned medium 
(5%) and b-FGF (4 ng/ml, R&D Systems #233-FB) (Grigoriadis et al., 2010).  
Mouse ESCs were grown under 3% O2 tension in DMEM (high glucose) supplemented with 
15% KnockOut™ Serum Replacement (Invitrogen), leukemia inhibitory factor (LIF) 1000 
u/ml, 2i (CHIR99021 (1 µM) and PD0325901 (1 µ"), Axon Medchem),! non-essential amino 
acids, glutamax and ß-mercaptoethanol. ESCs were routinely grown on feeder cells. For 
analyses, ESCs were adapted to gelatin-coated plates for at least 3 passages, and this was done 
in the absence of 2i. Nanog-/- (KO) ESCs (kindly provided by Ian Chambers and Austin Smith) 
carry a deletion of Nanog exons 2 and 3 and a GFP expression cassette under the control of the 
constitutively expressed CAG promoter (Chambers et al., 2007). 
For the reprogramming assays, we used MEFs containing a doxycycline-inducible cassette 
expressing the four Yamanaka factors (Abad et al., 2013) or primary human foreskin 
fibroblasts.  
2.2. Murine embryonic fibroblasts (MEFs) isolation and culture 
Primary mouse embryonic fibroblasts (MEFs) of wild-type or of the indicated genotypes (TG 
refers to transgenic, Rosa26rtTA/+;Col1a1tetO-Nanog/+; and CTR refers to control, 
Rosa26rtTA/+;Col1a1tetO-Nanog/+) were obtained from C57BL/6 mice as described previously 
(Palmero and Serrano, 2001) and cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
(Gibco) supplemented with 10% fetal bovine serum (Hyclone) and antibiotic-antimycotic 
solution (Gibco).  
2.3. Keratinocyte isolation and culture 
Primary keratinocytes were freshly isolated from wild-type C57BL/6 mice, p53-/- C57BL/6 mice 
(Jacks et al., 1994) or TG and CTR K5-Nanog-inducible C57BL/6 neonates (days 1–3 post-
partum). After dispase (STEMCELL Technologies) treatment the epidermis was separated from 
the dermis, minced and stirred. The derived cell suspension was then filtered through a sterile 
teflon mesh (Cell Strainer 0.7 !m, Falcon) to remove cornified sheets and keratinocytes were 
collected by centrifugation (160 g) and seeded on collagen I pre-coated cell culture plates (BD 
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Biosciences). Keratinocytes were cultured in Cnt-07 (CELLnTEC) medium supplemented with 
antibiotic-antimycotic solution (Gibco). Transgene activation was done by adding doxycycline 
to the medium (1 !g/ml) and changing the medium every 2-3 days.  
2.4. Reprogramming of murine cells 
MEFs were obtained from an inducible reprogrammable mouse generated in our laboratory that 
contains a polycistronic cassette with transcription factors Oct4, Sox2, Klf4 and cMyc (OSKM) 
under the control of the tetO element (tetO-OSKM), as well as, the reverse tetracycline 
transactivator in the Rosa26 locus (Rosa26::rtTA) (Abad et al., 2013). Passage 1 MEFs grown 
in DMEM/10%FBS were plated one day prior to infection (2x105 cells per well in 6 well gelatin 
coated plates). MEFs were infected with Nanog/NANOG expressing constructs pMXs-mNanog 
(Addgene plasmid #13354), (Takahashi and Yamanaka, 2006) pMXs-NANOG1K82 (Addgene 
plasmid #18115), (Lowry et al., 2008) site-directed mutated pMXs-NANOG1K82 (as described 
in the main text), pMXs-NANOGP8 (generated from pMXs-NANOG1K82 by triple site-directed 
mutagenesis) or with pMXs-empty (produced by excising NANOG1 by EcoRI restriction and 
re-ligation). 48 hr after the first round of infection, medium was changed to iPSC medium 
(DMEM (high glucose) supplemented with serum replacement (KSR, 15%, Invitrogen), LIF 
(1,000 U/ml), non-essential amino acids, glutamax and !-mercaptoethanol), with doxycycline (1 
!g/ml) to activate expression of OSKM. Three days after doxycycline addition (or when 
indicated), we supplemented the medium with inhibitors CHIR99021 (1 !M) and PD0325901 
(1 !M) (Axon Medchem). Medium was changed every 36 hr, always in the presence of 
doxycycline and the two inhibitors. Colonies were scored at day 14. 
2.5. Reprogramming of human cells 
Reprogramming of primary human foreskin fibroblasts was done as previously described. 
(Takahashi et al., 2007) Retroviral supernatants were produced in HEK-293T cells grown in 
DMEM supplemented with 10% fetal bovine serum (DMEM/10%FBS) (5x106 cells per 100 
mm diameter dish) transfected with the ectopic packaging plasmid pCL-Ampho (4 !g) and each 
of the following retroviral constructs (4 !g): pMXs-KLF4 (Addgene plasmid # 17219), pMXs-
SOX2 (Addgene plasmid #17218), pMXs-OCT4 (Addgene plasmid #17217)(Takahashi et al., 
2007)), and the NANOG expressing constructs described above (see “Reprogramming of 
murine cells” section). Transfections were performed using Fugene HD transfection reagent 
(Promega) according to the manufacturer’s protocol. Two days later, retroviral supernatants 
were collected serially during the subsequent 48 hr, at 12 h intervals, each time adding fresh 
medium to the cells (10 ml). Primary fibroblasts grown in DMEM/10%FBS had been seeded 
the previous day of infection (2x105 cells per well in 6-well gelatin coated plates) and received 
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1 ml of each corresponding retroviral supernatant (three factors, OCT4, SOX2, KLF4, and the 
fourth factor corresponding to the NANOG constructs or empty control vector). This procedure 
was repeated every 12 hr for 2 days (total of 4 additions). The day after infection was 
completed, medium was replaced by DMEM/10%FBS, and kept for three more days. At day 5, 
cells were trypsinized and reseeded on feeder plates. At day 6, medium was changed to human 
ES cell medium (see above under “Cell lines” section). 70% of the medium was replaced daily 
with fresh medium until colonies were visible and stained for alkaline phosphatase at day 28. 
2.6. Knockdown assays 
2.6.1. NANOG silencing assays using shRNAs 
Lentiviruses containing pLKO.1- scramble shRNA (SCR), and pLKO.1-NANOG-shRNA 
vectors (TRCN000004885, TRCN000004886 and TRCN000004887) obtained from Open 
Biosystems (Thermo Scientific Open Biosystems) were produced in 293T cells using the 
lentivirus packaging plasmids pLP1, pLP2 and pLP/VSVG (Invitrogen), by cotransfecting all 
plasmids using Fugene HD transfection reagent (Promega) according to the manufacturer’s 
protocol. Cells were plated the day prior to infection, and supernatants were collected 48 hr 
from 293T cells after transfection. Cell lines SCC38, SCC42B, MCF7, NCI-H727 and 22Rv1 
were infected concomitantly with all three lentiviruses that target NANOG to obtain a synergic 
silencing effect. Cells were selected with puromycin to obtain stable shNANOG cell lines.  
2.6.2. NANOG silencing assays using siRNAs 
For NANOG silencing, TE2 human esophageal cancer cells were transfected with a pool of four 
siRNA duplexes targeting NANOG (ON-TARGETplus Human NANOG (79923) siRNA, 
SMARTpool, Dharmacon) or with a pool of scramble siRNA duplexes (ON-TARGETplus Non-
targeting Control Pool, SMARTpool, Dharmacon) using Lipofectamine RNAiMAX in Opti-
MEM I (Invitrogen) according to the manufacturer’s instructions. Cells were processed for 
RNA extraction 48 hr after transfection. 
2.7. NANOG overexpression assays 
For human NANOG overexpression, HaCat cells were infected with lentiviruses expressing 
NANOG1 pSin-EF2-Nanog-Pur (Addgene plasmid #16578) (Yu et al., 2007) and with control 
empty vector pSin-EF2-empty-Pur (produced by excising NANOG1 by BamHI restriction and 
re-ligation). Lentiviruses were produced in 293T cells using the lentivirus packaging plasmids 
pLP1, pLP2 and pLP/VSVG (Invitrogen), by cotransfecting all plasmids using Fugene HD 
transfection reagent (Promega) according to the manufacturer’s protocol. Cells were plated the 
day prior to infection, and supernatants were collected 48 hr from 293T cells after transfection. 
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HaCat cells were infected with the lentiviruses and were selected with puromycin to obtain 
stable HaCat/NANOG1 or HaCat/EV cells.  
For murine NANOG overexpression, murine transformed keratinocyte cell line PB was 
transfected with the mouse NANOG expressing plasmid pPyCAG-Nanog-IP (Addgene plasmid 
# 13838) using Fugene HD transfection reagent (Promega) according to the manufacturer’s 
protocol. Cells were processed for RNA extraction 72 hr after transfection. 
2.8. Cell proliferation and cell cycle profiling assay 
For proliferation and cell cycle assays of HNSCC cell lines, cells were transfected and selected 
with shRNAs (SCR or NANOG), or treated for 48 hr with MLN8237 (1 !mol/l) or vehicle 
(DMSO) and pulsed for 1h with 10!M of EdU (5-ethynyl-2'-deoxyuridine). After EdU pulse, 
cells were collected, fixed in 4% PFA and processed following the Click-iT protocol 
(Invitrogen), we used EdU Alexa Fluor-488 and Hoechst 33342 (1 !g/ml) to analyze cell cycle 
phase. Samples were run in a BD FACSCanto II (Becton Dickinson, San Jose CA) equipped 
with a 488 nm and 407 nm lines, we used pulse processing to collect at least 10,000 single 
events. All data was analyzed using FlowJo v9.7.5 (Treestar, Oregon). 
A crystal violet assay was used to assess cell proliferation of HaCat infected cells. HaCat/EV 
and HaCat/NANOG1 cells were seeded in quadruplicate in 96-well cell culture plates. At each 
time point, the cells were washed with PBS, fixed in 1% glutaraldehyde, and stained with 0.5% 
crystal violet (Sigma) dissolved in methanol. The dye that stained the cells on the plates was 
eluted with 10% acetic acid and directly measured with the use of a spectrophotometer 
microplate reader (BioRad) at a wavelength of 590 nm. Cell number was expressed as the 
optical density at 590 nm.  
2.9. Migration assays 
For the in vitro migration assay, starved cells were pretreated with 10!g/ml mitomycin C for 
2hr to block proliferation and a cell-free area was created by scratching the monolayer with a 
200!l pipette tip. Cell migration into the wound area was monitored in serum-free medium or in 
the presence of chemoattractants 10% FBS. Photographs were taken using a phase-contrast 
microscope (DIAPHOT 300; Nikon). Keratinocyte migration into the denuded area was 
monitored for up to 24hr. Quantification of migration was done using using ImageJ software. 
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2.10. Immunofluorescence 
Cells were plated in chambers and fixed in 4% paraformaldehyde for 10 min. Sections were 
blocked with 1% FBS for 1 hr at r.t., and then incubated for 2 hr at r.t. with N-terminal NANOG 
(Cell Signaling XP) and C-terminal NANOG (R&D AF1997) in Dako Antibody Diluent with 
Background Reducing Components. After washing (3 times with PBS 0.1% Triton X-100), 
slides were then stained with donkey anti-rabbit AlexaFluor555-conjugated secondary antibody 
for Cterminal NANOG and with goat anti-mouse AlexaFluor488-conjugated secondary 
antibody for Nterminal NANOG (both secondary antibodies from Invitrogen) in Dako REALTM 
buffer, 1 hr at r.t., followed by 4’,6-Diamidino-2-phenylindole (DAPI) staining to visualize the 
nuclei. For NTERA2 cells, additional staining was performed with HCS CellMask™ Deep Red 
stain (Invitrogen, H32721) to view cell morphology. Slides were mounted with Vectashield 
antifade medium (Vector Laboratories) before confocal analysis. Confocal microscopy was 
performed with a TCS SP5 laser scanning spectral microscope (Leica Microsystems) equipped 
with a Plan-Apochromat 40x/1.2 NA oil objective. 8-bits images were acquired using the Leica 
LAS AF v.2.1 software (Leica Microsystems). The pictures show the maximum projection of Z-
stacks.  
2.11. Reprogramming efficiency 
For quantification of iPSC generation efficiency the total number of iPSC colonies was counted 
after staining plates for alkaline phosphatase activity (AB0300 Sigma Alkaline Phosphatase 
Blue Membrane Substrate Solution and SCR004 AP Detection Kit Chemicon) following the 
manufacturer’s instructions. 
3. Biochemical assays 
3.1. Multi-Nanog PCR and cloning 
Total RNA was obtained using RNeasy Mini Kit (Qiagen) following the manufacturer´s 
instructions. Samples were treated with DNase I (Qiagen) before reverse transcription. Total 
RNA (5 !g) preparations were treated with “Ready-to-go you-prime first-strand beads” (GE 
Healthcare) to generate cDNA according to the manufacturer's protocol. Control reactions 
without reverse transcriptase (-RT) were carried out to exclude DNA contaminations. PCR 
primers were as follows: 
multi-NANOG PCR:  
 multiNANOG-F1, 5’-GACGAGGTCCTGGTCAAG-3’ 
 multiNANOG-F2, 5’- ATCCTGAATCTTAGCTACAAACAG -3’ 
MATERIALS AND METHODS!!!
 
 61!
 multiNANOG-R, 5’- GTTGCTCTGCATTGGAAGG -3’  
These primers were selected to amplify all NANOG paralogs except NANOGP6 and NANOGP7, 
which were considered too divergent from the rest (see Figure 43). The primers were chosen 
based on their Tm values relative to all the NANOG paralogs under consideration, and their GC 
content. 
Two separate multi-NANOG PCR reactions were performed for each cDNA sample: primers F1 
and R; or primers F2 and R. The resulting PCR products were gel purified and then ligated into 
pGEM-T vector (Promega), transformed into DH!5 E. coli, and individual clones were 
sequenced. 
3.2. RNA extraction, cDNA synthesis and qRT-PCR 
In the case of cultured cells and tissues, total RNA was obtained using RNeasy Mini Kit 
(Qiagen) following the manufacturer’s instructions. In the case miRNA analysis, total RNA was 
obtained from tissues using the miRNeasy Mini Kit (Qiagen) following the manufacturer’s 
instructions. To generate cDNA, total RNA was reverse transcribed using iScript Advanced 
First Strand cDNA synthesis kit (BioRad), according to the manufacturer’s protocols. 
Quantitative real-time PCR (qRT-PCR) was performed using Master SYBR Green I mix 
(Invitrogen) or GoTaq qPCR Master Mix (Promega) in an ABI PRISM 7700 thermocycler 
(Applied Biosystems). Calculation for the values was according to the !!Ct method (Yuan et 
al., 2006) and using Gapdh/GAPDH as control.  
TaqMan® MicroRNA Assays (Applied Biosystems) were used to quantify miRNAs in samples 
according to the manufacturer instructions with the TaqMan® Universal PCR Master Mix 
reagent kit (Applied Biosystems). Normalization was performed using U6 as housekeeping 
small RNA. qRT-PCR for miRNA was performed in an ABI 7500fast Real-Time PCR System. 
Primer sets for quantitative real-time PCR   
PCR primers for mouse transcripts were as follows: 
Primer Sequence 5’ !  3' 
fw CAAGGGTCTGCTACTGAGATGCTCTG 
mNanog total 
rev TTTTGTTTGGGACTGGTAGAAGAATCAG 
fw GCTGGCAAGACAACGTGAAAG 
mZeb1 
rev GCCTCAGGATAAATGACGGC 
fw CAGGCTCGGAGACAGATGAAG 
mZeb2 
rev CTTGCAGAATCTCGCCACTG 
mVimentin fw CCACTTTCCGTTCAAGGTCAAG 
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 rev CGGCTGCGAGAGAAATTGC 
fw CTGATAGCCCGGTTTCACTTG 
mN-cadherin 
rev CAGGCTTTGATCCCTCTGGA 
fw ACGCTGCCCTCGGACAA 
mTwist1 
rev CCTGGCCGCCAGTTTG 
fw CTTCCCTCGCCATCACACT 
endogenous mNanog 
rev ACAGTCCGCATCTTCTGCTTC 
fw TTCACCACCATGGAGAAGGC 
mGapdh 
rev CCCTTTTGGCTCCACCCT 
fw TTTGAGCGGACACATTACCC 
mPrrx1 
rev GCTCATTCCTGCGGAACTT 
fw GCCAGACATTGACCCTGTTC 
mPdgfra 
rev TCTCGATGGCACTCTCTTCC 
fw GCACTCAGGAGAAGGAGCAG 
mKrt18 
rev CAACAGGCTCCACTTGGTCT 
fw TGTCTTTGGCAGGGTGATG 
mWnt5a 
rev AGCCACAGGTAGACAGCTCG 
fw AACTGCTTTCCTGATTGGCA 
mVcan 
rev GATAACAGGTGCCTCCGTTG 
fw CCATGTCAGTGTGCAGATTC 
mLrg1 
rev AAGAGTGAGAGGTGGAAGAG 
fw CTTGACATCCCAAAGCCAGT 
mPlet1 
rev GACTTTGAGGCTGTGCGATT 
fw ATGTGCAGCCTGGGAACTAC 
mLoxl1 
rev TCACCACGTTGTTGGTGAAG 
fw GAACAGAAGCATTCTAGGCTGG 
mH19 
rev TTCTAAGTGAATTACGGTGGGTG 
fw ACATCCTGGTGGGGGAATAC 
mSrc2 
rev CTGTCCACTTGATGGGGAAC 
fw CGTGTGGACCAACCTTACG 
mPecam1 
rev AAGCCATTCTTGCACAGCTC 
fw TGTGGCTGCTCATCCTCTTTA 
mCxcl12 
rev ACAACCTGGTCCAACTCAGC 
fw AGCTTGTGGAGCTTTAGATGC 
mE-cadherin 
rev TTTTCGGAAGACTCCCGATTCA 
fw TTGGCCATGGTTGGATACTT 
mCdc20 
rev GAGTGCTGTGGATGTGCATT 
fw TTCAACTCTCCGTTTGAGCC 
mAurka 
rev CCAAGTTTGACGAGCAGAGA 
fw TTCCGTAGGACTCTCTGGGA 
mAurkb 
rev TCGCTGTTGTTTCCCTCTCT 
fw TCTTCCTGTCGGTCCAACTC 
mKif20a 
rev TGTCCGAAAGGACCTGTTGT 
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fw CCACACATCCAGAGGGTCAT 
mBub1b 
rev TCATGTCCACACTTCAGGGA 
 
PCR primers for human transcripts were as follows: 
Primer Sequence 5’ !  3' 
fw TTCATTATAAATCTAGAGACTCCAGGA 
hEndogenous NANOG1 
rev CTTTGGGACTGGTGGAAGAATC 
fw CACTTCTGCAGAGAAGAGTGTCG 
hNANOG1/P8 
rev AGCTGGGTGGAAGAGAACACAG 
fw CCGGAGACCTAGATGTCATTG 
hTWIST1 
rev CACGCCCTGTTTCTTTGAAT 
fw GATGATGAATGCGAGTCAGATGC 
hZEB1 
rev ACAGCAGTGTCTTGTTGTTGT 
fw CAAGAGGCGCAAACAAGCC 
hZEB2 
rev GGTTGGCAATACCGTCATCC 
fw CGAGCTGCAGGACTCTAAT 
hSNAIL 
rev CCACTGTCCTCATCTGACA 
fw GAGCCAACGTCAAGCATCTC 
hCXCL12 
rev TCCACTTTAGCTTCGGGTCA 
fw AACATCAGTCAGCTGCTCCC 
hLGR5 
rev TGTAAAGGCCAGTGAATGCTC 
fw GGGAAATGGGAGGGGTGCAAAAGAGG 
hSOX2 
rev TTGCGTGAGTGTGGATGGGATTGGTG 
fw AGGTGGAACTGCAGCACTGT 
hWNT5A 
rev CTCATGGCGTTCACCACC 
fw TATGTGCAGAGAGCCCACCT 
hLOXL1 
rev GTAGCACCCGCACATCGTAG 
fw GAGGAGTCAGTGAAGGAGTCA 
hN-CADHERIN 
rev GGCAAGTTGATTGGAGGGATG 
fw CAGACTCAATTTAGTGAGCC 
h!Np63 
rev CTGCTGGTCCATGCTGTT 
fw AGCCACATCGCTCAGACACC 
hGAPDH 
rev GTACTCAGCGGCCAGCATGG 
fw GAGGTCCAAAACGTGTTCTCG 
hAURKA 
rev ACAGGATGAGGTACACTGGTTG 
fw CAGTGGGACACCCGACATC 
hAURKB 
rev GTACACGTTTCCAAACTTGCC 
fw ATGCAACCTGAAGACGTGTGA 
retroviralNANOG1/P8 
rev CCCTTTTTCTGGAGACTAAATAAA 
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3.3. Site-directed mutagenesis 
The plasmid pMXs-NANOG was obtained from Addgene (Addgene plasmid #18115). (Lowry 
et al., 2008) To obtain the different NANOG variants, site-directed mutagenesis was performed 
using the QuikChange™ Site-Directed Mutagenesis Kit (Agilent) following protocols provided 
by the manufacturer. Mutations were confirmed by Sanger sequencing of the entire NANOG1 
open reading frame. 
3.4. Protein extraction and immunoblots 
Nuclear protein extracts were prepared using the Nuclear/Cytosol Fractionation kit (K266-100, 
BioVision) following protocols provided by the manufacturer. Total lysates were prepared using 
lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 4 mM CaCl, 1.5% Triton X-100, protease 
inhibitors and micrococcal nuclease). In the case of tissue extracts, lysates were homogenized 
using a Precellys 24 tissue homogenizer. For mouse NANOG detection, we used two different 
antibodies: Novus Biologicals, NB100-58842 lot# 5-1 or Calbiochem, SC1000. For human 
NANOG detection, we used Cell Signaling, D73G4XP (N-terminal detecting) or R&D Systems, 
AF1997 (C-terminal detecting). Other antibodies used were: !-tubulin (Sigma, GTU-88), FLAG 
(FLAG M2, F1804, Sigma Aldrich), GAPDH (Sigma, G8795), phospho-p44/42 MAPK 
(Erk1/2) (Thr202/Tyr204) (Cell Signaling, 9101), p53 (Leica, NCL-P53-CM5P), histone H3 
(Abcam, Ab1791), AURKA (IAK1, BD Biosciences, 610938), p63 (4A4, Novus Biologicals, 
NB100-691) and SMC1 (Bethyl, A300-055A). 
3.5. Gene expression profiling 
3.5.1. Microarray 
Total RNA was extracted from esophagus using RNeasy Fibrous Tissue Mini Kit (Qiagen), and 
from liver by combining an initial lysis with Trizol (Invitrogen) with a clean-up with RNeasy 
Kit (Qiagen). Total RNA was labelled with the One-Color Microarray-Based Gene Expression 
Analysis (Quick Amp Labeling) kit (Agilent). Samples were hybridized to Whole Mouse 
Genome 4x44K microarrays (Agilent) by following the manufacturer’s instructions. 
Microarrays were scanned on a G2565C DNA microarray scanner (Agilent) and images were 
analyzed with Feature Extraction Software (version 10.1.1). The raw data has been deposited in 
the GEO repository (accession number GSE48370). Microarray background subtraction was 
carried out using normexp method. To normalize the dataset, we performed loess within arrays 
normalization and quantiles between arrays normalization. Gene set enrichment analysis 
(Subramanian et al., 2005) was applied using annotations from Reactome. Genes were ranked 
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based on limma moderated t statistic. After Kolmogorov-Smirnoff test, only those gene sets 
showing FDR<0.05 were considered enriched between classes under comparison.  
3.5.2. RNA-seq 
Total RNA was extracted from papillomas using RNeasy Fibrous Tissue Mini Kit (Qiagen). 
1!"g of total RNA, with RIN (RNA integrity number) numbers above 7 (Agilent 2100 
Bioanalyzer), were used. PolyA+ fractions were processed using TruSeq Stranded mRNA 
Sample Preparation Kit (Agilent). The resulting directional cDNA libraries were sequenced for 
40 bases in a single-read format (Genome Analyzer IIx, Illumina). The complete set of reads has 
been deposited in the GEO repository (accession number GSE56566). Reads were aligned to the 
mouse genome (GRCm38/mm10) with TopHat-2.0.4 (Trapnell et al., 2012) (using Bowtie 
0.12.7 (Langmead et al., 2009) and Samtools 0.1.16 (Li et al., 2009); allowing two mismatches 
and five multihits. Transcripts assembly, estimation of their abundances and differential 
expression were calculated with Cufflinks 1.3.0 -(Trapnell et al., 2012), using the mouse 
genome annotation data set GRCm38/mm10 from the UCSC Genome Browser (Karolchik et 
al., 2014).  
GSEAPreranked was used to perform a gene set enrichment analysis of the published EMT and 
CSC pathways. We used the RNA-seq gene list ranked by statistic, setting 'gene set' as the 
permutation method and we run it with 1000 permutations. We considered only those gene sets 
with significant enrichement levels (FDRq-value < 0.25) (Subramanian et al., 2005). 
3.6. Chromatin immunoprecipitation 
For human ChIP, NTERA2 and TE2 cells were crosslinked with 1% formaldehyde for 15 min at 
r.t.. Crosslinking was stopped by the addition of glycine to a final concentration of 0.125 M. 
Fixed cells were lysed in lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.0 and 
protease inhibitors) and sonicated. As input, 80 "g of protein extract were reserved. For 
immunoprecipitation, 800 "g of protein were diluted in dilution buffer (1.1% Triton X-100, 
0.01% SDS, 1.2 mM EDTA, 167 mM NaCl and 16.7mM Tris-HCl, pH 8.0 and protease 
inhibitors), pre-cleared with A/G plus-agarose pre-blocked with BSA (Santa Cruz) and 
incubated with an antibody against mouse NANOG (R&D Biosystems AF1997) or goat IgG 
isotype (Jackson ImmunoResearch, 005-000-003). Immune complexes were precipitated with 
A/G plus-agarose pre-blocked with BSA and washed sequentially with low-salt immune 
complex wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-
HCl pH 8.0), high-salt immune complex wash buffer (0.1% SDS, 1% Triton X-100, 2 mM 
EDTA, 500 mM NaCl, 20 mM Tris-HCl, pH 8.0), LiCl immune complex wash buffer (0.25 M 
LiCl, 1% NP-40, 1% deoxycholate-Na, 1 mM EDTA, 10 mM Tris-HCl, pH 8.0), and TE buffer 
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(1 mM EDTA, 10mM Tris-HCl pH 8.0), and finally eluted in elution buffer (1% SDS, 50mM 
NaHCO3). All samples, including inputs, were subjected to reverse crosslinking, treated with 
proteinase K and DNase-free RNase, and DNA was extracted with QIAGEN PCR purification 
column (Qiagen) and resuspended in TE buffer. qPCR was performed in triplicate (technical 
replicates) in two independent experiments. Negative control corresponds to a genomic region 
that does not bind NANOG, as a positive control we have used the NANOG promoter, since 
NANOG is known to bind to its own promoter (Gifford et al., 2013).  
For mouse ChIP, wild-type and Nanog-/- ESCs and p53-/- keratinocytes were crosslinked with 
1% formaldehyde for 15 min at r.t.. Crosslinking was stopped by the addition of glycine to a 
final concentration of 0.125 M. Fixed cells were lysed in lysis buffer (1% SDS, 10 mM EDTA, 
50 mM Tris-HCl, pH 8.0 and protease inhibitors) and sonicated. As input, 60 !g of protein 
extract were reserved. For immunoprecipitation, 600 !g of protein were diluted in dilution 
buffer (1.1% Triton X-100, 0.01% SDS, 1.2 mM EDTA, 167 mM NaCl and 16.7mM Tris-HCl, 
pH 8.0 and protease inhibitors), pre-cleared with A/G plus-agarose pre-blocked with BSA 
(Santa Cruz) and incubated with an antibody against mouse NANOG (Novus Biologicals, 
NB100-58842 lot# 5-1) or rabbit IgG isotype (Jackson ImmunoResearch, 011-000-003). 
Immune complexes were precipitated with A/G plus-agarose pre-blocked with BSA and washed 
sequentially with low-salt immune complex wash buffer (0.1% SDS, 1% Triton X-100, 2 mM 
EDTA, 150 mM NaCl, 20 mM Tris-HCl pH 8.0), high-salt immune complex wash buffer 
(0.1% SDS, 1% Triton X-100, 2 mM EDTA, 500 mM NaCl, 20 mM Tris-HCl, pH 8.0), LiCl 
immune complex wash buffer (0.25 M LiCl, 1% NP-40, 1% deoxycholate-Na, 1 mM EDTA, 
10 mM Tris-HCl, pH 8.0), and TE buffer (1 mM EDTA, 10mM Tris-HCl pH 8.0), and finally 
eluted in elution buffer (1% SDS, 50mM NaHCO3). All samples, including inputs, were 
subjected to reverse crosslinking, treated with proteinase K and DNase-free RNase, and DNA 
was extracted with QIAGEN PCR purification column (Qiagen) and resuspended in TE buffer. 
Primer sets for PCR after ChIP: 
Primer Sequence 5’ !  3' 
fw TTGTGTAGCACCAGGGTCA Nanog 
 negative control rev GCCTGGCCTGCAAATTATTA 
fw TCCGGCACAGGAAGTTAGTT 
hNANOG promoter 
rev AGACTCACCACCAGCAGCTT 
fw AGACTGACCACTGGATGCTTTTG 
hPRRX1 promoter 
rev GAAAAGCACATGGGAACCTGTC 
fw GGTGCCGTATGCAAATGGTT 
hPDGFRa promoter 
rev CTTTGTCATGCAGAGTACCTCGATT 
hTWIST1 promoter fw CTGCACATAAGGTCCGCTCAT 
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 rev GGGCGCTTTGCTCAATTA 
fw GCTGATTACCATGAGAAAGGCTGT 
hZEB2 promoter 
rev GAGATTGACAGTCGCGTGGAG 
fw TCCCCCAACATTCTTGCTCTT 
hCXCL12 promoter 
rev GGCTTCAGTGTTTTCAGGATGG 
fw TGGCTGAGCTCGAATTCTTTTC 
hLGR5 promoter 
rev CCATCAGTAGGAATGCACTGTGAG 
fw CTGGGGGTGAAAAACCACAA 
hPITX2 promoter 
rev CCAATCAAATCTGCAGCTCACTT 
fw GTTATGCTGAAACTGGGCTGCT 
hmiR-21 promoter 
rev CAAACCAAGAAATCCCCAGGTAG 
fw CAGAGGGGAGACAAAAGAGGAA 
mAurka-promoter 
rev TTAGCATGAGGCCAAGCAGA 
fw TCTGAGAGTTCAGCATGGGAAG 
mAurka-intronic 
rev TGACTACAAAGGGCAGAGGTACTG 
fw CTCTCGTCCTAGCCCTTCCT 
mOct4-promoter 
rev CCTCCACTCTGTCATGCTCA 
3.7. Co-immunoprecipitation 
For overexpression studies, U2OS cells were transfected with pSin-EF2-Nanog-Pur (Addgene 
plasmid #16578) (Yu et al., 2007) and/or deltaNp63alpha-FLAG (Addgene plasmid #26979) 
(Chatterjee et al., 2008) using the Lipofectamine® LTX Reagent (Invitrogen) according to the 
manufacturer’s protocol. Two days later cells were lysed in lysis buffer (1% Triton, 150 mM 
NaCl, 1 mM EDTA, 50 mM Tris-HCl, pH 7.4 and protease inhibitors) and sonicated. As input, 
25 !g of protein extract were reserved. For immunoprecipitation, 500 !g of protein were pre-
cleared with protein A/G UltraLink Resin (Thermo Fisher Scientific #53132) and incubated 
with an antibody against FLAG (FLAG M2, F1804, Sigma Aldrich) or NANOG C-terminal 
detecting antibody (AF1997, R&D Systems). Immune complexes were precipitated with A/G 
UltraLink Resin (Thermo Fisher Scientific #53132) and washed sequentially with lysis buffer. 
Bound immunoreactive proteins were then eluted at 95 °C for 5 min with 20 µl of 1 x Laemmli 
loading buffer in the presence of 20% "-mercaptoethanol using SigmaPrep columns (Sigma 
Aldrich). Twenty µl of sample was loaded per lane, and immunoblotting studies were performed 
as described previously. 
For endogenous detection, TE12 cells were grown and processed as above. For 
immunoprecipitation, 5 mg were pre-cleared with protein A/G UltraLink Resin (Thermo Fisher 
Scientific #53132) and incubated with an antibody against NANOG N-terminal detecting 
antibody (Cell Signaling Technology, D73G4XP) or rabbit IgG iaotype (Jackson 
ImmunoResearch, 011-000-003). Immune complexes and elution was done as mentioned above.  
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4. Analysis of human cancers 
Esophageal and head and neck squamous cell carcinomas were collected and handled 
anonymously at collaborating institutions (University College London Hospital and Hospital 
Clinic of Barcelona) with the approval of their institutional review boards and following 
standard ethical and legal protection guidelines regarding human subjects, including informed 
consent for all the subjects. The head and neck squamous cell carcinoma tissue array (n=46) 
was constructed at the Spanish National Cancer Research Centre and included 2 to 4 cylinders 
for each patient tumour. Consecutive paraffin sections were processed for 
immunohistochemistry performing antigen retrieval in a Leica Bond III (Leica) and incubating 
them with antibodies against human NANOG (Cell Signaling, D73G4). Following incubation 
with the primary antibodies, positive cells were visualized using 3,3-diaminobenzidine 
tetrahydrochloride plus (DAB+) as a chromogen. Counterstaining was performed with 
hematoxylin. Digital slides were acquired with a MIRAX SCAN (Zeiss), images captured with 
the Pannoramic Viewer Software (3DHISTECH). Slides were scored by a trained pathologist. 
Statistical analyses were performed using the SPSS statistical package (version 18.0). 
5. Statistical analysis 
Values were expressed as mean!±!SD or mean !±!s.e.m and differences with P value <0.05 were 
considered significant ((*) P<0.05, (**) P<0.01, (***) P<0.001). Comparisons between two 
groups were performed using unpaired two-tailed Student’s t-test. For survival curves, we used 
the Long-rank  (Mantel-Cox) test. Time courses were analyzed by two-way analysis of variance 
(ANOVA). These statistical analyses were performed using GraphPad Prism software.  
RESULTS 

PART I  
Role of NANOG in adult tissues 
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The results reported in this part I have been obtained in close collaboration with Daniela 
Piazzolla (CNIO). Other collaborators who have contributed to specific parts are mentioned in 
the text.  
1.1. NANOG expression in stratified epithelia 
Our first approach was to analyze if NANOG expression was detectable in adult tissues. We 
performed the analysis in the C57BL/6 mouse strain, which does not contain Nanog 
pseudogenes that could give rise to protein (Booth and Holland, 2004; Robertson et al., 2006). 
NANOG immunohistochemical staining was carried out in a wide range of tissues. Our 
observations show that NANOG is being expressed in the basal layer of stratified epithelia in 
adult tissues, including the esophagus, forestomach, skin, tongue, vagina, urinary bladder and 
urothelium, as well as in the myoepithelial layer of the mammary gland and prostate (Figure 
10A). Expression was not detected in the liver, lung, skeletal muscle, heart, intestine kidney, 
testis and brain (Figure 10B). To confirm these results, the group of Miguel Manzanares 
(CNIC, Madrid) detected the presence of Nanog transcripts by in situ hybridization with a 
Nanog probe in the epithelial layers of the esophagus, forestomach and skin. As a control, 
expression was not present in liver (Figure 10A and 10B).  
Figure 10. NANOG expression in mouse adult tissues 
(A) Hematoxylin and eosin (H&E) staining, immunohistochemistry (IHC) for NANOG, and in situ hybridization (ISH) using a 
Nanog RNA probe of the indicated mouse adult tissues. 
(B) IHC of NANOG in the indicated adult tissues. Negative tissues: lung, skeletal muscle, heart and small intestine. In the case of 
kidney, cortex and medulla are negative (upper part of the panel) and the urothelium is positive (lower part of the panel). 
Positive tissues: tongue (dorsal, upper part; ventral, lower part), vagina, urinary bladder, mammary gland and prostate.  
Bars correspond to 50 !m. Two magnifications are shown for each tissue. All samples derive from the C57BL/6 strain.  
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We decided to compare our results with those of SOX2 and OCT4, which are known partners of 
NANOG in ESCs (Boyer et al., 2005). As expected, OCT4 was absent in stratified epithelia and 
liver, and SOX2 was present in esophagus and forestomach, but weak in skin (Figure 11A) 
(Arnold et al., 2011; Lengner et al., 2007). NANOG and SOX2 coincide with the expression 
pattern of the basal progenitor cell marker P63 (Figure 11A).  
Additionally, immunoblots of total lysates from tissues corroborated NANOG expression in 
esophagus and forestomach, but not in liver or muscle (Figure 11B). To confirm the antibody’s 
specificity, we used wild-type ESCs (WT) and Nanog knock-out ESCs (KO) (Chambers et al., 
2007). Of note, NANOG levels in adult tissues are lower than in ESCs (Figure 11C), this is 
also relative because the basal layer of the epithelia accounts only for a fraction of the tissue. 
Adult tissues also seem to have different electrophoretic mobility, shown by two distinct bands 
in the immunoblots. This could be explained by the previously described isoforms or post-
translational modifications of NANOG (Saunders et al., 2013).  
 
Figure 11. NANOG expression in epithelial tissues 
(A) IHC for NANOG, SOX2, OCT4 and P63 of the indicated adult tissues. Stomach corresponds to forestomach. 
(B) Immunoblot of NANOG extracts from the indicated tissues. Extracts from wild-type (WT) and Nanog knock-out (KO) ESCs 
are included as positive and negative controls. GAPDH was used as loading controls. Eso, esophagus; Fs, forestomach; Liv, 
liver; Mu, muscle.  
(C) Immunoblot of NANOG in forestomach (Fs) extracts compared to extracts from WT and Nanog-KO (KO) ESCs. Different 
amounts of protein were loaded as indicated. !-TUB is used as a loading control. 
Bars correspond to 50 !m. Two magnifications are shown for each tissue. All samples derive from the C57BL/6 strain.  
 
Finally, we wondered about the epigenetic status of the Nanog promoter in NANOG-positive 
epithelia. In particular, the differentially methylated region (DMR) of Nanog is hypomethylated 
in pluripotent cells, such as ESCs, but it is heavily methylated in differentiated cells and in adult 
tissues, such as brain and testis, that do not express Nanog (Blelloch et al., 2006; Hattori et al., 
2007; Imamura et al., 2006; Wernig et al., 2007). To investigate the DNA methylation status of 
the Nanog promoter in stratified epithelia, with the help of María Lozano (CNIO) we 
microdissected the NANOG-positive basal layer of esophagus and forestomach, as well as the 
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underlying NANOG-negative muscular layers. The extracted DNA was analyzed by the group 
of Mario F. Fraga (IUOPA, Universidad de Oviedo, Asturias). Briefly, DNA was treated with 
bisulphite and directly subjected to pyrosequencing. We focused on two central CpG residues of 
the Nanog DMR core region (Figure 12A). Importantly, similarly to ESCs, Nanog promoter 
was essentially devoid of methylation in the basal epithelial layers of esophagus and 
forestomach, whereas their respective adjoining muscular layers were methylated to the same 
extent as liver or fibroblasts (Figure 12B).  
Figure 12. Methylation of the Nanog promoter region in adult epithelia  
(A) Scheme of the promoter region of the Nanog gene. The position of CpG dinucleotides is indicated with ovals. The green 
ovals indicate the CpG residues analyzed by pyrosequencing (-292 and -301) 
(B) Methylation status of the Nanog promoter determined by pyrosequencing. Microdissected epithelial (Epi) and muscular (Mu) 
layers from esophagus and forestomach (n=3 mice) from C57BL/6 mice were analyzed (a total of n=6 samples). Liver was 
also analyzed as a NANOG-negative tissue. MEFs (2 independent isolates) and ESCs (2 independent lines) were used as 
positive and negative controls, respectively. Values correspond to mean ± s.e.m. Statistical significance was determined by 
the two-tailed Student’s t test comparing epithelial vs. muscle, or vs. liver (left), or comparing ESCs vs. MEFs (right): 
***P<0.001 in all cases. 
 
In summary, multiple independent techniques (immunohistochemistry, in situ hybridization, 
immunoblotting, and DNA methylation) indicate that Nanog is expressed in the basal layer of 
stratified epithelia in adult mice.  
1.2. NANOG overexpression causes hyperplasia in stratified epithelia 
To interrogate the functional effects of NANOG in adult mice, we used a doxycycline-inducible 
transgenic mouse model (Rosa26::rtTA, Col1a1::tetO-Nanog) kindly provided by Konrad 
Hochedlinger (Harvard University, Boston, MA, USA) (Figure 13A). These mice are similar to 
a previously described Oct4-inducible mouse model (Hochedlinger et al., 2005). Upon 
increasing doses of doxycycline (DOX) administration (0.2 mg/ml, LOW; 2 mg/ml, HIGH), we 
observed increasing levels of NANOG by immunoblotting, qRT-PCR and 
immunohistochemistry, in all tissues tested except brain and testis that are poorly accessible to 
doxycycline (Figure 13B, 13C and 13D).  
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Figure 13. Inducible Nanog transgenic mice 
(A) Schematic representation of the knock-in alleles generated to produce Nanog-inducible mice. The M2-rtTA gene was targeted 
into the ubiquitously expressed Rosa26 locus. A cassette containing the Nanog-cDNA under the control of the doxycycline 
(DOX)-responsive promoter (tetO) was inserted downstream of the Col1A1 locus. SA, splice acceptor; pA, polyadenylation 
signal; tetO, tetracycline/doxycycline-responsive operator. Arrows indicate transcriptional start sites. 
(B) Immunoblot of NANOG in liver and esophagus of Nanog-inducible mice treated with different doses of DOX. Control mice 
(CTR) correspond to Rosa26rtTA/+,Col1a1+/+ and Nanog-inducible mice  (TG) correspond to Rosa26rtTA/+,Col1a1tetO-Nanog/+. 
Samples from two independent mice were used for each condition, labelled CTR1, CTR2 and TG1 to TG4, as indicated. Two 
lanes were loaded with CTR1 extract: 1X, as all the other samples; and 10X, in the leftmost lane. Mice were treated with 0.2 
mg/ml (LOW) or 2 mg/ml (HIGH) doxycycline (DOX) for 48 hr. WT and Nanog KO ESCs were used as positive and 
negative controls. !-TUBULIN was used as a loading control. 
(C) Relative log2 Nanog mRNA levels in the indicated organs determined by qRT-PCR of TG mice (n=3) and CTR mice (n=3) 
after 48 h after administration of LOW DOX (0.2mg/ml) in the drinking water. Gene expession was normalized to Gapdh. 
(n), number of mice. 
(D) Immunohistochemistry (IHC) for NANOG in the indicated tissues (bars indicate 50 !m). TG and CTR mice were treated 
with 2 dosis of DOX for 96 h. As controls, we used TG mice not treated with DOX (No DOX). Induction of NANOG was 
evident in all the tissues tested except in testis and brain, likely due to the low accessibility of DOX to these organs. 
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To assess the long-term impact of NANOG overexpression, we treated adult 
Rosa26rtTA/+;Col1a1tetO-Nanog/+ mice (abbreviated as TG) and their control littermates carrying 
only the transactivator Rosa26rtTA/+;Col1a1+/+ (abbreviated as CTR) with different doses of DOX 
and observed their phenotypic changes upon continuous administration. In the case of LOW 
DOX, half of the TG mice died within 16 weeks, and in the case of HIGH DOX, the median 
survival was 6 weeks (Figure 14A). Morbidity was associated with a lower body weight 
(Figure 14B). 
Figure 14.  Phenotype of Nanog-inducible mice 
(A) Survival curves of Nanog inducible mice upon continuous treatment with LOW or HIGH DOX, Control mice (CTR) 
correspond to Rosa26rtTA/+;Col1a1+/+ mice. As an additional control, we include TG mice not treated with DOX (No DOX). 
Statistical significance was determined by the long-rank (Mantel-Cox) test (n, number of mice). TG (LOW) vs. each of the 
three controls, *P<0.05. TG (HIGH) vs. each of the three controls, ***P<0.001. 
(B) Body weight change of CTR and TG mice continuously treated with LOW (left) or HIGH (right) DOX. All values are 
relative to the body weight at the start of the treatments (time 0). Red crosses indicate sacrificed animals that reached the 
humane endpoint. Values correspond to mean ± s.e.m. of the indicated number of mice (n). Statistical significance was 
determined by the two-way ANOVA.  
 
To identify the pathological effects of NANOG overexpression, with the help of Marta 
Cañamero (CNIO), we performed an extensive histological analysis of TG and CTR mice at 
their time of death or at the experimental endpoint. The most striking alteration in TG mice was 
a marked hyperplasia of the esophagus and forestomach (Figure 15A). As previously reported, 
we also observed thymus atrophy (Tanaka et al., 2007) consequence of Nanog overexpression 
in hematopoietic stem cells that leads to their erroneous differentiation (Figure 15B). In 
contrast, no significant changes were observed in major organs, such as liver, lung, heart and 
kidney. These alterations in the upper digestive tract could impair nutrition and thus explain the 
reduced body weight.  
Figure 15. Nanog overexpression promotes 
hyperplasia of stratified epithelia and thymus 
atrophy 
(A) Hematoxylin and eosin (H&E) staining in 
esophagus (left) and forestomach (right) upon 
NANOG overexpression showing epithelial 
hyperplasia. Control Rosa26rtTA/+;Col1a1+/+ mice 
(CTR) and Nanog-inducible 
Rosa26rtTA/+;Col1a1tetO-Nanog/+ mice (TG) were 
continuously treated with LOW or HIGH DOX. 
Histological analysis was performed at the humane 
endpoint of TG mice (approximately 2 months) or 
at the end of the experiment for CTR mice (11 
months). Bars correspond to 100 !m. 
(B) Representative images of the spleen and thymus 
from CTR and TG treated during 14 days with 
HIGH DOX.  
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To better define the effects of NANOG overexpression, we analyzed TG and CTR mice that had 
been treated for 2 weeks with HIGH DOX. We confirmed the induction of hyperplasia in 
esophagus by NANOG overexpression (Figure 16). Hyperplasia was accompanied by 
expression of cytokeratin 6 (CK6), which is associated with rapidly proliferating and 
hyperplastic squamous epithelial tissues (Navarro et al., 1995; Wilson et al., 1990). We also 
observed an altered differentiation pattern, characterized by an expansion of basal layer markers 
P63 and CK5 into suprabasal layers, and by a reduced expression of the differentiation marker 
LORICRIN (Figure 16). Additionally, the ventral side of the tongue was hyperplastic, and the 
skin presented hyperplastic foci. Other minor alterations were detected in the bladder and 
intestine, whereas no alterations were found in liver, lung, heart, smooth and skeletal muscle, 
kidney, prostate and mammary gland. 
Figure 16. Nanog-associated 
hyperplasia in the esophagus was 
accompanied by impaired 
differentiation 
Hematoxylin and eosin (H&E) and 
immunohistochemistry (IHC) of the 
indicated proteins in esophageal 
serial sections of CTR and TG mice 
treated for 2 weeks with HIGH 
doxycycline as in Figure 15A. Bars 
correspond to 100 !m. 
 
 
 
 
 
 
 
The lack of effect of NANOG on the functionality of liver and kidney was confirmed by normal 
blood levels of alanine transaminase (ALT) and total bilirubin (TBIL) (Figure 17A and 17B). 
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Figure 17. Nanog overexpression did not produce alterations in the liver or kidney function 
(A) Hematoxylin and eosin (H&E) and NANOG immunohistochemistry (IHC) in the liver of CTR and TG mice treated with 
2 weeks HIGH DOX (bars correspond to 50 !m).  
(B) Blood indicators of liver and kidney function in CTR and TG mice treated for 2 weeks with HIGH DOX, as in (A). The 
indicators measured are alanine transaminase (ALT) and total bilirubin (TBIL). Values correspond to mean ± s.e.m. of 
the indicated number of mice (n). No significant differences were observed using the two-tailed Student’s t test.  
  
In summary, the most noticeable effects of NANOG are restricted to stratified epithelia and, 
interestingly, these tissues correspond to those with high endogenous expression of NANOG.  
1.3. Mitotic activity of NANOG in stratified epithelia 
To understand the mechanisms underlying NANOG-induced hyperplasia in stratified epithelia, 
we treated TG mice and their control littermates with LOW or HIGH DOX for only 48 h to 
capture early events triggered by NANOG. At this early time point, TG mice presented an 
increased proliferation, measured by Ki67, in the basal and suprabasal layers of the esophagus 
and forestomach (Figure 18). In the esophagus, we also observed an increase in DNA damage, 
measured by phosphorylated H2AX (!H2AX), probably reflecting the induction of replicative 
stress by NANOG (Figure 18). Interestingly, we could not observe any increase in proliferation 
or DNA damage in the esophageal muscular layers. 
Figure 18. Nanog overexpression promotes replicative stress 
Immunohistochemistry of NANOG, proliferation marker Ki67, and DNA damage marker !H2AX in esophageal sections of control 
Rosa26rtTA/+;Col1a1+/+ mice (CTR) and Nanog-inducible Rosa26rtTA/+;Col1a1tetO-Nanog/+ mice (TG) treated with LOW or HIGH DOX 
for 48 hr. Bars correspond to 50 !m. The graphs below correspond to the percentage of Ki67 and !H2AX positive nuclear area for 
each condition in the basal and suprabasal (suprab.) epithelial layers.  
Values correspond to mean ± s.e.m. of the indicated number of mice (n). Statistical significance was determined by the two-tailed 
Student’s t test: *P<0.05; **P<0.01, ***P<0.005. 
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Based on the above observations at such an early time point, we surmised that NANOG is 
directly implementing a proliferative transcriptional program. To investigate this, we performed 
gene expression microarray analyses in collaboration with Orlando Dominguez (CNIO) and 
Gonzalo Gómez López (CNIO), at 48 hr after LOW DOX, in total esophagus and liver, which 
represent responsive and non-responsive tissues, respectively. Gene set enrichment analysis 
(GSEA) using public annotations from Reactome revealed that the overwhelming majority of 
pathways significantly upregulated by NANOG in the esophagus were related to mitosis 
(Figure 19A), being “M phase” set top upregulated pathway (Figure 19A and 19B). In contrast 
to the changes observed in esophagus, no pathways were significantly altered in liver. 
Inspection of the heatmaps for individual genes present in the Reactome “M phase” pathway 
suggested that NANOG could regulate the expression of pivotal mitotic genes specifically in 
esophagus but not in liver (Figure 19C). Validation by quantitative PCR was obtained for 
Aurka, Aurkb, Bub1b, Cdc20 and Kif20a, which showed upregulation upon NANOG induction 
in esophagus, but not in liver (Figure 19D). These results indicate that NANOG enforces a 
proliferative program selectively in the esophagus. 
Figure 19. Nanog overexpression promotes a 
mitotic transcriptional program in the 
esophagus 
(A) Gene set enrichment analysis (GSEA) plot 
of the “M phase” (mitotic phase) 
REACTOME pathway. GSEA ranks genes 
according to the ratio between TG and CTR 
esophagus, both treated with LOW DOX 
for 48 hr. Red-blue bar: red upregulated in 
TG and blue downregulated in TG. The 
false discovery rate (FDR) is indicated.  
(B) Heat map of the expression of selected 
mitotic genes in TG and CTR, as described 
in A, in esophagus and liver. Values 
correspond to tissues from three 
independent mice, labelled 1 to 3, for TG 
and CTR. The color intensity is 
proportional to the signal log2 intensity: red 
upregulated and blue downregulated. 
(C) Relative gene expression in esophagus of 
Nanog and indicated mitotic genes 
determined by qRT-PCR.  
(D) Relative gene expression in liver of Nanog 
and indicated mitotic genes determined by 
qRT-PCR  
In C and D, mice (n=3) were treated as in A. 
mRNA levels were normalized to Gapdh and then 
compared to CTR levels (fold change). Values 
correspond to mean ± SD of the indicated number 
of mice (n). Statistical significance was 
determined by the two-tailed Student’s t test: 
*P<0.05; **P<0.01; ***P<0.001. 
1.4. Aurka is a direct target of NANOG 
The above data on the transcriptional effects of NANOG in esophagus were based on the 
analysis of total esophageal tissue, which includes epithelial and muscular layers. By 
immunohistochemistry, we observed that NANOG induced an increase in Aurora kinase A 
(AURKA) positive cells in the esophageal epithelium (Figure 20A), but not in the underlying 
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muscular layer or in the liver (Figure 20A and 20B). These data indicate that NANOG 
increases AURKA protein specifically in the esophageal epithelium.  
Figure 20. Nanog 
overexpression induces 
Aurka upregulation 
Immunohistochemistry of 
AURKA in esophagus (A) 
and liver (B) of CTR and TG 
mice. The graphs to the right 
correspond to the percentage 
of AURKA positive nuclear 
area for each condition in the 
basal and suprabasal 
(suprab.) epithelial layers of 
the esophagus, or in the liver. 
CTR mice treated with LOW 
or HIGH DOX were pooled 
(H+L). Values correspond to 
mean ± s.e.m. of the 
indicated number of mice (n). 
Statistical significance was 
determined by the two-tailed 
Student’s t test: *P<0.05; 
***P<0.001. 
 
To further explore the link between NANOG and aurora kinases, we recapitulated the above in 
vivo observations in a mouse papilloma-derived cell line, PB (Bornachea et al., 2012; Yuspa et 
al., 1986). Indeed, overexpression of NANOG resulted in a significant transcriptional 
upregulation of Aurka and Aurkb mRNA levels (Figure 21A). We also wanted to confirm this 
data in human samples. We used ESCC cells, which have previously been reported to express 
NANOG (Du et al., 2012; Shimada et al., 2012). Interestingly, transfection of siRNAs in ESCC 
TE2 cells (Okano et al., 2000) against NANOG produced a significant decrease of NANOG 
mRNA (detected with PCR primers specific for NANOG1 paralog (see Part III, Figure 45 and 
47) and this was accompanied by a similar decrease in AURKA and AURKB mRNA levels 
(Figure 21B). Similar data were obtained in HNSCC cells (see Part II, Figure 27). 
 
Figure 21. Nanog overexpression leads to upregulation of mitotic targets in papillomas-derived cells  
(A) Relative mRNA levels of the indicated genes in PB cells transfected with a mouse NANOG expressing vector or mock 
transfected (control). Samples were analyzed 72 hr after transfection (n=3 technical replicates).  
(B) Relative mRNA levels of the indicated genes in esophageal SCC (ESCC) TE2 cells transfected with pools of scrambled (si-
scr) or anti-NANOG (si-NANOG) siRNAs. Samples were analyzed 48 h after transfection. Values correspond to mean ± 
s.e.m. (n=5 technical replicates).  
Levels of mRNA were normalized to Gapdh and then compared to the control. Values correspond to mean ± s.e.m. Statistical 
significance was determined by the two-tailed Student’s t test: *P<0.05; ***P<0.001. 
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Next, we wondered whether Aurka was a direct target of NANOG in epithelial cells. Inspection 
of previously published chromatin immunoprecipitation (ChIP) data of NANOG in mouse ESCs 
(Marson et al., 2008) uncovered a NANOG binding site ~7 kb upstream of the Aurka 
transcriptional start site.  
 
 
Figure 22. NANOG binding site in the Aurka promoter 
Peaks of NANOG binding to the mouse Aurka gene determined by chromatin immunoprecipitation sequence (ChIP-seq). Top row, 
ideogram of mouse chromosome 2 with Aurka located in 2qH3 (blue bar). Middle row, blue histogram corresponds to the frequency 
of NANOG ChIP reads and red bars correspond to the regions chosen to be amplified in the ChIP experiments. The leftmost bar 
corresponds to the Aurka promoter and the rightmost bar to the intronic region. Bottom row, Aurka gene exon-intron structure 
 
Based on this, we performed NANOG ChIP in WT and Nanog-KO ESCs and in primary mouse 
skin keratinocytes. For this, we took advantage of p53-null keratinocytes because of their robust 
proliferation and their higher basal levels of NANOG (Figure 23A), the latter being in 
agreement with the negative regulation of Nanog expression by p53 (Lin et al., 2005). We 
confirmed that NANOG binds the Aurka promoter in ESCs. Importantly, NANOG also bound 
the Aurka promoter in keratinocytes (Figure 23B), whereas it did not bind to an intronic Aurka 
region or to the Oct4 promoter, which is not active in somatic tissues (Lengner et al., 2007). As 
a positive control, we confirmed that NANOG binds the Oct4 promoter in ESCs (Figure 23B).  
 
Figure 23. Aurka is a direct target of NANOG in epithelial cells 
(A) Immunoblot of NANOG (using Millipore antibody) and p53 in nuclear extracts from primary mouse keratinocytes of the 
indicated genotypes. Histone H3 is used as loading control. We used two independent biological replicates, labeled WT1, 
WT2, KO1 and KO2, each from a different newborn mouse. 
(B) Chromatin immunoprecipitation (ChIP) of NANOG in WT or Nanog-KO ESCs or in primary p53-KO keratinocytes. The 
relative recovery with respect to NANOG ChIP in Nanog KO ESCs is shown for Aurka promoter or intronic regions, or for 
the Oct4 promoter. In the case of keratinocytes, we used two independent biological replicates, labelled KO1 and KO2, each 
from a different newborn mouse. Values correspond to mean ± s.e.m. of qPCR triplicates (Aurka promoter or intronic 
regions) or duplicates (Oct4 promoter). Statistical significance vs. NANOG ChIP in Nanog-KO ESCs was determined by the 
two-tailed Student’s t test: *P<0.05; *P<0.01; ***P<0.001. 
 
We conclude that NANOG is acting as a direct transcriptional activator of the mitotic kinase 
AURKA and this function is conserved in ESCs and in stratified epithelia. 
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1.5. NANOG binds to epithelial stem cell transcription factor !Np63!  
To understand why NANOG is specifically causing an effect in stratified epithelia and not in 
other tissues, we hypothesized that it must bind to specific epithelial transcription factors that 
regulate its role. Throughout our results, we have observed that NANOG has the same 
expression pattern as P63. Moreover, recent results have identified SOX2 to bind to P63 where 
both share a transcriptional program in SCC cells (Watanabe et al., 2014a). We overexpressed 
NANOG and !Np63!, which is the predominant p63 isoform expressed in stratified epithelia 
and is essential for epithelial maintenance and epidermal morphogenesis (Mills et al., 1999; 
Yang et al., 1998), in U2OS cells. We found by co-immunoprecipitation (CoIP), in cells 
exogenously overexpressing both proteins, that NANOG can bind to !Np63! (Figure 24A). To 
confirm this result using the endogenous proteins, we used ESCC cells, since !Np63! is known 
to be expressed in SCCs (Rocco et al., 2006; Yang et al., 1998). In TE12 cells (ESCC cell line) 
we confirmed endogenous NANOG binds to !Np63! (Figure 24B). From these results we 
conclude NANOG can form a complex with !Np63!, which could mediate the specific role of 
NANOG in stratified epithelia.   
Figure 24. NANOG binds to epithelial stem cell marker !Np63a.  
(A) Co-immunoprecipitation (CoIP) studies were carried out with lysates prepared from U2OS cells coexpressing the NANOG 
and !Np63!"FLAG constructs. For control purposes, U2OS cells were also transfected with NANOG or !Np63!"FLAG 
alone. Top: Proteins were immunoprecipitated with a C-terminal NANOG antibody and then immunoblotted using a FLAG 
monoclonal antibody. Bottom: In a reciprocal fashion, proteins were immunoprecipitated with the FLAG antibody and then 
immunoblotted using a N-terminal antibody. CoIP is indicated by a red box.  
(B) CoIP was performed in ESCC TE12 cells that express endogenous NANOG and !Np63!.  Proteins were immunoprecipitated 
with a N-terminal NANOG antibody and then immunoblotted using a p63 antibody. As a control, proteins were also 
immunoprecipitated using rabbit IgG isotype. 
L.E. and H.E. refer to low and high exposition times respectively after ECL incubation.   !
All together our results demonstrate NANOG is functional in specific adult tissues, where its 
overexpression can activate a mitotic transcriptional program that leads to hyperplasia.  
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PART II  
Role of NANOG in squamous cell 
carcinomas 
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2.1. NANOG is overexpressed in mouse and human squamous cell 
carcinomas 
The mitogenic activity of NANOG in stratified epithelia (shown in Part I) prompted us to 
investigate the possible role of NANOG in squamous cell carcinomas. We began by exploring 
NANOG expression in a number of different mouse tumors. Interestingly, those tumors derived 
from stratified epithelia, such as forestomach, skin and vagina, were strongly positive for 
NANOG. Mammary and prostate tumors contained NANOG-positive cells, albeit of moderate 
intensity and restricted to a fraction of tumor cells. Tumors derived from NANOG-negative 
tissues, such as fibrosarcomas, intestinal adenomas, and hepatocellular carcinomas (HCC), were 
completely negative for NANOG (Figure 25). These observations suggest that NANOG is 
strongly and widely expressed in cancers derived from stratified epithelia. 
Figure 25. NANOG is overexpressed in tumors derived from stratified epithelia  
NANOG IHC in archived mouse tumours, as indicated. mPIN: mouse prostate intraepithelial neoplasia; HCC: hepatocellular 
carcinoma. Bars correspond to 50 µm. 
 
Based on the above, we decided to examine NANOG in human cancers derived from stratified 
epithelia. We focused on esophageal squamous cell carcinomas (ESCCs) and head and neck 
squamous cell carcinomas (HNSCCs) for which there is evidence of NANOG expression 
(Chiou et al., 2008; Du et al., 2012; Shimada et al., 2012). These studies were performed in 
collaboration with Manuel Rodriguez-Justo (University College Hospital, London, UK) who 
provided and analyzed ESCCs and with Marta Sanchez-Carbayo (CIC bioGUNE, Derio, Spain) 
who provided and analyzed HNSCCs. We confirmed that NANOG expression is common in 
ESCCs (Figure 26A) and HNSCCs (Figure 26B). In fact, all the examined ESCCs (n=29) and 
HNSCCs (n=46) were positive for NANOG, often with very intense and widespread staining 
(Figure 26A and 26B).   
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Figure 26. NANOG is expressed in human ESCC and HNSCC and in derived cell lines 
(A) Top: Immunoblot of human NANOG in nuclear extracts from the indicated esophageal squamous cell carcinomas (ESCC) 
cell lines. Ntera2 (NT2) is used as a positive control for NANOG. SMC1 is used as a loading control. Bottom: IHC of 
NANOG and AURKA in two representative human ESCCs.  
(B) Top: Immunoblot of human NANOG in nuclear extracts from the indicated head and neck squamous cell carcinomas 
(HNSCC) cell lines. Ntera2 (NT2) is used as a positive control for NANOG. SMC1 is used as a loading control. Bottom: IHC 
of NANOG and AURKA in two representative human HNSCCs.  
 
Additionally, we also wanted to know if knockdown of NANOG in HNSCC cell lines has an 
effect in cell proliferation and cell cycle progression. As observed previously, many HNSCC 
cell lines express NANOG (Figure 26B). We took two HNSCC cell lines and infected them 
with lentiviruses encoding shRNAs that target NANOG or scrambled sequences (which has no 
target in the genome) as a negative control. Immunoblot analysis showed knockdown of 
NANOG leads to decreased levels of AURKA protein (Figure 27A). In agreement with this, in 
vitro 5-ethynyl-2!-deoxyuridine (EdU) proliferation assays indicate that silencing NANOG 
promotes a decrease of proliferation of HNSCC cells (Figure 27B and 27C). Further analysis 
showed that NANOG knockdown also caused alterations in their cell cycle compared to the 
control (Figure 27B and 27D).  
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Figure 27. Knockdown of NANOG in HNSCC cells decreases proliferation and promotes cell cycle arrest   
(A) Immunoblots of HNSCC cells (SCC38 and SCC42B) infected with shSCR (control) or shNANOG after selection with 
puromycin. NANOG knockdown promotes AURKA downregulation. TUBULIN is used as a loading control. L.E., low 
expostion after ECL incubation; H.E., high exposition after ECL incubation.  
(B) HNSCC cells were treated as in A. After puromycin selection, cells were subject to 1 hr EdU-pulse, collected and processed 
using the Click-It EdU kit (Invitrogen), together with Hoechst staining, and analyzed by flow cytometry. EdU positive cells 
correspond to the proliferating cells (S phase). Both cell lines upon NANOG knockdown showed cell cycle arrest and 
decreased proliferation.  
(C) Quantification of EdU positive cells after flow cytometry analysis in SCC38 and SCC42B cells treated as in B. Values 
correspond to mean ± SD in SCC38 (n=3 biological replicates) and SCC42B (n=2 biological replicates). Statistical 
significance was determined by the two-tailed Student’s t test: (*) P<0.05; (**) P<0.01; non significant (n.s.). 
(D) Cell cycle analysis using Hoechst staining of DNA content of HNSCC cells treated as in B.  
 
We conclude that NANOG expression is prevalent in many types of squamous cell carcinoma 
and this correlates also with its function in stratified epithelia. These observations reinforce the 
concept that NANOG could have an effect not only in stratified epithelia, but also in their 
derived cancers.  
2.2. NANOG promotes proliferation in the epidermis 
Based on our previous observations, our next objective was to address the in vivo role of 
NANOG in oncogenesis. Nanog ubiquitous overexpression showed a decreased survival of 
mice, where NANOG-overexpressing mice died after a few weeks and is not a suitable model 
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for long-term carcinogenesis assays. For this reason, we decided to use a tissue specific 
doxycycline-inducible Nanog transgenic mouse model. In this case, instead of using the 
Rosa26::rtTA mouse, we chose another available mouse model (K5-rtTA) kindly provided by J. 
Silvio Gutkind (NIH, Bethesda, USA), which has the bovine keratin 5 (K5) promoter directing 
the expression of the reverse tetracycline transactivator gene (rtTA) (Vitale-Cross et al., 2004) 
(Figure 28A). The combination of these transgenes (K5-rtTA;Col1a1::tetO-Nanog) provides a 
Tet-ON tool that allows the inducible expression of Nanog in the basal layer of the skin, which 
includes the stem cell compartments (Fuchs, 2009). We first examined whether transgenic 
Nanog was specifically expressed in the basal layer of stratified epithelium. We treated adult 
K5-rtTAtg/.;Col1a1tetO-Nanog/+ (from now on abbreviated as TG) and their control littermates 
lacking the transactivator Col1a1tetO-Nanog/+ (from now on abbreviated as CTR) with doxycycline 
in their drinking water (2 mg/ml) for a period of 48 hours. We observed Nanog expression by 
qRT-PCR selectively in stratified epithelia-containing tissues, such as, forestomach, tongue, tail 
and back skin and esophagus. As a negative control, we could not detect expression of 
transgenic Nanog in the liver and the small intestine (non-stratified epithelial tissues) (Figure 
28B). We also performed immunohistochemistry (IHC) to confirm NANOG overexpression in 
the basal layer of the skin of TG mice (Figure 28C). After 48-hour transgenic Nanog 
overexpression we could not detect histological alterations in the skin (Figure 28C).  
Figure 28. K5 Nanog-inducible mouse model  
(A) Schematic representation of the K5-
rtTA;Col1a1::tetO-Nanog mouse model. The 
reverse transactivator (rtTA) is under the 
control of the bovine cytokeratin 5 (K5) 
promoter. A cassette containing the Nanog-
cDNA is under the control of the 
doxycycline (DOX)-responsive promoter 
(tetO), which was inserted downstream of 
the Col1a1 locus. tetO, tetracycline/ 
doxycycline-responsive operator. Arrows 
indicate transcriptional start sites. 
(B) Relative Nanog mRNA levels in the 
indicated organs determined by qRT-PCR. 
Nanog-inducible mice (n=3) containing 
both transgenes (Col1a1tetO-Nanog/+;K5-
rtTAtg/.; abbreviated as TG) and control mice 
(n=3) lacking the transactivator (Col1a1tetO-
Nanog/+; abbreviated as CTR) were analyzed 
48 hr after administration of doxycycline 
(DOX) (2mg/ml) in the drinking water.   
(C) Immunohistochemistry (IHC) for NANOG 
of paraffin-embedded sections of tail skin 
from CTR and TG mice treated as indicated 
in (B). Two magnifications are shown for 
each tissue (bars correspond to 50 !m). 
 
To study the long-term effects of Nanog expression, mice were subjected to continuous 
doxycycline administration via the drinking water during 9 months. Transgenic expression of 
NANOG was clearly detectable in the basal layer of the skin after 9 months, but no alterations 
were observed in its tissue architecture (Figure 29). Esophagus and forestomach showed mild 
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hyperplasia in TG mice in agreement with our previous results, but this does not lead to 
decreased survival (Figure 29). 
Figure 29. Long-term Nanog overexpression in K5 Nanog-inducible mice  
Representative hematoxylin and eosin (H&E) staining of CTR and TG mice after 9 month-doxycycline treatment of epithelial 
tissues: back skin, esophagus, urinary bladder and forestomach. Immunohistochemistry (IHC) for NANOG of paraffin-embedded 
sections of tail skin from CTR and TG mice treated with doxycycline during 9 months (right). Bars correspond to 50 !m. 
 
To investigate the effect of NANOG in the context of mitogenic and inflammatory stimulation, 
we topically treated the tail skin of CTR and TG mice with 12-O-tetradecanoylphorbol 13-
acetate (TPA). In mice overexpressing transgenic Nanog (Figure 30A), four successive 
applications of TPA at 48-hour intervals resulted in augmented epidermal thickness compared 
to CTR mice (Figure 30B). This effect was accompanied by a clear increase in Ki67-positive 
proliferating keratinocytes in the basal and suprabasal layers of TG mice compared to CTR 
ones, as well as a decrease of the differentiation marker LORICRIN (Figure 30C). Therefore, 
NANOG has the capacity to induce epidermal hyperproliferation under conditions of mitogenic 
stimulation. 
Figure 30. Nanog overexpression 
promotes epidermal hyperproliferation 
upon TPA application 
(A) Relative Nanog mRNA levels in 
CTR and TG tail skin topically 
treated 4 times, at 48 hr intervals, 
with 12-O-tetradecanoylphorbol 
13-acetate (TPA) or acetone as a 
control. Mice (n=4) were exposed 
to doxycycline (2mg/ml) in their 
drinking water 48 hr prior to TPA 
treatment and throughout the 
remaining protocol. 
(B) Epidermal thickness (basal and 
suprabasal layers) of CTR and TG 
mice (n=5) treated as in (A). 
(C) Representative hematoxylin and 
eosin (H&E) staining and 
immunohistochemistry (IHC) for 
NANOG, KI67 and LORICRIN of 
TPA-treated CTR and TG mice as 
indicated in (D) (bars correspond to 
50 !m). 
In (A) and (B) values correspond to mean 
± SD of the indicated number of mice (n). 
Statistical significance was determined by 
the two-tailed Student’s t test: (*) P<0.05; 
(**) P<0.01. 
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2.3. NANOG promotes squamous cell carcinoma (SCC) formation 
As shown previously, NANOG is overexpressed in squamous cell carcinomas. To address 
whether high levels of NANOG can contribute to tumorigenesis, we induced skin tumors using 
the classical DMBA/TPA two-stage chemical carcinogenesis protocol (Abel et al., 2009). We 
used CTR and TG mice in a C57BL/6 background, which is known to be resistant to carcinoma 
formation (Hennings et al., 1993), and administered doxycycline throughout the entire protocol  
(Figure 31A). There were no significant differences in the kinetics of papilloma formation 
(Figure 31B), or in the total number (Figure 31C) or size (Figure 31D) of papillomas at the 
end of the experiment.  
 
Figure 31. Chemical carcinogenesis with DMBA/TPA 
(A) Experimental layout for two-stage chemical-induced carcinogenesis. CTR and TG mice (see Figure 1A) were treated with 
doxycycline (DOX) in their drinking water (2 mg/ml) during the entire protocol. DMBA was applied 48 hr after initiation of 
DOX treatment. TPA application started the following week, twice a week during 15 weeks. Tumors were counted and 
measured weekly. Histological analysis was performed at the humane endpoint or at the end of the experiment (30 weeks). 
(B) Average number of tumors per mouse during the treatment. Values correspond to mean ± SD of the indicated number of mice 
(n). Statistical significance was determined for each time point by two-tailed Student’t test: (*) p<0.05. 
(C and D) Average number of total tumors (C) and large tumors (>4mm) (D) per mouse. Quantification was performed at the 
humane endpoint or at the end of the experiment (30 weeks). Values correspond to mean ± SD of the indicated number of 
mice (n). Statistical significance was determined by the two-tailed Student’s t test: n.s. non significant 
 
Interestingly, at around 20 weeks of treatment, tumors resembling squamous cell carcinomas 
(SCCs) started to appear exclusively in the TG mice (Figure 32A). In many cases (~40%), TG 
mice had to be sacrificed before the finalization of the observation period because carcinomas 
were larger than 1.5 cm (humane endpoint) (Figure 32B). All tumors were characterized at the 
end of the protocol or at the humane endpoint. As expected for the C57BL/6 background, all 
CTR tumors were papillomas (benign). In contrast, a significant fraction of tumors (>15%) from 
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the TG mice had progressed to SCCs (Figures 32C and 32D). Moreover, some of these SCCs 
presented areas with spindle component and in one case metastasis to a lymph node (Figure 
32E). 
 
Figure 32. Nanog overexpression promotes epidermal squamous cell carcinoma 
(A) Survival curve of CTR and TG mice upon DMBA/TPA treatment and continuous treatment with doxycycline. Statistical 
significance was determined by the Long-rank (Mantel-Cox) test. (n), number of mice.  
(B) Representative images of DMBA/TPA treated mice. Arrow indicates a squamous cell carcinoma.  
(C) Hematoxylin and eosin (H&E) staining of TG carcinomas and lymph node metastasis. Two magnifications are shown for 
each tissue (bars correspond to 50 !m).  
(D) Percentage of CTR and TG mice with squamous cell carcinomas (SCCs) at the end of the treatment. Statistical significance 
was determined by the two-tailed Student’s t test: (**) p<0.01.  
(E) Conversion rate showing the number of SCCs relative to the total number of tumors. Statistical significance was assessed by 
the Fisher’s exact test: (**) p<0.01. 
 
We confirmed NANOG overexpression in the TG mice skin, papillomas and carcinomas 
(Figure 33A and 33B). We also noticed that the endogenous Nanog gene was upregulated in 
TG mice (Figure 33B), suggesting that transgenic Nanog may upregulate the endogenous 
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Nanog gene. Interestingly, carcinomas showed the highest levels of Nanog (transgenic and 
endogenous), suggesting an association with malignancy. To explore this further, we analyzed 
NANOG protein levels in different cell lines previously obtained from these types of tumors 
kindly provided by Miguel Quintanilla (Instituto de Investigaciones Biomédicas "Alberto Sols", 
Madrid). Spindle SCC-derived cell lines (CarB, CarC and MSC11A5) expressed the highest 
levels of NANOG, compared to cell lines derived from SCCs, papillomas or immortalized 
keratinocytes (Figure 33C). 
Figure 33. Nanog expression levels in back skin, papillomas and SCCs 
(A) Relative total Nanog mRNA levels (left) and endogenous Nanog mRNA levels (right) in CTR (n=4) and TG (n=4) back skin; 
CTR (n=4) and TG (n=3) papillomas; and TG (n=3) SCCs. mRNA levels were normalized by Gapdh levels. Values 
correspond to mean ± SD of the indicated number of mice (n). Statistical significance was determined by the two-tailed 
Student’s t test: n.s. non significant; (*)P<0.05; (**) P<0.01; (***) P<0.001 
(B) IHC of NANOG and P63 in representative CTR and TG papillomas. Bars correspond to 50 !m.  
(C) Immunoblots of NANOG using total lysates from the indicated cell lines. TUBULIN was used as a loading control. Kerat., 
immortalized keratinocytes; PAP, papilloma; SCC, squamous cell carcinoma; SpSCC, spindle SCC.  
 
Together, these results demonstrate that NANOG can promote malignant progression to 
squamous cell carcinomas. 
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2.4. NANOG induces EMT targets in skin papillomas 
To obtain mechanistic insight on how NANOG promotes skin tumorigenesis, we performed 
with the help of Orlando Dominguez (CNIO), Osvaldo Graña (CNIO) and Gonzalo Gómez 
López (CNIO), RNA-seq analysis of CTR (n=4) and TG (n=3) papillomas to capture early 
events during Nanog-driven tumorigenesis. This analysis revealed a small number of 
differentially-expressed genes (98 genes; see Table S1). Interestingly, genes associated to 
epithelial-mesenchymal transition (EMT) were remarkably over-represented in Nanog-
papillomas, including Prrx1, a master driver of EMT (Ocana et al., 2012). This was confirmed 
by gene set enrichment analysis (GSEA) of a number of EMT signatures (Blick et al., 2010; 
Jechlinger et al., 2003; Taube et al., 2010) (Figure 34).  
 
Figure 34. Nanog overexpression in papillomas induces an EMT signature 
Gene set enrichment data (GSEA) showing the enrichment of three published EMT gene signatures (Blick et al., 2010; Jechlinger et 
al., 2003; Taube et al., 2010) in TG papillomas as compared with CTR papillomas. NES: normalized enrichment score. The false 
discovery rate (FDR; q-value) is indicated. 
 
We validated the upregulation of EMT drivers and markers by qRT-PCR (Figure 35A) and by 
immunohistochemistry (Figure 35B) in Nanog-driven papillomas and carcinomas. Of note, 
downregulation of E-cadherin was also observed (Figure 35A and 35B).  
Figure 35. Nanog overexpression 
upregulates EMT targets in vivo.  
(A) Relative gene expression in CTR and 
TG papillomas and TG SCCs of 
stemness related genes analyzed by 
qRT-PCR. mRNA levels were 
normalized by Gapdh levels and, then 
compared to levels of CTR papillomas 
(shown as fold change). Values 
correspond to mean ± SD of the 
indicated number of mice (n). 
Statistical significance was determined 
by the two-tailed Student’s t test 
relative to CTR papillomas: (*) 
P<0.05; (**) P<0.01; (***) P<0.001. 
(B) Representative hematoxylin and eosin 
(H&E) staining of a TG SCC. Top 
corresponds to magnified back skin 
and bottom to magnified invasive 
carcinoma. Serial sections were stained 
by IHC for NANOG, P63, E-
CADHERIN and VIMENTIN (bars 
correspond to 50 !m).  
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Based on this, we wanted to know whether NANOG had the ability to initiate an EMT program 
in primary keratinocytes. For this, we extracted keratinocytes from CTR and TG neonates and 
added doxycycline to their culture medium for 48 hours. Interestingly, NANOG was able to 
upregulate a subset of EMT mediators in primary keratinocytes as soon as 48 hours after 
induction (Figure 36A and 36B).  
 
Figure 36. Nanog overexpression in primary keratinocytes upregulates EMT markers 
(A) Immunoblots of NANOG using nuclear lysates from CTR and TG keratinocytes after 48 hr doxycycline treatment. SMC-1 
was used as a loading control. Mouse embryonic stem cells (ES) were used as a positive control.  
(B) Relative mRNA levels of the indicated genes in primary keratinocytes extracted from CTR and TG newborn pups (n=2) and 
treated during 48 hr with doxycycline. mRNA levels were normalized by Gapdh levels and then compared to levels of CTR 
keratinocytes (shown as fold change).  
 
MicroRNAs have been also implicated as important regulators of EMT and malignancy, being 
particularly important miR-21, as a positive inducer, and miR-200 and miR-34 families, as 
negative regulators (Bornachea et al., 2012; Cufi et al., 2013; Dykxhoorn, 2010; Garzon et al., 
2010; Ma et al., 2011; Medina et al., 2010). In collaboration with the group of Jesus M. Paramio 
(CIEMAT, Madrid), we examined the expression of these miRNAs in normal skin, papillomas 
and carcinomas. Interestingly, we found that oncomiR miR-21 is significantly upregulated by 
NANOG in back skin, papillomas and carcinomas (Figure 37).  
Figure 37. Nanog overexpression in vivo upregulates expression of miR-21 
Left: Relative miR-21 levels in CTR (n=4) and TG (n=4) back skin; CTR (n=4) and TG (n=3) papillomas; and TG (n=3) SCCs. 
Expression levels were normalized to U6. Values correspond to mean ± SD of the indicated number of mice (n). Statistical 
significance was determined by the two-tailed Student’s t test: n.s., non significant; (*) P<0.05. Right: In situ hybrdization (ISH) of 
miR-21 in representative CTR and TG back skin and papillomas (bars correspond to 50 !m).  
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In contrast, miRNAs from the miR-200 and miR-34 families were essentially unchanged 
between control and Nanog transgenic samples (Figure 38).  
Figure 38. Nanog overexpression 
in vivo does not alter expression 
of miR-34 and miR-200 families. 
Relative expression levels of 
indicated microRNAs in CTR (n=4) 
and TG (n=4) back skin; CTR 
(n=4) and TG (n=3) papillomas; 
and TG (n=3) SCCs. Expression 
levels were normalized to U6. 
Values correspond to mean ± SD of 
the indicated number of mice (n). 
No statistically significant 
differences were found using the 
two-tailed Student’s t test.  
 
 
 
 
 
 
Importantly, NANOG in association to pSTAT3 has been shown to bind the promoter of miR-
21 and upregulate its expression in head and neck SCC cell lines (Bourguignon et al., 2012a). In 
this regard, we found that NANOG-overexpressing papillomas also express high levels of 
pSTAT3 (Figure 39A), thereby lending support to the above-mentioned link between NANOG 
and pSTAT3 in SCCs. MicroRNA miR-21 has been reported to function through a variety of 
mechanisms, including upregulation of pAKT and pERK (Bornachea et al., 2012; Hatley et al., 
2010; Ma et al., 2011). In agreement with this, we observed increased pAKT (Figure 39A) and 
pERK (Figure 37B) in NANOG-driven tumors.  
Figure 39. Nanog overexpressing papillomas 
and carcinomas have increased levels of 
pSTAT3, pAKT and pERK. 
(A) IHC of phospho-STAT3 (Tyr705) and 
phospho-AKT (Ser473) in representative 
CTR and TG papillomas (bars correspond 
to 50 !m).  
(B) Immunoblots of phospho-ERK 
(Thr202/Tyr204) in lysates from back 
skin, papillomas and SCCs from CTR and 
TG mice. TUBULIN was used as a 
loading control. 
 
Together, these observations indicate that NANOG drives SCC tumorigenesis in association 
with the upregulation of EMT drivers, notably including Prrx1 and miR-21. 
2.5. NANOG induces stemness in skin papillomas  
Examination of the list of differentially expressed genes in CTR and TG papillomas also 
revealed a high frequency of genes previously related to stemness (Table S1). Gene set 
enrichment analysis (GSEA) on a cancer stem cell signature from breast cancer (Gupta et al., 
2009) confirmed this idea (Figure 40A). Several stemness-associated genes were validated by 
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qRT-PCR, including Cxcl12/Sdf-1, Pecam1/CD31, Plet1, Lgr5, Lrg1, Pdgfra and H19, which 
were all significantly upregulated in TG papillomas and carcinomas (Figure 40B).  
 
Figure 40. NANOG induces stemness in skin papillomas 
(A) Gene set enrichment data (GSEA) showing the enrichment of a published breast cancer stem cell signature (Gupta et al., 
2009) in TG papillomas as compared with CTR papillomas. NES: normalized enrichment score. The false discovery rate 
(FDR, q-value) is indicated. 
(B) Relative gene expression in CTR and TG papillomas and TG SCCs of stemness related genes analyzed by qRT-PCR. mRNA 
levels were normalized by Gapdh levels and, then compared to levels of CTR papillomas (shown as fold change). Values 
correspond to mean ± SD of the indicated number of mice (n). Statistical significance was determined by the two-tailed 
Student’s t test relative to CTR papillomas: (*) P<0.05; (**) P<0.01; (***) P<0.001. 
 
2.6. NANOG directly activates EMT and stemness genes 
NANOG is a well-known transcription factor in embryonic stem cells where it binds to a large 
amount of promoter regions (Loh et al., 2006). We took advantage of the ENCODE project 
(Rosenbloom et al., 2013) to examine ChIP-seq data of NANOG in the above-described EMT 
and stemness genes upregulated in NANOG-driven papillomas. All the examined genes had 
NANOG binding sites in human embryonic stem cells according to the ENCODE data 
(Rosenbloom et al., 2013) and these sites were confirmed by us using human embryonic 
carcinoma NTERA2 cells (Figure 41A). Interestingly, many of these NANOG binding sites 
were also occupied by endogeneous NANOG in human esophageal SCC cell line TE2 (Figure 
41B). In particular, we observed direct binding of endogenous NANOG to EMT mediators 
MIR21, TWIST1, PRRX1 and ZEB2, as well as, to stemness associated genes LGR5, PDGFRA, 
CXCL12 and PITX2 (Figure 41B).  
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Figure 41. NANOG directly regulates EMT and stemness 
genes 
(A) Chromatin immunoprecipitation (ChIP) of NANOG 
and goat IgG in NTERA2 teratocarcinoma cells. 
(B) Chromatin immunoprecipitation (ChIP) of NANOG 
and goat IgG in TE2 esophageal SCC (ESCC) cells. 
Values were first normalized to the input values, and then 
compared to levels of the IgG control (shown as fold 
change). Values correspond to mean ± SD of two 
independent biological replicates (n=2). Control, genomic 
region that does not bind NANOG (Gifford et al., 2013). 
Statistical significance was determined by the two-tailed 
Student’s t test: (*) P<0.05. (*) P<0.05; (**). 
 
 
 
 
 
 
2.7. NANOG promotes EMT in a cell-autonomous manner  
To investigate if NANOG overexpression in keratinocytes could recapitulate the observed in 
vivo phenotype, we infected human immortalized HaCat keratinocytes with a lentivirus 
encoding NANOG under the CMV promoter, as well as a control empty lentivirus. After 
puromycin selection, we confirmed NANOG overexpression by immunoblotting (Figure 42A), 
as well as by qRT-PCR (Figure 42B). By immunofluorescence we confirmed that exogenous 
NANOG correctly localized to the nucleus (Figure 42C). Additionally, we also confirmed 
upregulation of some EMT-inducing factors, such as TWIST1 and ZEB1 (Figure 42B). To 
examine the functional consequences of NANOG overexpression, we focused on some 
properties associated to EMT. In particular, NANOG overexpressing HaCat cells had a more 
pronounced migration capacity (Figure 42D). Also, EMT is known to decrease the proliferative 
capacity of cells (Nieto and Cano, 2012) and, consistent with this, we observed that NANOG 
overexpressing HaCat cells  had a decreased proliferation rate (Figure 42E).  
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Figure 42. NANOG promotes EMT in epithelial cells 
(A) Immunoblot of NANOG and p63 in nuclear extracts from HaCat cells infected with a human NANOG expressing vector 
(HaCat/NANOG1) or empty vector control (HaCat/EV). NTERA2 teratocarcinoma cells were used as a positive control. SMC-
1 was used as a loading control. 
(B) Relative mRNA levels of the indicated genes in HaCat cells treated as in (A). Samples were analyzed after puromycin 
selection. mRNA levels were normalized by GAPDH levels and then compared to levels HaCat/EV (shown as fold change). 
Values correspond to two independent biological replicates (n=2).  
(C) Immunofluorescence of NANOG using two different antibodies (C-terminal and N-terminal detecting) of HaCat cells treated 
as in (A). DAPI was used to view the cell nuclei. 
(D) Percentage of migration (24 hr) of HaCat cells infected with NANOG1 or empty vector (n=3). Areas were measured as 
percentage of migrated distance (measured across the scratch wound width). 
(E) Growth-curve of HaCat cells overexpressing NANOG or empty vector. The experiment was repeated three independent times 
(each with a new NANOG infection of HaCat cells) obtaining similar results. The figure corresponds to one experiment. 
Quadruplicate wells were analyzed.  
Values correspond to mean ± SD. Statistical significance was determined by the two-tailed Student’s t test: n.s., non significant; (*) 
P<0.05; (**) P<0.01; (***) P<0.001.  
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Finally, we performed loss of function assays in a cellular model of esophageal squamous cell 
carcinoma (ESCC), given the fact that ESCCs are known to express high levels of endogenous 
NANOG (Bahl et al., 2012; Du et al., 2012; Fujiwara et al., 2013; Shimada et al., 2012; Yang et 
al., 2012; Zhang et al., 2012a). We silenced NANOG mRNA in TE2 ESCC cells using a 
NANOG-siRNA pool and compared it to its control (siRNA-scrambled). We confirmed NANOG 
knockdown by immunoblotting (Figure 43A) and by qRT-PCR (Figure 43B). We also 
confirmed downregulation of some EMT transcription factors and stemness related genes such 
as SOX2, LOXL1, ZEB1, ZEB2, WNT5A and CXCL12 (Figure 43C).  
Figure 43. NANOG knockdown in ESCC TE2 cells leads to downregulation of EMT targets.  
(A) Immunoblots of NANOG using TE2 (esophageal squamous cell carcinoma, ESCC, cell line) nuclear lysates cells transfected 
with pools of scrambled (siRNA SCR) or anti-NANOG (siRNA NANOG) siRNAs. Samples were analyzed 48 hr after 
transfection. SMC-1 was used as a loading control.  
(B) Relative NANOG1/P8 mRNA levels (abbreviated as NANOG) of TE2 cells as indicated in (A). mRNA levels were normalized 
by GAPDH levels. Values correspond to two transfections (n=2). 
(C) Relative mRNA levels of the indicated genes in TE2 cells transfected as indicated in (A). mRNA levels were normalized by 
GAPDH levels and then compared to levels TE2/siRNA SCR (shown as fold change). Values correspond to two transfections 
(n=2). 
Values correspond to mean ± SD. Statistical significance was determined by the two-tailed Student’s t test: (*) P<0.05; (**) 
P<0.01; (***) P<0.001.  
 
Together, our results unravel a novel function of NANOG in promoting squamous cell 
carcinoma conversion in vivo by directly activating EMT and stemness genes.  
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PART III  
Role of NANOG variants in human cancer 
and reprogramming 
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3.1. Expression of NANOG paralogs in human cells 
Research on NANOG is confounded by the presence of up to 11 known paralogs in the human 
genome (Booth and Holland, 2004). Many studies have characterized NANOG expression in 
different human tumors (Table 1), but very few studies have distinguished which paralog is 
being expressed. The importance to differentiate among paralogs is that 3 of the NANOG 
variants, NANOG1, NANOG2 and NANOGP8, give rise to functional protein and have 
aminoacid changes between them.  
Our first approach was to design a strategy to identify the NANOG variants expressed in a 
specific sample. We designed a multi-NANOG RT-PCR based on two forward primers and one 
reverse primer with the potential to amplify most NANOG paralogs (Figure 44A and 45). 
NANOGP6 and NANOGP7 were excluded due to their divergence compared to the rest of the 
variants. As a control of the PCR specificity we performed the PCR using genomic DNA 
extracted from human BJ fibroblasts. The PCR product was run on a gel, and the resulting PCR 
band was extracted, cloned into a pGEMT plasmid, transformed in competent DH5! E. coli and 
colonies were individually picked and sequenced (Figure 44B).  
Figure 44. Multi-NANOG PCR  
(A) Scheme of all NANOG paralogs and positions of the multi-NANOG primers (horizontal arrowheads and black boxes). The 
start codons are marked by vertical arrowheads, and stop codons by circles. NANOG variants with capacity to encode a 
functional NANOG protein are colored in blue. The remaining variants present numerous amino acid changes (not indicated), 
premature stop codons (circles) and gaps. 
(B) NANOG variant identifying strategy. PCR product is cloned into pGEMT vector, transformed in E. coli and positive colonies 
are sent to sequence. 
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Figure 45. Alignment of all NANOG paralogs and primer binding sites 
Alignment report comparing the coding sequence (CDS) of NANOG1 to all NANOG paralogs. The upper sequence corresponds to 
the consensus sequence among all paralogs. The color and height of the bars above each nucleotide indicate the level of divergence 
between paralogs (see color key at the end of the alignment). The binding sites of the NANOG primers used in the paper are 
indicated with boxes. The symbol ‘.’ hides residues that match the consensus sequence exactly. Gaps are indicated as ‘-’. 
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The analysis of 201 clones obtained from the genomic DNA of the BJ fibroblast cell line 
confirmed that the multi-NANOG PCR was able to amplify NANOGP2, NANOGP3, 
NANOGP4, NANOGP5, NANOGP8 and NANOGP10 of the NANOG variants. As expected, 
NANOG1 and NANOG2 were not amplified due to the presence of an intron between the 
primer-anchoring sites, but their presence was later on confirmed in other cDNA samples. Also, 
NANOG1, NANOG2 and NANOGP8 possess identical primer-anchoring sites and NANOGP8 
was correctly amplified. As an exception, NANOGP9 was not amplified for unknown reasons. 
Therefore the multi-NANOG PCR strategy can detect and distinguish 8 out of the 11 NANOG 
variants, and most importantly all of the protein-coding variants (Figure 46A). 
We then decided to determine which NANOG paralogs were being expressed in a widespread 
panel of human cancer cell lines. HES2 (human embryonic stem cell line) and NTERA2 
(human embryonic teratocarcinoma cell line) were used as a positive control since they are 
known to express NANOG1 (Chambers et al., 2003; Mitsui et al., 2003) (Figure 46A and 46B). 
It was important to ascertain that the cDNA was free of genomic DNA contamination since 
most of the paralogs are intronless. For this purpose, samples were treated with DNase I and 
additionally we performed the PCR on the original RNA samples (without addition of 
retrotranscriptase, -RT) (Figure 46B). In agreement with previous studies (Ambady et al., 2010; 
Ishiguro et al., 2012; Jeter et al., 2009; Jeter et al., 2011; Uchino et al., 2012; Zbinden et al., 
2010; Zhang et al., 2006a), intronless NANOGP8 is the most abundant protein-coding NANOG 
in cancer cell lines (14 out of 17 cell lines analyzed). All cancer cell lines (17 out 17) expressed 
NANOGP5 and many (7 out of 17) expressed also NANOGP4, an observation that again is in 
line with previous reports (Jeter et al., 2009; Zhang et al., 2006a) (Figure 46A).  
The NANOG expression pattern is different in pluripotent cells. In HES2 cells, NANOG1 and 
NANOG2 were the two variants identified. In NTERA2 cells, all protein-coding NANOG 
variants were detected: NANOG1, NANOG2 and NANOGP8 (Figure 46A). This is the first 
study demonstrating NANOG2 expression in embryonic stem cells. Of note, some cancer cell 
lines also showed expression of NANOG1 in agreement with other studies (Ishiguro et al., 2012; 
Zbinden et al., 2010; Zhang et al., 2010).  
From these analyses, we conclude that the majority of human cancer cells tested express 
NANOGP8. 
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Figure 46. Analysis of NANOG variants in a panel of human cancer cell lines  
(A) RT-PCR using multi-NANOG primers. cDNA was derived from RNA preparations of the indicated human cell lines. RNA 
samples not treated with reverse transcriptase (-RT) were used to monitor the absence of contamination by genomic DNA. 
(B) Identification of NANOG variants after multi-NANOG RT-PCR and sequencing analysis of cDNA from human cell lines. 
Genomic DNA from BJ fibroblasts was used to evaluate the amplification potential of the different variants (BJ DNA). The 
number of sequences analyzed for each cell line is shown on the top and corresponds to the sum of the two PCR reactions 
F1/R and F2/R. 
3.2. Expression of NANOG1 and NANOGP8 in human cells 
The multi-NANOG RT-PCR strategy provides a qualitative rather than a quantitative estimate 
of the variants being expressed. The next approach was to obtain a quantitative analysis of the 
different protein-coding NANOG variants expressed in cancer.  
NANOG1 and NANOGP8 have very high homology, and only differ in 3 aminoacid changes at 
the protein level. This high similarity makes it difficult to design specific primers that can fully 
distinguish between both variants without interference from the remaining paralogs. We were 
able to design PCR primers that specifically amplify NANOG1 thanks to a unique site present in 
the 5’UTR (Figure 45 and 47). On the other hand we designed another pair of primers binding 
to the coding region that amplify simultaneously NANOG1 and NANOGP8 (Figure 45 and 47).  
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Figure 47. Specificity of NANOG1 and NANOG1/P8 primers  
Top: Semi-quantitative RT-PCR of NANOG1 in indicated cell lines. The primers used selectively amplify NANOG1 and their 
position is indicated in the inset. The light gray box indicates the region of 5´UTR that is conserved between NANOG1 and 
NANOGP8. The blue box indicates the coding region. Other symbols are as in Figure 44A. The forward primer binds to the 5’UTR 
of NANOG1 at a region not conserved in NANOGP8 5´UTR. HES2 and NTERA2 cells were used as positive controls. 293T cells 
infected with a lentivirus expressing the CDS of NANOG1 (without the 5’UTR) is also used as a control.  
Bottom: Semi-quantitative RT-PCR of NANOG1/P8 in indicated cell lines. The primers bind both to NANOG1 and NANOGP8 at 
the positions indicated in the inset. These primers do not amplify the other NANOG paralogs. 
GAPDH is used as a loading control. l.e.: low exposition; h.e.: high exposition 
 
PCR analyses show that NANOG1 is abundantly expressed in pluripotent cells (HES2 and 
NTERA2) (Figure 47 and 48A), but almost undetectable in most of the cancer cell lines. On 
the other hand, NANOG1/P8 primers reveal detectable expression levels (Figure 47 and 48B). 
We also ran the PCR product on a gel to corroborate that the products detected correspond to 
the correct size (Figure 47). These data confirm that NANOGP8 is expressed in human cancer 
cell lines.  
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Figure 48. Expression of NANOG1 and NANOGP8 in human cell lines 
(A) NANOG1 expression levels in a panel of human cancer cell lines. HES2 and NTERA2 cells were used as positive controls.  
(B) NANOG1/P8 expression levels in human cancer cell lines.  
mRNA levels were normalized by GAPDH levels and, then, compared to NTERA2 levels (100%). Values correspond to the average 
± SD (n=6 technical replicates).  
 
Based on the qRT-PCR data, we wanted to determine if NANOGP8 expression gave rise to a 
detectable protein. We performed NANOG immunoblots on nuclear fractions from the 
previously studied cell lines. NTERA2 cells were used as a positive control. Several bands were 
observed in most cancer cell lines, a strong band below 50 kDa and a fainter double band at 37 
kDa. This mobility pattern has already been reported and is in line with our results (Eberle et al., 
2010; Jeter et al., 2009; Oh et al., 2005). Our previous results have shown that most cancer cell 
lines express NANOGP8, but not NANOG1 (see above Figures 46, 47 and 48), therefore the 
~37 kDa and ~50 kDa bands detected by immunoblot must derive from NANOGP8. Of note, the 
most abundant NANOG band in NTERA2 cells corresponds to the ~50 kDa band and is 
relatively abundant in cell lines 22Rv1, Du145, LnCAP, NCI-H727 and especially prominent in 
MCF-7 (Figure 49). 
 
Figure 49. NANOG protein levels in human cancer cell lines  
Nuclear extracts were immunoblotted using an antibody against the N-terminal region of NANOG (which only recognizes the 
proteins derived from NANOG1 and NANOGP8, but not of NANOG2). Sizes of protein markers are indicated. NTERA2 cells were 
used as a positive control. For NTERA2 cells the amount of protein loaded was 1 !g; for all the other cell lines, the amount loaded 
was 10 !g. The cohesin subunit SMC1 was used as a loading control of the nuclear extracts. 
 
To confirm that the ~37 kDa and ~50 kDa bands are produced by NANOG we performed 
knockdown of NANOG using three shRNAs targeting NANOG transcripts, with perfect matches 
towards NANOG1 and NANOGP8. In the case of NTERA2 cells, each shRNA potently 
decreased the ~50 kDa band and, to a lower extent, also the ~37 kDa bands (Figure 50). 
Additionally, we also performed immunoflurescence using the same antibody to assure specific 
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NANOG nuclear detection as well as correct silencing (Figure 50). NANOG silencing in 
NTERA2 cell affected their morphology (Figure 50) in line with other reports (Greber et al., 
2007). 
Figure 50. NANOG knockdown in NTERA2 cells 
Left: Nuclear extracts from NTERA2 cells expressing different shRNA against NANOG, as well as scramble shRNA as a control 
(SCR), were immunoblotted using an antibody against the N-terminal region of NANOG. 5 !g were loaded for NTERA2 cells. 
Nuclear protein SMC1 was used as a loading control. H.E. and L.E. refer respectively to high and low exposition times after ECL 
incubation.  
Right: Immunofluorescence of NANOG in NTERA2 cells after NANOG knockdown. Samples were analyzed after puromycin 
selection. DAPI was used to view the cell nuclei. HCS CellMask Stain was used to view the cell morphology (cytoplasm and 
nucleus).  
 
A similar pattern was observed in cancer cell lines treated with a cocktail of the three shRNAs 
(Figure 51). We performed qRT-PCR using the NANOG1/P8 primers to detect silencing as well 
as immunoblots. Nuclear lysates were collected from cell lines 48 hours and 2 weeks after 
shNANOG lentiviral infection. The 50 kDa band was more prominent and a clear decrease was 
observed after silencing. The ~37 kDa band is fainter and observed with higher exposition times 
but also decreases after NANOG knockdown in the case of cell line 22Rv1 (Figure 51). Similar 
results were observed in HNSCC cells (see Part II, Figure 27A). These observations confirm 
that the ~37 kDa and ~50 kDa bands correspond to NANOG-derived proteins. At present, 
however, the molecular bases or significance of the various NANOG protein mobility forms 
remain speculative. 
Figure 51. NANOG knockdown in cancer cell 
lines  
Left: Nuclear extracts from cell lines 22Rv1, NCI-
H727 and MCF-7 expressing shRNAs (pooled 
shRNAs a, b, and c) against NANOG, as well as 
scramble shRNA as a control (SCR). Two time-
points were collected after shNANOG infection of 
cell lines to view decrease of NANOG protein levels 
(2d and 14d refer to 2 days and 14 days post-
infection of shNANOG). 10 !g were loaded for 
cancer cell lines, and 5 !g were loaded for NTERA2 
cells. Nuclear protein SMC1 was used as a loading 
control. H.E. and L.E. refer respectively to high and 
low exposition times after ECL incubation.  
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We can conclude from the mRNA and protein data that most of the human cancer cell lines 
analyzed contain detectable levels of NANOG protein derived from NANOGP8.  
3.3. Reprogramming activity of NANOGP8 
Once we have determined that NANOGP8 is the main NANOG variant expressed in human 
cancer, our next approach was to view the pluripotency potential of NANOGP8. Several studies 
have already shown that NANOGP8 contributes to the clonogenic and tumorigenic potential of 
human cancer cells (Jeter et al., 2009; Jeter et al., 2011; Uchino et al., 2012; Zbinden et al., 
2010; Zhang et al., 2010). Therefore, we decided to focus on determining the reprogramming 
activity of NANOGP8. The NANOG protein encoded by NANOGP8 presents two amino acid 
changes relative to the one derived from NANOG1, namely, at positions 16 and 253 (Figure 
52A). These two changes occur in functional protein domains of NANOG. In particular, residue 
16 is part of a transcriptional repression domain, (Chang et al., 2009) whereas residue 253 is 
within a potent transcriptional activation domain (Do et al., 2009; Pan and Thomson, 2007). In 
addition, NANOG1 presents a coding single nucleotide polymorphism (SNP) at position 82, 
which can encode for lysine or asparagine (Zbinden et al., 2010), and it is part of the 
transcriptional repression domain of NANOG1 (Chang et al., 2009). Of note, this residue is not 
polymorphic in NANOGP8, which always encodes an asparagine at position 82 (Figure 52A). 
Site-directed mutagenesis was used to generate the two polymorphic versions of NANOG1, i.e. 
NANOG1K82 and NANOG1N82. We also obtained a construct to express NANOGP8, as well as 
constructs carrying NANOG1K82 with each of the two NANOGP8’s changes, i.e. 
NANOG1A16E;K82 and NANOG1K82;Q253H. Expression from these vectors was confirmed by 
transfection of the retroviral vectors into 293T cells by immunoblotting and qRT-PCR (Figure 
52B and 52C). Surprisingly when we performed NANOG immunoblots from transfected 293T 
cells using two different antibodies, we observed clear mobility shifts between NANOG1, its 
point mutants and NANOGP8 (Figure 52B). Subsequent analysis by qRT-PCR ensured that 
NANOG overexpression did not activate the endogenous locus (Figure 52D).  
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Figure 52. Expression of NANOG variants in 293T cells 
(A) Cartoon showing differences between proteins encoded by NANOG1 and NANOGP8. NANOG1 presents two polymorphic 
variants at codon 82, one of which (N82) coincides with NANOGP8. NANOGP8 has two amino acid changes relative to 
NANOG1N82 (E16 and H253). 
(B) Immunoblots of NANOG using two different antibodies (C-terminal and N-terminal) in 293T cells transfected with control 
(EV: empty vector), NANOG1K82 and NANOG1N82 variants, NANOG1K82 point mutants A16E and Q253H, or NANOGP8. 
(C) Expression levels of total NANOG1/P8 in 293T cells transfected with the indicated retroviral constructs. 
(D) Expression levels of endogenous NANOG1 in 293T cells transfected with the indicated retroviral constructs. 
(E) Teratocarcinoma cell line NTERA2 was used as a positive control and IMR90 fibroblasts as a negative control. Values 
correspond to the average ± SD (n=6 PCR replicates).  
 
We began by testing the ability of the above-mentioned NANOG expressing constructs to 
improve the reprogramming efficiency of mouse cells. For this, we used MEFs derived from a 
reprogrammable transgenic mouse strain developed in our laboratory and carrying a 
polycistronic OSKM cassette under the control of the tetO element and the reverse 
transactivator (rtTA) in the Rosa26 locus. Upon doxycycline addition to the medium these 
inducible-OSKM MEFs are efficiently reprogrammed (Abad et al., 2013). To establish a 
NANOG-dependent reprogramming assay in murine cells, we took advantage of the following 
two facts. On one hand, Nanog accelerates reprogramming (Hanna et al., 2009) and promotes 
the pre-iPSC to iPSC transition (Silva et al., 2009). On the other hand, only bona fide iPSCs are 
able to grow in the presence of MEK and GSK inhibitors (abbreviated as 2i), whereas 2i 
medium blocks the proliferation of pre-iPSCs (Figure 53A) (Silva et al., 2008; Ying et al., 
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2008). To identify the conditions at which reprogramming is more dependent on NANOG, 
inducible-OSKM MEFs were infected with control (EV) or human NANOG1K82 and were 
subsequently treated with doxycycline (day 0). At different time points (day 3, 5, 7 or never), 
medium was supplemented with 2i and the final number of alkaline phosphatase positive (AP+) 
colonies was scored at day 14. Addition of NANOG1K82 greatly increased the reprogramming 
efficiency and this was most apparent when adding 2i from day 3 (Figure 53B). In particular, 
addition of 2i at day 3 almost completely prevented the emergence of colonies in the absence of 
NANOG1K82. In contrast, the presence of NANOG1K82 allowed the formation of colonies in 2i 
medium confirming its ability to accelerate the emergence of fully reprogrammed iPSCs 
(Figure 53B).  
Figure 53. NANOG reprogramming assay 
(A) NANOG is necessary for the second step during reprogramming of differentiated cells into fully reprogrammed iPSCs. 
Addition of 2i to the medium eliminates pre-iPS cells and promotes growth of naïve iPSCs.  
(B) Quantification of the total number of alkaline phosphatase positive (AP+) colonies. Inducible-OSKM MEFs were infected 
with either empty vector (OSKM + EV) or NANOG1K82 (OSKM + NANOG1K82) and subsequently treated with doxycycline 
(day 0).  Addition of 2i (CHIR99021 and PD0325901) was initiated at the indicated time or never (-) after doxycycline 
addition. AP staining was done at day 14. Three replicates were used. Values correspond to the average ± SD. 
 
Having set up a NANOG reprogramming assay, inducible-OSKM MEFs were infected with 
retroviruses expressing mouse Nanog, human NANOG1K82, NANOG1N82, NANOGP8, as well as, 
NANOG1K82 point variants NANOG1A16E;K82 and NANOG1K82;Q253H. As mentioned above, we 
added 2i at day 3 and we scored AP+ colonies at day 14. The two NANOG1 polymorphic 
variants were indistinguishable in this assay. Interestingly, NANOGP8 had a reprogramming 
activity similar to NANOG1K82 and NANOG1N82 (Fig. 54A and 54B). In agreement with this, 
the two NANOG1 point mutations, NANOG1A16E;K82 and NANOG1K82;Q253H, also showed similar 
reprogramming activity compared to the wild-type NANOG1 variants (Figure 54B). Finally, 
mouse and human Nanog/NANOG had a comparable reprogramming activity (Figure 54B), 
extending the previous reported functional conservation of Nanog/NANOG in the pre-iPSC to 
iPSC transition (Theunissen et al., 2011). We confirmed similar retroviral expression levels in 
MEFs after infection (Figure 54C). Of note, retroviral expression of Nanog/NANOG did not 
activate expression of the endogenous mouse Nanog gene (Figure 52D).  
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Figure 54. Activity of NANOG variants during reprogramming of MEFs 
(A) Alkaline phosphatase staining of inducible-OSKM MEFs infected with empty vector (EV), NANOG1K82 or NANOGP8 with 
subsequent doxycycline addition (day 0) cultured with or without 2i media (added from day 3). 
(B) Relative reprogramming activity of inducible-OSKM MEFs infected with control (EV: empty vector), mouse Nanog 
(mNanog), NANOG1K82 and NANOG1N82 variants, NANOG1K82 point mutants A16E and Q253H, or NANOGP8. 
Reprogramming conditions were in the presence of 2i added from day 3 post-doxycycline. AP+ colonies were scored at day 
14. Values correspond to the average ± SD. Four different biological replicates were performed (each using independent 
inducible-OSKM MEF isolates). For each replicate, the number of colonies was normalized to the number of colonies 
appearing in inducible-OSKM MEFs infected with mouse Nanog. Reprogramming efficiency was significantly increased by 
all the Nanog/NANOG constructs compared to the control (EV) (Student’s t test p<0.05). The reprogramming efficiencies of 
the indicated NANOG constructs were not significantly different amongst themselves.   
(C) Expression levels of retroviral NANOG1/P8 in inducible reprogrammable OSKM MEFs infected with the indicated retroviral 
constructs. Values correspond to the average ± SD (n=4 full biological replicates each with an independent MEF isolate).  
(D) Expression levels of total mouse Nanog and total human NANOG1/P8 in inducible reprogrammable OSKM MEFs infected 
with the indicated retroviral constructs. Values correspond to the average ± SD (n=3 PCR replicates). NTERA2 and mouse 
embryonic stem cells (mESCs) were used as positive controls respectively, and MEFs were used as negative control. 
 
We wanted to corroborate the above data in the reprogramming of human cells. For this, we 
used human primary foreskin fibroblasts and the three factor cocktail OCT4, SOX2 and KLF4 
(OSK). Cells were retrovirally infected simultaneously with OSK retroviruses together with 
retroviruses carrying empty vector (EV), or the above-described NANOG constructs. Expression 
of NANOG variants was confirmed 48 hours post-infection (Figures 55A and 55B) and it did 
not activate expression of the endogenous NANOG1 gene (Figure 55C). 
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Figure 55. Expression levels of NANOG variants in retrovirally infected primary human fibroblasts 
(A) Expression levels of total NANOG1/P8 in primary human fibroblasts infected with the previously described retroviral 
NANOG constructs.  
(B) Expression levels of retroviral NANOG1/P8 in primary human fibroblasts infected with the previously described retroviral 
NANOG constructs.  
(C) Expression levels of endogenous NANOG1 in primary human fibroblasts infected with the previously described retroviral 
NANOG constructs.  
NTERA2 was used as a positive control. Values correspond to the average ± SD (n=6 PCR replicates). 
 
After 28 days, human iPSC colonies were clearly visible and had the standard morphology 
(Figure 56A). Plates were stained with alkaline phosphatase and the number of AP+ colonies 
was scored (Figure 56B and 56C). Interestingly, the two polymorphic variants of NANOG1 
and NANOGP8 increased reprogramming efficiency to a similar extent and, accordingly, the 
two NANOG1 point mutants also had a similar effect (Figure 56B and 56C).  
 
Figure 56. Activity of NANOG variants during reprogramming of MEFs 
(A) Phase contrast microphotographs of representative human iPSC colonies at day 28. 
(B) AP staining of human primary fibroblasts infected with OCT4, SOX2 and KLF4; as well as empty vector (EV); NANOG1K82 
or NANOGP8.  
(C) Relative reprogramming activity of primary human fibroblasts infected with three factors OCT4, SOX2, KLF4 (OSK), 
together with control (EV: empty vector), with NANOG1K82 and NANOG1N82 variants, NANOG1K82 point mutants A16E and 
Q253H, or NANOGP8. AP+ colonies were scored at day 28. Values correspond to the average ± SD. Three replicates were 
performed and the number of colonies was normalized to the number of colonies appearing in fibroblasts infected with OSK 
and NANOG1K82. The reprogramming efficiency of all the NANOG variants was significantly increased compared to the EV 
control (Student’s t test p<0.05). The reprogramming efficiencies of the indicated NANOG constructs were not significantly 
different amongst themselves.   
 
Together, these results demonstrate that NANOGP8 possesses pluripotency capacity comparable 
to NANOG1. 
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Expression of NANOG has been always thought to be restricted to embryonic development and 
pluripotent cells (ESCs and iPSCs). In our work, we have uncovered new roles for NANOG in 
stratified epithelia and in cancer by use of an inducible Nanog-overexpressing mouse model. 
Additionally, we have analyzed a cancer-associated NANOG variant, NANOGP8 and its role in 
pluripotency during reprogramming of differentiated cells. 
1. NANOG and stratified epithelia  
For a long time pluripotency factors were thought to only have a role during embryonic 
development. SOX2 perfectly exemplifies that a pluripotency transcription factor can have 
distinct roles in adult tissue homeostasis, depending on the tissue context and its binding 
partners. In our work we have discovered that NANOG is expressed in stratified epithelia of 
adult tissues. Specifically, it is expressed in the basal layer, which contains stem cell 
compartments that maintain the homeostasis of the epithelial tissue.  
By using a mouse model that induces NANOG ubiquitous overexpression, we have observed 
that it can promote alterations in specific stratified epithelia such as forestomach and esophagus. 
Esophagus is unique compared to other epithelia such as skin, in the organization of its stem 
cell population. It contains a single layer of progenitor stem cells in the basal layer, which are in 
constant self-renewal to maintain the tissue (Doupe et al., 2012) (different from other adult stem 
cell populations which are normally quiescent (Blanpain and Fuchs, 2009)). Interestingly, 
NANOG overexpression is only effective in those tissues with endogenous levels of NANOG. 
This opens the possibility that tissue context is responsible for NANOG function in adult 
tissues.  
NANOG-induced esophageal hyperplasia is also associated to an impaired differentiation, as 
shown by a decrease in differentiation markers and disorganization of the basal layer markers. 
This data indicates that NANOG could be promoting proliferation of the progenitor layer or 
dedifferentiation of the suprabasal layers. Already at short induction times (48 hr), microarray 
data revealed NANOG-overexpressing esophagus is capable of inducing a mitotic 
transcriptional program, in contrast to the liver.   
1.1. NANOG and AURKA 
Based on our microarray results, we have focused on the mitotic inducer Aurora kinase A 
(AURKA) as a potential mediator of NANOG’s mitogenic activity. Consistent with this, we 
have proved that NANOG directly binds the Aurka promoter in ESCs and in keratinocytes. 
Moreover, we have demonstrated that NANOG can regulate AURKA expression levels and this 
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can directly affect proliferation of HNSCC cells. This is clearly shown by knockdown of 
NANOG in two HNSCC cell lines, which was associated to a significant reduction of AURKA 
protein levels and cells in S-phase. 
AURKA and cell cycle 
Aurora kinases play important roles during the mammalian cell cycle. AURKA is best known 
for its requirement in mitosis, where it is necessary for centrosome separation, mitotic entry and 
microtubule dynamics in order to build a bipolar spindle (Carmena and Earnshaw, 2003; 
Malumbres, 2011). Consistent with this, alterations of its expression lead to mitotic alterations 
that impair cell cycle. AURKA genetic ablation leads to early embryonic lethality because of its 
requirement in mitotic progression (Lu et al., 2008; Sasai et al., 2008). In the case of 
overexpression, AURKA can produce aberrant mitosis that lead to chromosomal aneuplodies 
(Bischoff et al., 1998; Meraldi et al., 2002; Zhou et al., 1998).  
The function of AURKA is not only limited to mitosis, but it additionally has a role in DNA 
replication. This has been demonstrated by overexpression of AURKA which has been 
associated to increased proliferation in gastric cancer cells (Dar et al., 2009); consistent with a 
recent study showing that AURKA has a role in the induction of DNA replication by regulating 
the pre-replicative complex assembly (Tsunematsu et al., 2013).  
Because of its critical role in mitosis and cell cycle, it has also been widely analyzed in cancer. 
Aurka has been identified as an oncogene in human cancer and it is amplified in a large number 
of cancer cell lines and tumors (Bischoff et al., 1998; Meraldi et al., 2002; Zhou et al., 1998). In 
human HNSCC this has also been observed, and overexpression of AURKA is associated with 
decreased survival, and a reduction of AURKA expression inhibits cell growth and increases 
apoptosis (Mehra et al., 2013). Its tumorigenic role in skin tumors in vivo has also been 
demonstrated, where ablation of Aurka in the basal layer of stratified epithelia leads to tumor 
arrest and decreased proliferation (Perez de Castro et al., 2013).  
NANOG can upregulate AURKA, therefore it was important to determine if AURKA was 
responsible for the hyperplasia phenotype of the NANOG ubiquitous expressing mouse. Studies 
in our laboratory in collaboration with Ignacio Pérez de Castro and Marcos Malumbres (CNIO, 
Madrid) have shown that ubiquitous overexpression of AURKA in mice leads to increased 
proliferation and aneuploidy of the basal layer of the esophagus (D.P., in revision). These 
results show AURKA is a potential mediator for the mitotic function of NANOG. Of note, 
AURKA overexpression showed a milder phenotype (proliferation and aneuploidy) than the one 
observed for NANOG overexpression, suggesting that although AURKA is an important 
effector, it is not the only downstream target of NANOG. 
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AURKA and polarity 
Aurora kinases have also been associated to regulation of the balance between symmetric and 
asymmetric cell divisions, because of their role in the establishment of polarity during cell 
divisions (Malumbres, 2011). Asymmetric and symmetric divisions are important for the 
maintenance of stem cell populations and tissue homeostasis in adults. In vivo, this is 
determined by the stem cell niches that possess polarized cells regulating the orientation of cell 
division to determine the fate of daughter cells (Neumuller and Knoblich, 2009).  
The epithelium is a good example of polarized tissues. Here the cells of the basal layer are 
polarized establishing two membrane domains, the apical and basolateral membranes (Figure 
57). In symmetric divisions the division plane is parallel to the polarity axis (basement 
membrane), and cell fate constituents will be equally segregated into daughter cells remaining 
in the basal layer (stem cell niche). On the other hand, asymmetric divisions consist on 
orientating the spindle perpendicular to the basement membrane, where daughter cells inherit 
different contents and diverge in differentiation (Figure 57) (Blanpain and Fuchs, 2009; 
Neumuller and Knoblich, 2009; Niessen et al., 2012). AURKA is involved in asymmetric 
divisions due to its role in centrosomal and spindle function, and by regulating localization of 
asymmetric marker Numb (Wirtz-Peitz et al., 2008). AURKA hypomorphic loss in neuroblasts 
of flies impairs asymmetric localization and increases symmetric cell division (Berdnik and 
Knoblich, 2002; Wang et al., 2006a).  
Figure 57. Symmetric and asymmetric divisions in epithelia.  
During epithelial homeostasis, asymmetric cell divisions occur with the plane of division parallel to the basement membrane and 
gives rise to two different daughter cells, one remains a stem cell, whereas the other becomes committed to terminal differentiation. 
To maintain the pool of stem cells, symmetric cell division occurs resulting in two equal daughters, also known as stem cell self-
renewal.    
 
In mammals, a recent study has also shown that AURKA is essential to regulate stem cell fate in 
mouse mammary epithelium, through the function of AURKA in mitotic spindle regulation 
(Regan et al., 2013). All this evidence, points to AURKA as a key player in determining cell 
fate by controlling symmetric and asymmetric division, and maintenance of the stem cell 
population.  
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An imbalance of these divisions has also been related to cancer. An increase of symmetrical 
divisions promotes carcinogenesis in Drosphila (Castellanos et al., 2008; Caussinus and 
Gonzalez, 2005), although it remains as a hypothesis to be confirmed in mammals. Since we 
have demonstrated NANOG can regulate AURKA in epithelial cells, this opens the possibility 
that it could also have an effect in tissue homeostasis, maintenance of the stem cell niche and 
tumorigenesis thorough AURKA activity as a “polarity related kinase”. This is an interesting 
line of work that should be further studied, for which a conditional knockout model for 
NANOG would be required.  
All together, our observation of direct regulation of NANOG over AURKA opens the 
possibility that NANOG can have a causal effect in tumorigenesis. AURKA inhibitors are 
potential drugs that are now used in clinical trials in cancer, including HNSCC (Manfredi et al., 
2011; Mehra et al., 2013). When we knockdown NANOG in HNSCC cells, proliferation 
decreased and cell cycle is arrested together with significant reduction of AURKA protein 
levels. Further studies in our laboratory in collaboration with the group of Juana Maria García-
Pedrero, Marta Sánchez-Carbayo and Manuel Rodrigo-Justo have found a positive correlation 
between NANOG and AURKA expression in HNSCC and ESCC. These results show that 
NANOG could be used as an informative biomarker in cancer to predict the response to 
AURKA inhibitors.  
1.2. NANOG long-term overexpression in stratified epithelia 
Regarding long-term overexpression of NANOG in mice, we have found different results 
depending on the compartments where we express NANOG: (1) In the ubiquitous 
overexpression model (ubiquitous-Nanog), mice die within weeks and show clear hyperplasia of 
stratified epithelia as well as thymus atrophy. (2) In the epithelial basal layer overexpression 
model (K5-Nanog), there is no apparent phenotype even after 9 months of doxycycline 
administration. This should be analyzed in detail, but several clues could account for this:  
(1) The pattern of expression is different: In the ubiquitous-Nanog mice, NANOG is not only 
expressed in the basal layer but also in the suprabasal layers. In the K5-Nanog mice, NANOG is 
only expressed in the basal layer.  
(2) The hematopoietic stem cell phenotype: In the ubiquitous-Nanog mice show atrophy of the 
thymus. In the K5-Nanog, the thymus is normal and presents no phenotype. A previous report 
has shown that Nanog is expressed at low levels in some hematopoietic progenitor lineages (B-
cell lineage; sub-population of the myeloid lineage, and thymus double positive stage cells). In 
this same report, transplant assays done with Nanog overexpressing hematopoietic stem cells 
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(HSC) show that NANOG inhibits T-cell development and promotes dominance of !"T-cells in 
the thymus leading to thymus atrophy. Furthermore, long-term overexpression of NANOG in 
HSCs leads to development of a lymphoproliferative disorder (Tanaka et al., 2007). This 
phenotype could be key for the epithelial phenotype observed in the Rosa26::rtTA, 
Col1a1::tetO-Nanog mice. !"T-cells constitute a small percentage of the T cell population but 
are enriched (> 50%) in epithelial cell-rich compartments like the skin, digestive tract and 
reproductive organ mucosa. These T-cells have been implicated as early and rapid responders to 
tissue damage (Havran and Jameson, 2010; Komori et al., 2006). They are in close contact to 
epithelial keratinocytes, and upon activation they can secrete cytokines and chemokines which 
play roles in inflammation, and recruit immune cells to the tissue (Macleod and Havran, 2011). 
Based on these results, we can hypothesize that in our ubiquitous mouse model, NANOG 
overexpression also forces HSCs to a !"T-cell fate. Moreover, we also observe thymic atrophy 
in our mice. A shift towards !"T-cells can also be driving a hyperplasic effect in epithelia 
modulated by inflammation. In our case, the K5-inducible Nanog mouse model only showed a 
distinct phenotype upon TPA application, known to promote proliferation and inflammation. In 
this case we also see an increased hyperplasia and impaired differentiation of the basal layer in 
the skin.  
Interestingly, another group also tried to answer the role of Nanog in stratified epithelia and 
cancer by generating a transgenic mouse model overexpressing the human NANOG variant, 
NANOGP8 under the control of the cytokeratin 14 (K14) promoter. These K14-NANOGP8 
transgenic mice show partial perinatal lethality. However K14-NANOGP8 mice that survive 
grow normally as adults showing subtle abnormalities such as atrophy in the skin and tongue 
hyperplasia. In agreement with our results, they do not develop spontaneous tumors (Badeaux et 
al., 2013). 
1.3. NANOG partners in stratified epithelia 
Another question is why NANOG overexpression has a specific effect in stratified epithelial 
tissues. As already mentioned, SOX2 binding to different partners regulates its roles in adult 
tissues. Of particular interest, P63 has been shown to bind to SOX2 in SCC cells and drive a 
different transcriptional program compared to ESCs (Watanabe et al., 2014a). Our results reveal 
that NANOG follows the same expression pattern as P63. In addition, we have also seen that 
NANOG interacts with !Np63# in ESCC cells. We will further address this issue by analyzing 
ChIP-seq of NANOG in ESCC cells, and clearly identifying the NANOG transcriptional 
program in SCC.   
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1.4. NANOG and tissue homeostasis 
Our approach to examine the role of Nanog in tissue homeostasis has consisted on using an 
inducible-Nanog overexpression mouse model. Forced overexpression of ubiquitous Nanog 
results in hyperplasia of squamous epithelia, such as esophagus and forestomach. With these 
results we confirm that Nanog can have an effect in epithelia, but what still remains to be 
elucidated is the role and requirement of endogenous Nanog for tissue homeostasis. This can 
only be addressed with a loss-of-function model. As Nanog deletion is early embryonic lethal, a 
conditional KO strategy should be used. In our laboratory, this mouse model is currently being 
developed to answer this question.  
In summary we have observed that NANOG is expressed in adult tissues in stratified epithelia, 
and ubiquitous overexpression of Nanog causes hyperplasia and induction of a mitotic 
transcriptional program specifically in stratified epithelia (most accentuated in the mucosal 
epithelia). The specificity of NANOG in stratified epithelia suggests that it might bind to 
partners that regulate its function, being !Np63# and SOX2 good candidates. Together, these 
results indicate that NANOG has a lineage-restricted mitogenic function in stratified epithelia.    
2. NANOG and cancer 
As mentioned previously, NANOG can directly regulate AURKA expression, which could have 
a role in tumor initiation. Our results show that Nanog expression alone is not sufficient to 
induce tumors. Other well-known oncogenes have also been demonstrated to not spontaneously 
give rise to tumors when overexpressed. This is the case for cMyc, not only a well-established 
oncogene, but also one of the reprogramming “Yamanaka” transcription factors. cMyc 
overexpression leads to increased epidermal proliferation and ultimately to depletion of stem 
cells, rather than expansion to form tumors (Arnold and Watt, 2001; Gandarillas and Watt, 
1997; Waikel et al., 2001). K14-NANOGP8 overexpressing transgenic mice phenocopy this, 
where NANOG overexpression during a long period of time shows a depletion of the stem cells 
and lack of tumor formation (Badeaux et al., 2013).  
Hence, we decided to use a chemical carcinogenesis approach to view NANOG’s role in 
tumorigenesis. We demonstrate that NANOG can promote progression in a resistant mouse 
background upon chemical carcinogenesis by activating an EMT and stemness program. These 
results unravel NANOG as an oncogenic driver in skin tumors and strengthens the idea of 
pluripotent transcription factors as tumorigenic in a cancer context (Suva et al., 2013). Nanog 
overexpression alone is not sufficient to induce alterations in skin. But in Nanog-overexpressing 
papillomas, we could already determine some histological differences including disorganization 
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of the basal layer and atypia, as shown by epithelial stem cell marker P63 IHC. This suggests 
NANOG requires additional events (Ras mutation and TPA mitogenic stimulation) to act as a 
driver of oncogenesis. 
2.1. NANOG, EMT and CSCs 
Cancer cells and pluripotent cells share similarities. Both reprogramming to induced 
pluripotency and malignant transformation can be defined as stepwise processes, where only a 
small percentage of cells undergo the necessary changes to create either iPSC or cancer cells. 
iPSCs and cancer cells share properties such as unlimited proliferation, self-renewal and 
tumorigenic potential (Apostolou and Hochedlinger, 2013). Although still controversial, there 
are several lines of evidence showing the idea that tumor heterogeneity relies on a fraction of 
cells that has the capacity to self-renew and give rise to the different lineages of cancer cells 
known as cancer stem cells (CSC). Cell plasticity refers to the ability of cells to reversibly 
change their phenotype, in tumor cells this could refer to a certain subpopulation of cells which 
dedifferentiates and acquires CSC properties under certain conditions (Friedmann-Morvinski 
and Verma, 2014). Related to cancer, tumor plasticity and CSCs have also been related to EMT 
and to the invasion-metastasis cascade (Mani et al., 2008). EMT and its reverse process 
mesenchymal-epithelial transition (MET) are common processes both in development and in 
cancer. In development, cells can migrate after undergoing EMT and once at their destination 
undergo MET to give rise to different tissues. Likewise, this process also occurs in cancer, 
where tumor cells undergo EMT, extravasate into lymphatic and blood vessels, and 
subsequently extravasate following MET to form metastasis (Nieto, 2013). These steps required 
for metastasis formation require certain plasticity from cancer cells, since EMT TFs must be 
downregulated to form the metastasis, and once at the secondary site return to an epithelial cell 
resembling the primary tumor. 
Our results show that Nanog-overexpressing papillomas have an increased expression of EMT 
TFs. There are already several reports linking NANOG to an EMT phenotype in cancer cells 
(Table 1), including one study showing that NANOG can directly regulate TGF-ß1 expression 
in melanoma cells, a potent inducer of EMT (Hasmim et al., 2013). Our study is the first to 
show that Nanog overexpression is capable of driving an EMT program in skin tumors. Our 
RNA-seq data revealed that in papillomas, EMT inducer Prrx1 (Ocana et al., 2012) was 
upregulated. Further analysis by qRT-PCR of Nanog-overexpressing papillomas and 
carcinomas confirmed upregulation of other EMT drivers such as Zeb1, Zeb2 and Twist1, as 
well as downregulation of E-cadherin, a key property of EMT (Sanchez-Tillo et al., 2012). 
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PRRX1 
PRRX1 was recently discovered as a driver of EMT in breast cancer, and its downregulation is 
essential for extravasated cells to colonize distant tissues during metastasis (Ocana et al., 2012). 
In relationship to the finding of Prrx1 as an upregulated target in our Nanog-overexpressing 
papillomas, we did not find Snail or Slug upregulation in Nanog-overexpressing papillomas, 
carcinomas or keratinocytes. Snail and Slug are master regulators of the EMT process (Cano et 
al., 2000). However, a recent study has hypothesized that Prrx1 can induce a different type of 
EMT independent of Snail and Slug. These two types of EMT (Snail-type and Prrx1-type) could 
be either parallel or exclusive processes in a tumor (Ocana et al., 2012). There are some theories 
linking EMT with stemness properties, where dedifferentiated cells in a tumor are the ones 
giving rise to cells with migration capacity (Brabletz et al., 2005). New studies show metastasis 
requires both processes (EMT and MET) (Ocana et al., 2012; Tsai et al., 2012). This suggests 
that metastatic cells require cell plasticity, a property that could be given by stemness factors. In 
our case, we have performed RNA-seq of the whole tumor population and cannot distinguish 
different subpopulations. It would be interesting if we could capture circulating tumor cells in 
the bloodstream of Nanog-overexpressing mice to confirm the EMT and dissemination 
hypothesis. Likewise, it would be appealing to analyze if there are tumor subpopulations which 
are more dedifferentiated to understand mechanistically what Nanog is promoting in a tumor: 
EMT coupled to stemness; or two subpopulations, one linked to EMT (Prrx1-related), and 
another to stemness. 
ZEB1, ZEB2 and TWIST1 
Our results also show that Nanog-overexpressing papillomas and carcinomas regulate other key 
EMT TFs, including Zeb1, Zeb2 and Twist1. ZEB1 and ZEB2 form part of the ZEB family that 
are zinc finger/homeodomain proteins. They are known to mediate EMT by repression of 
epithelial markers (either directly or through regulation of miRNAs) and activation of 
mesenchymal markers (Thiery et al., 2009). TWIST1 is also a basic helix-loop-helix with DNA 
binding capacity protein with a “Twist box” at its C-terminal, which can regulate gene 
expression either by activation or repression of target genes involved in EMT (Thiery et al., 
2009). Our results have shown that NANOG can upregulate the ZEB factors (Zeb1 and Zeb2) 
and Twist1 in a cell-autonomous manner. Interestingly, we have observed NANOG can bind to 
the promoters of Zeb2 and Twist1 providing a direct link of NANOG with EMT induction.  
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2.2. NANOG and stemness 
Our RNA-seq data showed Nanog-overexpressing papillomas are enriched in genes related to 
stemness. Interestingly, two well-known markers related to CSCs came up, ALDH1 and 
CXCL12/SDF-1. Among our targets we also observed upregulation of stemness related genes 
LGR5, PDGFRA and PITX2.  
ALDH1 
ALDH1 has been well characterized to identify breast stem cells and breast CSCs associated to 
malignancy (Ginestier et al., 2007). It has also been identified to mark CSC populations in 
melanoma, liver, lung, pancreatic and prostate tumors (Medema, 2013). In HNSCC, reports 
have demonstrated ALDH1 expression had a positive correlation to staging and a negative 
correlation to patient outcome (Chen et al., 2009). ALDH1 is a member of the aldehyde 
dehydrogenase family, with functions ranging from detoxification by oxidation of intracellular 
aldehydes (Magni et al., 1996) to early stem cell differentiation by conversion of retinol to 
retinoic acid (Chute et al., 2006). Related to the above association of stemness and EMT, 
ALDH1 has also been connected to EMT, where ALDH1+ HNSCC CSCs were found to 
increase expression of EMT inducer Snail (Chen et al., 2009).  
CXCL12 
Regarding CXCL12 (also known as stromal cell-derived factor-1, SDF-1), chemokines have 
long been known to determine the development of primary tumors and metastasis (Balkwill, 
2004). Chemokine receptors are able to induce directional migration of cells toward chemokines 
(chemotactic cytokines), and were initially identified for their ability to cause directed leukocyte 
migration to sites of inflammation (Baggiolini, 1998). Further studies revealed their importance 
in other processes such as embryogenesis, angiogenesis, hematopoiesis, HIV1-infection and 
cancer (Balkwill, 2004; Doitsidou et al., 2002; Feng et al., 1996; Romagnani et al., 2004). 
CXCL12 is a homeostatic chemokine, which specifically binds and initiates signaling through 
receptor CXCR4, a well-known 7 transmembrane domain G-protein-coupled receptor (GPCR). 
The CXCR4/CXCL12 pathway has shown to play a critical role in cancer progression and 
metastasis (Teicher and Fricker, 2010). As mentioned before, CXCL12 has been associated to 
stemness, since its receptor has been identified as a CSC marker in pancreatic cancer, where 
CD133+ CXCR4+ cells were found to be essential in determining tumor metastasis (Hermann et 
al., 2007). CXCR4 is widely expressed in many tumor types and is responsible for metastasis to 
the lung, liver and bone marrow (Zlotnik et al., 2011). CXCL12 can also stimulate survival and 
growth of neoplastic cells in a paracrine fashion and promote tumor angiogenesis by attracting 
endothelial cells (Burger and Kipps, 2006). The relationship of NANOG to this pathway is also 
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related to its role in embryogenesis. The CXCL2/CXCR4 pathway is key for PGC migration 
(Doitsidou et al., 2002), where Nanog is also known to be essential. In agreement with this, one 
report found that NANOG could directly regulate the expression of Cxcr4 in PGCs and mediate 
their migration in medaka (Sanchez-Sanchez et al., 2010). Our results indicate NANOG can 
directly regulate CXCL12 expression, which can play a driving effect in progression of 
squamous tumors. The CXCL12/CXCR4 pathway is a current target for anticancer therapy 
since it is known to activate oncogenic signaling pathways PI3K/Akt, IP3 and MAPK (Duda et 
al., 2011); if NANOG is upstream of this pathway it could also be a potential therapeutic target. 
LGR5  
LGR5 is a 7-transmembrane domain receptor protein targeted by the Wnt signaling pathway, 
which has been found to mark the stem cell populations of the hair follicle in the skin, stomach 
and intestine. It has also been associated to cancer where it is overexpressed in multiple cancer 
types, including colorectal cancer, basal cell carcinomas and ovary and liver tumors (Schuijers 
and Clevers, 2012). The Wnt signaling pathway has also been shown to be essential to maintain 
pluripotency in ESCs (ten Berge et al., 2011).  
PDGFRA 
Platelet derived growth factor receptor alpha (PDGFRA) is a tyrosine kinase receptor required 
for embryonic development and is frequently activated in cancers where it promotes EMT; 
tumor growth, angiogenesis, invasion, and metastasis (Andrae et al., 2008). A recent report has 
shown that breast CSCs require a shift to PDGFRA signaling after activation of an EMT 
program (Tam et al., 2013).  
PITX2 
Pituitary homeobox-2 (PITX2) is a member of the bicoid/paired-like homeobox gene family, 
and is known to play a central role in determining left-right asymmetry in vertebrates and 
development of multiple organs. Here it serves as a downstream effector of Nodal, TGF", and 
the Wnt signaling pathway (Kioussi et al., 2002). It has also been shown to have an oncogenic 
role in thyroid (Huang et al., 2010). 
Others 
We also observed upregulation of a marker of an epidermal progenitor cell population, 
Plet1/MTS24 (Nijhof et al., 2006) (Figure 8). Expansion of the epidermal stem cell 
compartments could also be related to tumorigenesis. Recently, a study has shown Snail 
overexpression in the basal layer of stratified epithelia can lead to proliferation of the 
keratinocyte stem cells shown by expansion of the MTS24+ progenitor population and 
DISCUSSION !!!
 
 131!
ultimately this can also mediate the development of spontaneous skin tumors (De Craene et al., 
2014).  
In ESCs, NANOG is capable of binding to many sites and recruiting chromatin remodelers. 
Interestingly, one of our upregulated targets was Hdac7, a histone deacetylase involved in 
chromatin remodeling that could mediate aberrant gene silencing in tumors (Johnstone, 2002). 
In our case, ChIP of NANOG in ESCC cells showed direct binding to many promoters of 
upregulated genes in Nanog-overexpressing papillomas. NANOG has been shown to bind many 
genes in ESCs, by cooperating with SOX2 and OCT4 (Boyer et al., 2005; Kim et al., 2008). 
SOX2 has been shown to be an important tumor-promoting factor in SCC (Bass et al., 2009). 
Consistently, NANOG could also be cooperating with SOX2 in these tumor types, but a recent 
study of SOX2 binding partners in ESCC, did not show NANOG as one of the hits (Watanabe 
et al., 2014a). With ChIP-seq data of NANOG in ESCC we will be able to identify its 
transcriptional network, and compare it to its role in ESCs.  
2.3. NANOG and microRNAs 
MicroRNAs (miRNAs) have been shown to be key in somatic and pluripotent stem cells 
(Gangaraju and Lin, 2009) and are frequently deregulated in cancer (Zhang et al., 2006b). In 
cancer, miRNAs can act as tumor suppressors or oncogenes, depending on the cellular context 
(Spizzo et al., 2009). One of the miRNAs we found to be upregulated in Nanog-overexpressing 
back skin, papillomas and carcinomas was miR-21.  
miR-21 has been extensively studied since it was found to be upregulated in cardiovascular 
diseases and cancer (Jazbutyte and Thum, 2010). miR-21 has been demonstrated to be 
oncogenic, and it is also known as an oncomiR. Overexpression of miR-21 has a driving role in 
pre-B lymphoma and in Kras-mediated lung tumorigenesis (Hatley et al., 2010; Medina et al., 
2010), and consistently, deletion of miR-21 reduces tumorigenesis of skin carcinogenesis 
(DMA/TPA protocol), its oncogenic effect has been associated to upregulation of the ERK, 
AKT and JNK pathways (Ma et al., 2011). miR-21 has also been associated to EMT and 
metastasis in SCCs (Bornachea et al., 2012). Previous studies have already linked NANOG to 
expression of miR-21 in HNSCC cells (Bourguignon et al., 2012a). In our case we have 
observed this in vivo, and we also confirmed that NANOG could directly bind to the miR-21 
promoter. This reinforces NANOG’s oncogenic potential through upregulation of oncomiR 
miR-21.   
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What still are unknown are the regulators of NANOG activation in cancer. From our results, we 
can already see differences in ChIP performed in pluripotent NTERA2 cells compared to ESCC 
cells. In pluripotent cells, NANOG is known to bind its own promoter (Gifford et al., 2013), in 
our results we confirmed this finding in NTERA2 cells. On the other hand NANOG binding to 
its own promoter is absent in ESCC cells. This suggests that there are other regulators of 
NANOG expression in cancer or that its locus is epigentically inaccessible. Another possibility 
is that NANOGP8 is being expressed in these cells and therefore follows a different regulation 
pattern compared to its paralog NANOG1. NANOG regulation has been extensively studied in 
ESCs, where numerous factors regulate its transcription (Apostolou et al., 2013), but this still 
should be further studied in the context of cancer. 
We have demonstrated that NANOG has a driving role in tumor progression. To ultimately 
demonstrate if Nanog is a good target for cancer therapies, we would require addressing the 
requirement of NANOG during tumorigenesis. This would entail the use of a conditional KO 
Nanog strategy and similarly a chemical carcinogenesis approach to view if it possible to induce 
tumors (benign or malignant) after Nanog deletion.  
All together, NANOG activation in cancer can lead to upregulation of multiple targets that are 
known to promote tumor progression and metastasis, which reinforces the oncogenic potential 
of NANOG in SCCs (Figure 58).  
 
Figure 58. Oncogenic potential of NANOG 
in SCCs. We have observed NANOG can 
directly regulate EMT factors, PRRX1, 
TWIST1 and ZEB2; stemness related factors 
CXCL12, LGR5, PDGFRA and PITX2; and 
oncomiR, miR-21. All these factors can 
contribute to NANOG’s oncogenic potential in 
cancer.  
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3. NANOG variants  
The NANOG gene family is highly complex in humans, but only three of its members have the 
capacity to produce full-length proteins, namely NANOG1, NANOG2 and NANOGP8. NANOG1 
is highly expressed in pluripotent cells, where it is known to play a critical role and is 
considered one of the master regulators of pluripotency (Chambers et al., 2003; Chambers and 
Tomlinson, 2009; Mitsui et al., 2003; Wang et al., 2003). Although our current work is focused 
on NANOGP8, it is worth mentioning that we present evidence indicating that NANOG2 is 
expressed in hESCs at significant levels.  
NANOGP8 is gaining relevance since it has been shown to be expressed in many cancer cell 
lines and tumors where it contributes to oncogenic features, including CSC properties, 
proliferation, clonogenicity and tumorigenicity (Table 1). Although, the protein encoded by 
NANOGP8 only differs in two amino acids relative to NANOG1, these two amino acids are 
located in important domains for transcriptional regulation (Chang et al., 2009; Do et al., 2009; 
Pan and Pei, 2005), opening the possibility that NANOGP8 function could differ from 
NANOG1. Also NANOG1 and NANOGP8 have distinct regulatory sequences, therefore 
activating factors of NANOG in cancer could be unrelated to its known regulators in ESCs.  
With our results we demonstrate that NANOGP8 is the functional variant most widely expressed 
in the analyzed cancer cell lines. At the protein level, NANOG1 and NANOGP8 are 
indistinguishable using antibodies due to their high degree of identity. With qRT-PCR, we 
discarded NANOG1 expression in most cancer cell lines, confirming that NANOG protein arises 
from the NANOGP8 gene. Distinctively, NANOG protein detection in cancer cells shows a 
complex mobility pattern in agreement with previous reports (Eberle et al., 2010; Jeter et al., 
2009; Kim et al., 2005). The molecular bases are still unclear for this, but a number of potential 
mechanisms could account for the different NANOG mobilities, amongst them phosphorylation 
(Moretto-Zita et al., 2010), ubiquitylation (Moretto-Zita et al., 2010; Ramakrishna et al., 2011), 
and caspase-mediated cleavage (Fujita et al., 2008). With use of knockdown techniques, we 
confirm that the detected complex pattern corresponds to NANOG protein. Overexpression of 
NANOG variants in 293T cells also gives rise to different bands and the pattern differs among 
NANOG1, its point mutants and NANOGP8. This suggests different PTMs could be occurring 
in NANOG1 and NANOGP8, and also cellular context could be affecting this, as observed in 
the cancer cell lines.  
We also provide evidence of the pluripotent capacity of NANOGP8. In particular, we have 
employed two assays, using human and mouse fibroblasts, and in both assays NANOGP8 
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improved reprogramming efficiency to the same extent as NANOG1. NANOG1 and NANOGP8 
have an identical homeodomain, which could account for their equal effect in pluripotency. This 
is in agreement with other studies that have shown that the homeodomain is sufficient to 
establish pluripotency in Nanog deficient cells (Theunissen et al., 2011). 
We have focused on NANOG variants with coding capacity, but it is also interesting that most 
cancer cell lines widely express high levels of pseudogenes NANOGP4 and NANOGP5. 
Although pseudogenes have always been considered to be biologically inconsequential due to a 
lack of an ORF, several reports have shown they may be relevant in regulation of their ancestral 
genes and to have a role in carcinogenesis (Poliseno et al., 2010). Further analysis should 
examine if these pseudogenes have an effect in expression of NANOG in cancer.   
Our data demonstrate that NANOGP8 is also a reprogramming factor and, therefore, its 
widespread expression in cancer cells may contribute to the tumorigenic phenotype by 
promoting undifferentiated states, thus refueling cancer growth.  
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1. The pluripotency factor Nanog is expressed in adult tissues, specifically in the basal 
layer of stratified epithelia.  
2. The ubiquitous overexpression of Nanog induces hyperplasia of mucosal stratified 
epithelial tissues, including the esophagus and forestomach, by induction of a mitotic 
transcriptional program, including direct binding to the Aurka promoter and its 
upregulation. 
3. NANOG is expressed in esophageal squamous cell carcinomas (ESCC) and head and 
neck squamous cell carcinomas (HNSCC).  
4. The inducible overexpression of Nanog in mouse skin epithelia favours the malignant 
conversion of skin tumors induced by chemical carcinogenesis, leading to increased 
SCC formation by upregulating epithelial-mesenchymal transition (EMT) and stemness 
drivers. 
5. NANOG is a cell autonomous and direct activator of EMT and stemness programs in 
epithelial cells, including squamous cell carcinoma cells. 
6. Human cancer cells show predominant expression of NANOGP8, whereas pluripotent 
cells (embryonic stem cells and embryonal carcinoma cells) express the NANOG variant 
NANOG1, and to a less extent, NANOG2.  
7. NANOGP8 possesses the same pluripotent activity as NANOG1 in the reprogramming 
of human and mouse differentiated cells.  
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1. El factor de pluripotencia NANOG se expresa en tejidos adultos, específicamente en la 
capa basal de epitelio estatificado.  
2. La sobreexpresión ubicua de Nanog induce hiperplasia de tejidos estratificados 
epiteliales mucosales al promover un programa transcripcional mitótico, incluyendo la 
regulación directa de la expresión de Aurka por unión a su promotor.   
3. NANOG se expresa en carcinomas de células escamosas  de esófago y de cara y cuello.  
4. La sobreeexpresión de Nanog en la epidermis de ratón promueve la progresión maligna 
de tumores de piel inducidos por carcinogénesis epitelial, llevando a un incremento en 
la formación de carcinomas de células escamosas al sobre-regular genes clave 
implicados en transición epitelio-mesenquimal (EMT) y en troncalidad. 
5. NANOG activa de forma directa programas de EMT y troncalidad en células epiteliales, 
incluyendo en células tumorales provenientes de carcinomas de células escamosas de 
cara y cuello. 
6. Células tumorales humanas expresan de forma predominante la variante NANOGP8, 
mientras que células pluripotentes expresan la variante NANOG1 y en menor medida 
NANOG2.  
7. NANOGP8 posee la misma actividad pluripotente comparado a NANOG1 en la 
reprogramación de células diferenciadas de ratón y humano.  
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Table S1. Differentially expressed genes in NANOG-overexpressing papillomas versus 
controls (DEG) (red: EMT-related genes; blue: stemness-related genes). 
DEG (FDR<0.05)a 
Upregulated in TG (n=3) vs CTR (n=4) papillomas 
GENE Log2 (fold change) NOM p-val FDR q-val 
Atp2a1 6,55967 0 0 
Ttn 7,82508 4,44089E-16 2,48312E-12 
Ckm 6,68657 1,76119E-11 4,92385E-08 
Car3 7,56808 1,46252E-11 4,92385E-08 
Myh1 6,19826 2,97422E-11 6,65214E-08 
Rps4y2 4,83277 3,1267E-10 5,82765E-07 
Myh4 9,76944 3,86907E-10 6,18112E-07 
Neb 4,78852 1,05064E-09 1,30548E-06 
Nanog 3,3504 2,89841E-09 2,86892E-06 
H19 5,14505 3,33506E-09 2,86892E-06 
Pygm 5,47646 3,15503E-09 2,86892E-06 
Myh2 6,82759 2,9939E-09 2,86892E-06 
Fhl1 3,27325 5,39424E-09 4,30885E-06 
Cxcl5 4,01 7,31023E-09 5,45002E-06 
Ldb3 5,1954 9,29079E-09 6,49368E-06 
Tspan1 6,34179 1,34298E-08 8,83443E-06 
Myl1 7,41907 1,82127E-08 1,13151E-05 
Hdac7 0,507551 2,88639E-08 1,69887E-05 
Muc4 5,43117 4,65719E-08 2,60407E-05 
Slc6a14 3,3864 5,37199E-08 2,86071E-05 
Gm9573 4,1772 6,145E-08 2,98781E-05 
Mybpc2 6,61558 5,92222E-08 2,98781E-05 
Ppbp 4,45723 6,57444E-08 3,06341E-05 
Xirp2 8,84208 8,05238E-08 3,60199E-05 
Cmya5 7,71368 9,43437E-08 4,05787E-05 
Plet1 3,23664 1,44838E-07 5,99897E-05 
Liph 0,824535 1,87919E-07 7,50535E-05 
Dynap 4,28125 2,90942E-07 0,000108454 
Acta1 3,42611 4,84392E-07 0,00017474 
Cxcl12/Sdf-1 3,48094 8,7566E-07 0,000306016 
Mylpf 3,604 1,18551E-06 0,000401745 
Tnnc2 7,86144 1,66602E-06 0,000547974 
Slfn4 3,15787 2,49068E-06 0,000773701 
Des 3,83497 2,43019E-06 0,000773701 
Stfa2l1 2,52101 2,64669E-06 0,000799944 
Hand1 4,7656 3,03465E-06 0,000893066 
Slc15a2 5,59142 5,62084E-06 0,00157145 
Ppp1r3a 7,49906 7,86352E-06 0,00214482 
Actn3 7,91031 9,18878E-06 0,00244662 
Acpp 1,34887 1,01814E-05 0,00260871 
Prnd 1,69616 1,07306E-05 0,00260871 
Slc5a8 2,13379 1,06291E-05 0,00260871 
Scn8a 2,81525 1,13129E-05 0,00269175 
Cxcl3 2,82839 1,15923E-05 0,00270075 
C3 3,62271 1,46215E-05 0,00333699 
Thbs4 5,83514 1,62731E-05 0,00363964 
Stfa2 2,51483 2,27001E-05 0,00489649 
Gprc5a 2,98638 2,27682E-05 0,00489649 
Ivl 2,38136 2,42188E-05 0,00501553 
Aldh1a3 2,13392 2,63686E-05 0,00536145 
Myom1 3,71599 2,92021E-05 0,00583156 
Myh8 6,86279 3,32031E-05 0,00651421 
Col14a1 3,37758 4,04415E-05 0,00779753 
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Nov 4,20451 4,12846E-05 0,00782518 
Irg1 3,22614 4,80172E-05 0,00894961 
Tgm2 2,91676 5,20011E-05 0,00953325 
Nmes1 2,58447 6,08827E-05 0,0109815 
Mb 5,11013 6,29326E-05 0,011032 
Cyp2g1 6,25924 7,84593E-05 0,0132941 
Ryr1 3,14644 8,07453E-05 0,0134772 
Cilp 2,90297 8,34107E-05 0,0137174 
Casq1 5,88079 8,68645E-05 0,0140783 
Atp1a2 3,84829 9,05208E-05 0,0144613 
Lcn2 2,36315 0,000104649 0,016254 
Sell 3,91241 0,000107728 0,016503 
Plat 2,21234 0,000110605 0,0167148 
Clec4e 3,35531 0,000115642 0,0172429 
Myoz1 5,24086 0,000135532 0,0196838 
Jph2 2,56037 0,000147204 0,0211049 
Lcp1 1,75582 0,000155746 0,022047 
Krt71 4,64116 0,000199048 0,0274809 
Sec14l2 2,09105 0,000211102 0,0284428 
Slco3a1 1,13427 0,000221865 0,0288502 
Scara5 4,58217 0,000221295 0,0288502 
Vcan 1,02296 0,000232356 0,029625 
Cpn1 2,95868 0,000235771 0,029625 
Myom2 6,00486 0,000235284 0,029625 
Gm5416 2,20526 0,000247856 0,0304691 
Cd300lf 3,29543 0,000252813 0,0307305 
Fa2h 4,0605 0,000266412 0,0320353 
Ltf 3,26081 0,000271416 0,0322898 
Sgcg 6,2053 0,000281906 0,0331848 
Pkia 3,97673 0,000300045 0,0349521 
Retnla 3,374 0,000333794 0,0384827 
Plau 1,58562 0,000337397 0,0385011 
Lgals1 1,77197 0,000343726 0,0388272 
Il1b 2,24167 0,00036124 0,0403974 
Srgn 2,15106 0,000375829 0,0416128 
Tmc5 3,77452 0,00038531 0,0422443 
Mybpc1 1,7977E+308 0,000393614 0,0427358 
Tcap 4,36964 0,000434202 0,0465468 
Prrx1 1,39363 0,000443961 0,0468379 
Wnt5a 1,31548 0,000449316 0,0469598 
Hdc 2,7227 0,000467022 0,0483584 
Tdh 1,80571 0,000476752 0,048913 
Lpo 2,40731 0,000485072 0,0493142 
Nrap 6,51767 0,000495117 0,0498819 
Tcap 4,36964 0,000434202 0,0465468 
 
a  FDR q-val, false discovery rate q-value; NOM p-val, nominal p-value 
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